



# Gene Therapies for Sickle Cell Disease

**Draft Evidence Report**

**April 12, 2023**

**Prepared for**



ICER Staff	Modeling Team
<p><b>Francesca Beaudoin, MD, PhD, MS</b> Senior Medical Advisor Institute for Clinical and Economic Review</p> <p><b>Dmitriy Nikitin, MSPH</b> Research Lead, Evidence Synthesis Institute for Clinical and Economic Review</p> <p><b>Jon Campbell, PhD, MS</b> Senior Vice President for Health Economics Institute for Clinical and Economic Review</p> <p><b>Avery McKenna</b> Associate Research Lead Institute for Clinical and Economic Review</p> <p><b>Steven D. Pearson, MD, MSc</b> President Institute for Clinical and Economic Review</p> <p><b>David M. Rind, MD, MSc</b> Chief Medical Officer Institute for Clinical and Economic Review</p>	<p><b>Praveen Thokala, MSc, PhD</b> Senior Research Fellow University of Sheffield</p> <p><b>Eldon Spackman, MA, PhD</b> Associate Professor, Community Health Sciences University of Calgary</p> <p><i>The role of the University of Sheffield is limited to the development of the cost-effectiveness model, and the resulting ICER report does not necessarily represent the views of the University of Sheffield.</i></p>

None of the above authors disclosed any conflicts of interest defined as more than \$10,000 in health care company stock or more than \$5,000 in honoraria or consultancies relevant to this report during the previous year from health care manufacturers or insurers.

**DATE OF**

**PUBLICATION:** April 12, 2023

**How to cite this document:** Beaudoin F, Thokala P, Nikitin D, Campbell J, Spackman E, McKenna A, Pearson SD, Rind DM. Gene Therapies for Sickle Cell Disease: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, April 12, 2023.

<https://icer.org/assessment/sickle-cell-disease-2023/>.

Francesca Beaudoin served as the lead author for the report. Dmitriy Nikitin led the systematic review and authorship of the comparative clinical effectiveness section in collaboration with Avery McKenna. Praveen Thokala developed the cost-effectiveness model and authored the corresponding sections of the report. Jon Campbell, David M. Rind, and Steven D. Pearson provided methodologic guidance on the clinical and economic evaluations. The modeling team would like to thank Marina Richardson and Ashton Moradi for sharing their expertise and resources, which were valuable in developing the cost-effectiveness model. We would also like to thank Laura Cianciolo, Emily Nhan, and Becca Piltch for their contributions to this report.

## About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at <https://icer.org/>.

The funding for this report comes from government grants and non-profit foundations, with the largest single funder being Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers, or life science companies. ICER receives approximately 24% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/pharmacy benefit managers and life science companies. There are no life science companies relevant to this review who participate in this program. For a complete list of funders and for more information on ICER's support, please visit <https://icer.org/who-we-are/independent-funding/>.

For drug topics, in addition to receiving recommendations [from the public](#), ICER scans publicly available information and also benefits from a collaboration with [IPD Analytics](#), an independent organization that performs analyses of the emerging drug pipeline for a diverse group of industry stakeholders, including payers, pharmaceutical manufacturers, providers, and wholesalers. IPD provides a tailored report on the drug pipeline on a courtesy basis to ICER but does not prioritize topics for specific ICER assessments.

## About CTAF

The California Technology Assessment Forum (CTAF) – a core program of ICER – provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. CTAF seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care.

The CTAF Panel is an independent committee of medical evidence experts from across California, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy. All Panel members meet strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions. More information about CTAF is available at <https://icer.org/who-we-are/people/independent-appraisal-committees/ctaf>.

The findings contained within this report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future.

The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost-effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical or cost outcomes for any specific patient. In addition, data inputs to ICER models often come from clinical trials; patients in these trials may differ in real-world practice settings.

*In the development of this report, ICER’s researchers consulted with several clinical experts, patients, manufacturers, and other stakeholders. The following experts provided input that helped guide the ICER team as we shaped our scope and report. It is possible that expert reviewers may not have had the opportunity to review all portions of this draft report. None of these individuals is responsible for the final contents of this report, nor should it be assumed that they support any part of it. The report should be viewed as attributable solely to the ICER team and its affiliated researchers.*

*For a complete list of stakeholders from whom we requested input, please visit:*

[https://icer.org/wp-content/uploads/2022/11/Sickle-Cell-Disease-Key-Stakeholders-List\\_112322.pdf](https://icer.org/wp-content/uploads/2022/11/Sickle-Cell-Disease-Key-Stakeholders-List_112322.pdf)

## **Expert Reviewers**

**Julie Kanter, MD**

**Director, University of Alabama at Birmingham Adult Sickle Cell Clinic**

**Co-Director, Lifespan Comprehensive SCD Center, University of Alabama at Birmingham**

**Associate Professor, Division of Hematology and Oncology**

**University of Alabama at Birmingham Medicine**

*Dr. Julie Kanter has consultancy relationships with Guide Point Global, GLG, Novartis, bluebird bio, GlaxoSmithKline, Graphite bio, Glycomimetics, and Johnson and Johnson.*

**Maia Laing, MBA**

**Vice President, Health Equity**

**Optum**

*Through her position at Optum, Maia Laing received monetary value in excess of \$5,000 and >25% funding. Maia has equity interests in excess of \$10,000 at United Health Group.*

**Patrick McGann, MD, PhD**

**Director, Lifespan Comprehensive Sickle Cell Center**

**Rhode Island Hospital and Hasbro Children’s Hospital**

**Associate Professor of Pediatrics and Medicine**

**Alpert Medical School of Brown University**

*Dr. Patrick McGann has received monetary value in excess of \$5,000 as part of a Safety Advisory Board for Novartis.*

# Table of Contents

Executive Summary.....	ES1
1. Background .....	1
2. Patient and Caregiver Perspectives .....	4
An All-Encompassing Condition .....	4
Stigma and Limitations on Daily Life.....	5
Racial Bias.....	6
Pain Relief .....	7
Lack of Specialists and Optimal Treatment.....	8
Attitude Toward Gene Therapies.....	9
3. Comparative Clinical Effectiveness .....	11
3.1. Methods Overview.....	11
Scope of Review .....	11
Evidence Base .....	11
3.2. Results.....	13
Clinical Benefits.....	13
Harms .....	18
Subgroup Analyses and Heterogeneity.....	20
Uncertainty and Controversies .....	20
3.3. Summary and Comment .....	21
4. Long-Term Cost Effectiveness.....	23
4.1. Methods Overview.....	23
4.2. Key Model Assumptions and Inputs .....	24
Population.....	26
Interventions.....	27
Comparator .....	27
Modeling Treatment Effectiveness.....	27
Health State Utilities .....	28
Cost Inputs .....	29
Treatment Costs.....	29

Societal Perspective Inputs .....	29
Model Outcomes .....	30
Model Analysis .....	30
Sensitivity Analyses .....	30
Scenario Analyses.....	31
4.3. Results .....	31
Base-Case Results.....	31
Sensitivity Analyses .....	32
Scenario Analyses.....	34
Threshold Analyses .....	36
Model Validation.....	36
Uncertainty and Controversies .....	37
4.4 Summary and Comment .....	39
5. Contextual Considerations and Potential Other Benefits.....	40
6. Health-Benefit Price Benchmarks .....	41
7. Potential Budget Impact .....	42
7.1. Overview of Key Assumptions .....	42
7.2. Results.....	42
References .....	44

## Supplemental Materials

A. Background: Supplemental Information .....	A1
A1. Definitions.....	A1
A2. Potential Cost-Saving Measures in SCD.....	A3
B. Patient Perspectives: Supplemental Information.....	B1
B1. Methods.....	B1
C. Clinical Guidelines .....	C1
American Society of Hematology.....	C1
National Heart, Lung, and Blood Institute .....	C3
D. Comparative Clinical Effectiveness: Supplemental Information .....	D1
D1. Detailed Methods .....	D1

Population, Interventions, Comparators, Outcomes, Timing, Settings .....	D1
Data Sources and Searches .....	D6
Study Selection.....	D10
Data Extraction and Quality Assessment.....	D10
Assessment of Level of Certainty in Evidence .....	D10
Assessment of Bias.....	D10
Data Synthesis and Statistical Analyses .....	D11
D2. Evidence Tables .....	D12
D3. Ongoing Studies.....	D23
D4. Previous Systematic Reviews and Technology Assessments .....	D26
E. Long-Term Cost-Effectiveness: Supplemental .....	E1
Information .....	E1
E1. Detailed Methods.....	E1
Rates of Acute and Chronic Complications for Patients on Standard of Care.....	E3
Mortality for Patients on Standard Care.....	E4
Treatment Effectiveness on Acute Complications.....	E5
Treatment Effectiveness on Chronic Complications.....	E6
Treatment Effectiveness on Mortality.....	E7
Disutilities.....	E8
Costs.....	E9
Standard of Care Costs.....	E9
Non-Drug Costs .....	E10
Description of evLY Calculations.....	E11
Description of Optimistic and Conservative Scenarios.....	E12
Results of Probabilistic Sensitivity Analysis .....	E12
F. Potential Budget Impact: Supplemental Information.....	F1
Methods.....	F1
Results.....	F2

## List of Acronyms and Abbreviations Used in this Report

ASCT	Autologous stem cell transplant
evLY	Equal value life year
FDA	Food and Drug Administration
g/dL	gram per deciliter
GVHD	Graft-versus-host disease
HLA	Human leukocyte antigen
HSCT	Hematopoietic stem cell transplantation
ICER	Institute for Clinical and Economic Review
QALY	Quality-adjusted life year
SCD	Sickle cell disease
US	United States
VOC	Vaso-occlusive crisis
VOE	Vaso-occlusive event



# Executive Summary

---

Sickle cell disease (SCD) is a broad term referring to a group of inherited blood disorders caused by mutations in *HBB*, the gene that encodes the beta ( $\beta$ ) subunit of hemoglobin. The rigid and inflexible sickle shape of erythrocytes (red blood cells) results in hemolysis and vaso-occlusion with numerous profound downstream consequences on the health and wellbeing of affected people. The incidence of SCD is estimated at 300,000 to 400,000 live births globally per year. In the United States (US), it is estimated that approximately 100,000 people are living with SCD, although the exact prevalence is unknown.<sup>2</sup>

Recurrent acute pain crises, or vaso-occlusive crises (VOC), are a hallmark manifestation of SCD. Patients can also experience serious acute medical complications such as acute chest syndrome, life-threatening infections, acute splenic sequestration crisis, stroke, and priapism.<sup>3</sup> Chronic complications affecting nearly all organ systems often develop as patients age, including delayed puberty, avascular necrosis, skin ulcers, chronic pain due to recurrent bone infarctions, neurocognitive impairment, chronic kidney disease, pulmonary hypertension, cardiovascular disease, and can result in early mortality.<sup>3</sup> Associated health care costs are high, with the total economic costs of SCD estimated at \$2.98 billion per year in the US.<sup>4</sup> This does not even consider other economic costs (e.g., childcare, missed work) nor impacts on quality of life. Quality of life of both patients and their caregivers is adversely affected by not only the health-related burden of disease, but also by limited treatment options, discrimination, stigma, inadequate pain management, disruption of family and social activities, and missed school and/or work.<sup>5</sup>

In the most severe forms of SCD, standard of care usually involves hydroxyurea, as-needed blood transfusions, and supportive care for acute pain crises and other acute and chronic complications. Hematopoietic stem cell transplantation (HSCT) is currently the only potentially curative treatment for SCD, but HSCT has a risk of graft failure/rejection, graft-versus-host disease (GVHD), acute complications during the transplant process, and carries at least 4% risk of mortality even with a perfectly matched sibling donor that carries less risk of GVHD and graft failure. There is a lack of compatible donors (especially donors that are related to the patient) and thus most people with SCD are not able to pursue HSCT as a therapeutic option even if there is interest.

Lovotibeglogene autotemcel (“lovo-cel,” bluebird bio) and exagamglogene autotemcel (“exa-cel,” Vertex Pharmaceuticals and CRISPR Therapeutics) are emerging transformative gene therapies for SCD. Lovo-cel works by using a modified virus (lentivirus vector) to insert a functioning version of the *HBB* gene into the patient’s own stem cells whereas exa-cel utilizes a gene editing approach using CRISPR-based technology to increase the amount of fetal hemoglobin in red blood cells by deleting a portion of the *BC11A* gene. The manufacturer of exa-cel submitted its Biologics License Application to the Food and Drug Administration (FDA) in April 2023 and the manufacturer of lovo-cel is expected to submit in the first half of 2023.

We compared the therapies with each other and with standard of care consisting of supportive care, hydroxyurea, and blood transfusions in some patients. In trials of both therapies, the main outcome was the number of vaso-occlusive events or crises (VOEs or VOCs) over two years of follow-up. In the pivotal lovo-cel trial, 90% of participants achieved complete resolution of all VOEs between six and 18 months after lovo-cel infusion and 30 of 31 patients were free of *severe* VOEs. In a single trial of exa-cel in 31 participants, only seven participants had 12 months of follow-up available for review, and all seven were free of severe VOCs during that time. In both trials of both lovo-cel and exa-cel, serious adverse events were observed in the trials. Although serious adverse events were attributed to myeloablative conditioning, they were not infrequent and chemotherapy is required before receiving both lovo-cel and exa-cel. However, uncertainty still remains about the degree of risk of gene therapies in the real world, particularly over the long-term. In particular, there were two instances in which the FDA placed a partial clinical hold on lovo-cel due to safety concerns surrounding hematologic malignancies, including two cases of acute myeloid leukemia that resulted in death. Events were felt not to be due to the gene insertion, but were atypical events for SCD patients and will be important to follow closely over the long term as more patients receive these gene therapy treatments. It is also not known whether results from the trial will generalize to a broader population of people with SCD who might not have met trial eligibility criteria.

In considering net health benefit, the marked improvement seen with lovo-cel in a small number of patients with severe SCD needs to be balanced with the potentially severe harms of myeloablative conditioning in SCD and uncertainties about duration of benefit. For people with severe SCD, we conclude that lovo-cel provides at least an incremental net benefit compared with standard of care and may provide a substantial net health benefit. We rate this comparison as “Incremental or Better” ([B+](#)).

Exa-cel presents similar concerns with additional uncertainties given the small number of patients treated to date and that CRISPR therapy is even newer than lentiviral gene therapy. For people with severe SCD, we conclude that compared with standard of care, treatment with exa-cel may be comparable, result in incremental net benefit, or result in substantial net benefit. We rate this comparison as “Comparable or Better” ([C++](#)).

Comparing lovo-cel with exa-cel, we rate the evidence as “Insufficient” ([I](#)). Given the different mechanisms of action, it is possible that future research may identify differences in effectiveness or safety between the two therapies.

We modeled each therapy compared with standard of care over a lifetime time horizon. We assumed identical efficacy for the two therapies given the small number of people studied. At a placeholder price of \$2 million for each therapy, we found the following results from the health care system perspective and the societal perspective.

**Table ES1. Incremental Cost-Effectiveness Ratios for Sickle Cell Gene Therapies**

Treatment	Comparator	Cost per QALY Gained*	Cost per evLY Gained*	Cost per VOC Averted*
<b>Health Care System Perspective</b>				
<b>lovo-cel or exa-cel</b>	Standard of care	\$211,000	\$186,000	\$15,900
<b>Modified Societal Perspective</b>				
<b>lovo-cel or exa-cel</b>	Standard of care	\$180,000	\$158,000	\$13,500

evLY: equal-value life year, QALY: quality adjusted life year, VOC: vaso-occlusive crisis

\*Using a placeholder price of \$2 million.

Although uncertainties about durability and harm remain, both lovo-cel and exa-cel are likely to substantially improve quality and length of life. Ultimately, cost effectiveness will depend on the actual prices for these therapies.

# 1. Background

---

ICER reviewed non-curative therapies for sickle cell disease (SCD) in 2021; much of the background information in this report is updated from that review. SCD is an inherited blood disorder caused by a genetic mutation of the *HBB* gene responsible for the  $\beta$ -globin component of hemoglobin; hemoglobin is the protein in red blood cells that carries oxygen. To have clinically significant disease, a person typically must have two affected copies of the *HBB* allele: either two copies of the specific sickle mutation (HbSS) or one copy with the sickle mutation compounded with another abnormal variant of the *HBB* gene (e.g., sickle beta thalassemia). The resulting abnormal hemoglobin makes red blood cells prone to take on an abnormal sickle shape, particularly when oxygen levels are low in the cell, and also reduces their ability to carry oxygen, which in turn can make sickling worse. This shape is also more rigid and “sticky,” two features that drive the pathophysiology of SCD: vascular obstruction and ischemia; and a shortened lifespan and early destruction (hemolysis) of red blood cells.<sup>6</sup> People with only one copy of HbS and who do not co-inherit other hemoglobin abnormalities do not typically experience these sequelae and are considered to be carriers or have “sickle cell trait.”

The clinical manifestations of microvascular obstruction, ischemia, endothelial damage, and hemolysis can be severe. Acute pain crises, or vaso-occlusive crises (VOCs), are one of the most prevalent manifestations of SCD and the largest driver of morbidity. A substantial proportion of patients experience recurrent, severe, VOCs, averaging several events each year that can lead to hospitalization.<sup>7</sup> Patients can also experience other serious health complications such as acute chest syndrome (a life-threatening pulmonary complication), serious infections, stroke, renal necrosis, and priapism.<sup>3</sup> Chronic complications can emerge across multiple organs and include delayed puberty, avascular necrosis, skin ulcers, chronic pain, neurocognitive impairment, chronic kidney injury, pulmonary hypertension, and cardiovascular disease, and SCD can result in early mortality.<sup>3</sup> Resultant health care costs are high, with the total health system economic burden of SCD estimated at \$2.98 billion per year in the United States (US) with 57% due to inpatient costs, 38% due to outpatient costs, and 5% due to out-of-pocket costs.<sup>4</sup> The incidence of SCD is estimated at 300,000 to 400,000 live births globally per year. In the US, the current best prevalence estimate is approximately 100,000 people with SCD, although comprehensive surveillance and reporting is lacking and the exact number of cases in the US is unknown.<sup>2</sup>

The impact of SCD on quality of life is complex and affects both patients and their caregivers in many ways. In addition to the health-related impact of disease, many other factors further diminish quality of life. The lack of treatment options, discrimination, stigma around the need for acute and chronic pain management, disruption of family and social activities, missed school and/or work all increase the difficulty of living with SCD.<sup>5</sup> We heard from both patients and clinicians that the picture of “baseline” or “usual” care for patients with SCD is highly variable. Deep dysfunction in

care is driven by poor coordination within provider systems and by barriers to access that arise from a broad range of factors including systemic racism, uninformed clinicians, poverty, and insurance systems poorly designed to coordinate coverage for patients with multi-system chronic conditions.

The severity of SCD, even in those with HbSS disease, is variable from patient to patient. One modifier of severity is the amount of other forms of hemoglobin produced, including fetal hemoglobin, which does not include a  $\beta$ -globin component. While production of fetal hemoglobin typically nearly disappears by age one for people without hemoglobin disorders, most SCD patients have some residual fetal hemoglobin expression. The amount of residual fetal hemoglobin is highly variable from patient to patient and higher levels of fetal hemoglobin expression typically result in fewer short- and long-term complications of SCD.

Hydroxyurea is considered the mainstay of treatment for SCD and has been shown to be effective at reducing the number of acute VOCs, reducing chronic complications, and improving quality of life and survival. The exact mechanisms of action of hydroxyurea are not fully understood, but the primary benefits are derived by increasing the fetal hemoglobin content of red blood cells, by altering the adhesion and rigidity of sickled cells, and by reducing neutrophil production. Some people with SCD, particularly those with a history of stroke or other serious complications, may require chronic (lifelong), monthly blood transfusions to prevent additional complications. Many people with SCD require multidisciplinary care and acute and chronic pain management as supportive care for complications related to their SCD. While highly effective, chronic transfusion therapy carries its own risk and expense including iron overload, allo-immunization, problems with vascular access, and rare infectious complications. Newer therapies are available, but they are generally reserved for people with persistent or frequent painful episodes despite hydroxyurea therapy (i.e., l-glutamine [Emmaus], crizanlizumab [Novartis]) or persistent, severe hemolytic anemia (i.e., voxelotor [Global Blood Therapeutics]). We heard from experts that although these therapies may also be an alternative for people with SCD who do not want to take hydroxyurea, their uptake in clinical practice is still quite low and we previously found that the prices of these newer therapies are not aligned with their clinical benefits.<sup>8,9</sup>

Hematopoietic stem cell transplantation (HSCT) is currently the only potentially curative treatment for SCD. Ideally, HSCT is performed with a human leukocyte antigen (HLA)-matched sibling donor. When performed at a younger age (<14 years of age) and with a sibling match, the five-year event-free-survival is likely 95% or higher for transplants performed in recent years.<sup>10,11</sup> However, graft-versus-host disease (GVHD) is still a serious risk, many patients do not have a compatible sibling-matched donor (preferred option), and the risks of HSCT increase with age.<sup>12</sup>

Lovotibeglogene autotemcel (“lovo-cel,” bluebird bio) and exagamglogene autotemcel (“exa-cel,” Vertex Pharmaceuticals and CRISPR Therapeutics) are transformative gene therapies with the potential for clinical cure of SCD. Lovo-cel works by using a modified virus (lentivirus vector) to insert a functioning version of the *HBB* gene into the patient’s own stem cells. This is accomplished

by retrieving stem cells from the patient’s blood, engineering them outside of the body, and then transplanting the cells with functioning *HBB* back into the body. The patient must receive myeloablative chemotherapy to prepare the bone marrow to receive the corrected cells and to produce new red cells with normal  $\beta$ -globin/hemoglobin. A closely related product for beta thalassemia was recently reviewed in another [ICER report](#). Exa-cel employs similar procedures (e.g., autologous transplantation of modified cells), but rather than relying on a viral vector to insert a functioning gene, it utilizes a gene editing approach using CRISPR-based technology to turn off one of the genes known to suppress fetal hemoglobin and thus increase the amount of fetal hemoglobin in red blood cells. The manufacturer of exa-cel submitted its Biologics License Application to the Food and Drug Administration (FDA) in April 2023 and the manufacturer of lovo-cel is expected to submit in the first half of 2023.

**Table 1.1. Interventions of Interest**

<b>Intervention</b>	<b>Mechanism of Action</b>	<b>Delivery Route</b>
Lovotibeglogene autotemcel (lovo-cel)	Lentiviral addition of anti-sickling Hb, HbAT87Q	IV infusion following myeloablative conditioning chemotherapy
Exagamlogene autotemcel (exa-cel)	CRISPR/Cas9 gene-edited cell therapy targeting BCL11A to increase fetal Hb	IV infusion following myeloablative conditioning chemotherapy

Hb: hemoglobin, IV: intravenous

## 2. Patient and Caregiver Perspectives

---

This report was developed with input from diverse stakeholders, including patients and their families, clinicians, researchers, and manufacturers of the agents of focus in this review and incorporates feedback gathered during calls with stakeholders. We have included patient and caregiver perspectives from ICER’s 2021 report on non-curative therapies for SCD, updated with new insights from additional stakeholder input. ICER looks forward to continued engagement with stakeholders throughout its review and encourages comments to refine our understanding of the clinical effectiveness and value of preventive treatments.

---

*“SCD is long overdue for a treatment and cure. It is buried in years of racial discrimination and to this day, health care professionals treat based on assumptions not science. We need new drugs and treatments. [It’s] about time we matter.” – Parent of a person living with SCD*

---

### An All-Encompassing Condition

Patients, family members, clinicians, and other members of the sickle cell community conveyed that for someone without SCD, it is hard to understand the physical, emotional, and mental toll of SCD. Pain crises are an enormous burden to the patient not only when they are happening, but due to their accumulated negative impact over the years. It is a danger to minimize the impact of the condition by characterizing it as pain crises alone because of the cumulative multitude of adverse effects that impact both physical and mental health.<sup>13</sup> The range of acute adverse effects of SCD include painful crises, but also life-threatening events such as strokes and blood clots. These acute effects also contribute to long-term risks for additional major organ dysfunction such as congestive heart failure and liver failure.<sup>14</sup> Other health effects such as chronic pain also play an enormous role in daily living. In addition to both acute and chronic effects on almost every major organ system, there is an enormous impact on quality of day-to-day life.

People living with SCD and others emphasized that there is truly an all-encompassing biopsychosocial impact of disease that is hard to capture, particularly in the setting of research. People with SCD not only described intense fatigue, anxiety, and depression, but at

---

*“SCD is extremely unpredictable, even for the most aware patient. There is such a stigma that I feel from having this disease, wanting to do so much and contributing to society and yet I am limited from achieving many of my hopes and dreams.” – Person living with SCD*

---

times extreme hopelessness. One person told us that pursuing a curative option allowed them to

“give up on giving up.” The condition presents challenges at home, school, work, and social relationships.<sup>15</sup> People with SCD often end up on formal disability programs, which unfortunately carry stigma.

This is not to say that people with SCD are unable to function at a high level in society, but that the challenges and the barriers faced are distinct from other chronic health conditions. One of the most important perspectives we learned from the SCD community was that SCD remains a misunderstood and marginalized condition. To fully appreciate the potential benefits of new treatments, a broad appreciation for the impact of SCD on the lives of patients and their families must be achieved and must be kept front and center when making judgments about the value of these treatments.

---

*“Day to day is hard. [We] are in pain a lot and our energy levels are low. We just want to be treated like the next. We are not lazy, we want fairness.”*  
– Person living with SCD

---

## Stigma and Limitations on Daily Life

People living with SCD may appear healthy. An outward appearance of wellbeing can present additional barriers to appropriate care and contribute to social stigmas surrounding the disease. A general lack of awareness about the disease among nurses, hospitalists, and society at large means that healthy-looking people with SCD suffering from an acute pain crisis, acute chest syndrome, or other SCD-related complication may not be taken seriously. Patients presenting at the emergency room may be made to wait longer before receiving attention.<sup>16,17</sup> One particularly concerning anecdote that was recorded in the FDA’s *Voice of the Patient* report described a child who was sent back to class by the school nurse after suffering a central nervous system event because he was “deemed unruly.”<sup>5</sup> We also heard patient testimony of young men being called “perverts” because they were experiencing priapism. Misperceptions about appearance, coupled with a lack of SCD awareness in broader communities, can lead to bias both in and out of the health care setting. People living with SCD who are unable to participate in their daily commitments at work or school due to insurmountable fatigue, pain, or other complications may be accused of laziness or subject to bullying. Children and their caregivers felt SCD challenged their ability to perform well in school and work.<sup>15</sup> Chronic daily pain, fatigue, and the sudden onset of acute pain crises increase absenteeism make it difficult to concentrate, disrupt school and social interactions, and create a lot

---

*“My son feels very isolated by sickle cell, and I know he thinks he prevents our family from doing many things because so much of the year we have to stay indoors. He loves to visit places where the temperature is nice and he can easily be outside.”*  
– Parent of a person living with SCD

---



of stress and anxiety. SCD can cause neurocognitive impairment; some people with the disease have reported difficulty remembering tasks, retaining what they learn in school, and difficulty staying engaged and focused on school activities.<sup>18-20</sup> Some children reported frustration and social isolation from limitations on their ability to participate in physical activities, travel on long flights, play outside in cold weather, or swim in unheated water. One person with SCD who had undergone curative therapy told us that they now enjoy winter sports and swimming, something unimaginable before treatment. Although SCD is an inherited condition, a lack of societal awareness about the disease leads some people to hide their diagnoses so their peers will not misperceive them as contagious.

---

*“To improve health care access, the sickle cell community is faced with the awesome task of trying to rewrite the dominant narratives about their patients whose genetic disease marks them in the US as quintessentially Black. This narrative presumes that sickle cell patients are socially dysfunctional, dependent on narcotics, and poorly educated or, worse, uneducable. Knowing only a patient’s race or ethnicity, even a well-meaning doctor may make presumptions that influence how he or she communicates with and medically treats a patient.”<sup>1</sup> – Rouse, 2009*

---

Family members described the tremendous responsibility of caregiving, including the need to leave the work force to provide care for their loved ones while facing the impact of lost wages and significant out-of-pocket expenses. Adults with SCD reported difficulty in maintaining employment because of frequent, unexpected, or prolonged absences due to acute SCD-related events. Some people with SCD and their family members described making decisions to avoid marriage to maintain health insurance or forego having children to avoid passing on the gene to the next generation. We heard from a number of stakeholders that mental health issues such as depression, anxiety, and suicidal thoughts are common; such statements are corroborated in the clinical literature.<sup>13,15,21</sup>

## **Racial Bias**

We heard consistently from people with SCD, family members, clinicians, and other members of the sickle cell community that the experience of living with SCD and all aspects of its treatment are mired in racism. Although SCD affects people of different races and ethnicities, it has historically been viewed in the US as a “Black disease.”<sup>1,22</sup> Racism and implicit bias presents substantial obstacles to care in what is already a condition with high morbidity and mortality.<sup>1</sup>

We heard frustration from the sickle cell community about the lack of investment in research or comprehensive treatment centers that might increase access to better treatment, improve health outcomes, and reduce other disparities faced by SCD patients and their families. Historically, SCD has been underfunded with no breakthroughs or developments in two decades. Although the

populations of people living with other severe hereditary conditions such as cystic fibrosis are significantly smaller than that of SCD, these conditions often receive greater funding for research and treatment. Cystic fibrosis, for example, affects approximately 30,000 people in the US (vs. about 100,000 with SCD) and receives seven to 11 times the amount of funding per patient.<sup>16,23,24</sup> Structural racism as well as implicit bias affect the allocation of resources toward research, health care delivery, and quality improvement.<sup>25,26</sup>

## **Pain Relief**

Racial bias and treatment disparities for people with SCD have been well documented, particularly when it comes to pain management. Patients who present at emergency departments may experience delays in treatment and diagnosis as well as inadequately treated pain.<sup>1,16,27-30</sup> We heard from some people that they dress in professional attire while in crisis before going to the emergency department in an effort to avoid categorization as drug-seeking. People with SCD expressed a hesitancy to reveal any familiarity with pain regimens they know to be effective out of fear they would be denied relief and labeled as drug-seeking. We heard that many adults with SCD have an advocate accompany them on visits to an emergency department to increase their chance of receiving appropriate treatment for pain.

Health inequity in the management of pain is compounded by racial bias and stigma of the condition itself, including beliefs about opioid use and addiction. A survey of more than 100 physicians who care for people with SCD suggested that provider attitudes toward substance use disorders can have negative implications for patients, including undertreatment of pain and discrediting a patient's report of pain severity.<sup>16,28</sup> Furthermore, a 2014 study of attitudes toward patients with SCD among 215 emergency department providers (nurses and physicians) found that relative to physicians who have less frequent and shorter interactions with patients, nurses had greater levels of negative attitudes toward patients with SCD; nurses expressed more frustration in caring for patients, estimated a higher prevalence of opioid use disorders among patients, and reported less unease with the ways in which their colleagues treated patients.<sup>16,29</sup>

The ongoing opioid epidemic has further complicated a person's ability to access pain medicine, as doctors have grown increasingly wary of prescribing opioids. Many state laws, payer coverage policies, and hospital protocols follow "one size fits all" approaches to pain management, which limit dosing or cease dispensing after a predetermined period of time, irrespective of whether a person's pain is adequately managed. The recently revised Clinical Practice Guideline for Prescribing Opioids for Pain (2022) from the Centers for Disease Control specifically excludes SCD, acknowledging the important role of opioids in pain management and the dangers of inadequate pain management. In addition, the Centers for Medicare and Medicaid Services recently issued a policy to recommend that Medicare beneficiaries with SCD be exempt from opioid safety

restrictions; similar exemptions have been recommended in some state Medicaid programs, although such policies will not improve patient access if provider attitudes do not also change.<sup>16,31,32</sup>

## Lack of Specialists and Optimal Treatment

People with SCD lamented that education and awareness among clinicians (even among hematologists) is severely lacking. Patients commonly receive care from generalists, emergency nurses, and hospitalists who may be less equipped to help them manage their disease.<sup>16,33,34</sup> We heard repeated concerns that there were not enough doctors and other medical providers who are adequately trained in the management of SCD, particularly for adults. A national survey of over 3,000 family physicians revealed that only 20% of respondents felt comfortable treating SCD.<sup>33,34</sup>

---

*“Most of us aren’t coming into the hospitals until the pain is at ridiculous levels because we hate feeling judged all the time. I don’t know what these doctors are being taught, but it seems compassion ain’t part of the curriculum! [...] Most times when describing my pain I don’t look at them at all, because if I do and I see that apathetic or judge-y, doubtful look on they face it makes me instantly regret coming in. It’s hard because they want you to give eye contact, speak clearly and be so detailed, all of which are incredibly hard when you in pain [...]. I’ve felt like I had to put on a show when I was younger because if I said I’m an 8, 9, or 10 without crying or writhing in pain, they’d never believe me. It was obvious they didn’t believe it by how long it would take me to get my medication, or all the tests I’d be forced to take before getting anything for pain.” – Person living with SCD*

---

Clinical experts and people with SCD alike commented that incompetent care can be catastrophic; we heard several anecdotes about deaths that might have been prevented had the person received care from a more knowledgeable provider. People with SCD are conscious of the deaths and irreversible damage that result from long wait times in the emergency room as well as the increased mortality from events that occur in the hospital; they reported feeling intense anxiety and stress about going to the hospital, sometimes delaying, or avoiding seeking necessary care. We also heard that some people experience post-traumatic stress disorder following severe episodes of illness.

Among non-specialist providers, we heard there is often the misperception that SCD is a pain condition. This oversimplification can lead to inappropriate care of the disease’s many complications. In the emergency room, treatment with fluids, oxygen, and other medicines may be lacking and patients may not be appropriately triaged. One caregiver, who was not a trained clinician, told us about needing to adjust a person’s oxygen level while in the hospital out of fear that inadequate attention from the attending providers would prove fatal.

---

*“Too often sickle cell patients are marginalized, treated with stereotypical idealism and inherent bias that ultimately leads to them avoiding going for help or simply not receiving it in their greatest time of need, during the VOC. This leads to many damaging side effects including death but more so the damage taking place in their bodies while they are lingering in an untreated state of ongoing necrosis taking place throughout their bodies!” – Person living with SCD*

---

While the management of pediatric patients with SCD has improved dramatically in recent years, the transition from pediatric to adult care coincides with a period of high risk for many people as SCD often worsens during the late teens/early twenties. There is a significant shortage of adult care providers with the requisite knowledge and skill set. People with SCD described the difficulty they faced trying to navigate a very different system of care and recounted a worsening of health as a result of limited access to multidimensional care. Because of the course of SCD, there is a sharp increase in mortality following the transition from pediatric to adult care.<sup>35,36</sup>

This problem is magnified in smaller cities, towns, and rural areas where people report needing to travel several hours to see a specialist, participate in a clinical trial, or access treatment through compassionate use

---

*“Finding a great doctor that knows information about sickle cell is like finding a needle in a haystack.” – Person living with SCD*

---

programs. People with SCD were anxious that the retirement of a community’s only specialist would lead to a spike in SCD mortality. A retired specialist from California, Dr. Keith Quirolo, provided sobering statistics about the severe shortage of sickle cell hematologists: in the state of California, there are only about five physicians who specialize in the treatment of SCD for every 7,000 residents living with the condition.<sup>33</sup>

## **Attitude Toward Gene Therapies**

There is consensus in the SCD community about the dire need for disease-modifying drugs and curative therapies. Over the past several years, few treatment options aside from analgesia were available. Enthusiasm for gene therapy stems from not only interest in a cure, but also concerns about current treatments’ effectiveness, accessibility, and side effects (e.g., running to the bathroom from gastrointestinal side effects of L-glutamine, hair loss from hydroxyurea). Stakeholders identified the importance of community engagement in the research and development of new therapies, but key challenges were noted including inherent trust issues between members of the SCD community and the clinical/research community, challenges identifying members of the SCD community to participate in engagement, inconsistency with definitions of SCD variants between the research community and SCD community, and lack of longitudinal data collection regarding people and disease progression.

---

*“The quality of life for most sickle cell patients is a life of extreme suffering from pain and rejection of medical care. We are stigmatized as drug seekers because there are hardly any tools a care provider can offer us but pain killers. Life is painful and frustrating, and we have few choices in our options for care.” – Person living with SCD*

---

There is cautious optimism about gene therapies that may soon become available. One person with SCD described her feelings as both “joy and apprehension” – joy at the prospect of a cure and apprehension related to a new therapy with unknown long-term effects. We spoke with people who had received

curative treatment (either HSCT or gene therapy as part of a trial) and they all cited life-changing improvements in their health and quality of life. While they acknowledged that there was risk and uncertainty with curative therapies, they felt that their health had deteriorated to a point that potential benefit far outweighed potential risks.

People living with SCD and their families worry about being able to afford the treatment itself and other costs associated with treatment such as fertility preservation. It is possible also that there are other financial costs that are unknown at this time. People with SCD expressed concern that high drug prices may cause insurance policies to implement barriers to access. People are concerned that doctors will not know enough about the new therapies and that many people with this condition do not live in areas where they will have ready access to emerging gene therapies. Both patients and clinicians expected gene therapies to be available only at major medical centers or centers of excellence. People also wonder whether they will be eligible for treatment with these new treatments. We heard from some people with SCD that they fear they will be too old or have too much organ damage to be candidates for gene therapy.

Finally, stakeholders emphasized the importance of multidisciplinary care. New therapies need to be integrated into treatment plans that care for the whole patient. Care coordination across different systems and payers was underscored as a huge area of unmet need.

## 3. Comparative Clinical Effectiveness

---

### 3.1. Methods Overview

Procedures for the systematic literature review assessing the evidence on lovo-cel and exa-cel for the treatment of severe SCD are described in [Supplement Section D1](#). A research protocol is published on Open Science Framework and registered with PROSPERO (CRD42023385515).

#### Scope of Review

We reviewed the clinical effectiveness of lovo-cel and exa-cel versus standard of care for the treatment of severe SCD. We also intended to compare lovo-cel to exa-cel via any evidence directly comparing the two therapies or by indirect comparisons of key outcomes. We sought evidence on patient-important outcomes, including resolution of VOs, health-related quality of life, and adverse events. The full scope of the review is described in [Supplement Section D1](#).

#### Evidence Base

##### *lovo-cel*

Our evaluation of lovo-cel consists of two trials, HGB-205 and HGB-206. Upon completion of these trials (~two years), participants were eligible to enroll in a long-term follow-up study, LTF-307.

HGB-205 was a Phase I/II proof of concept trial that evaluated lovo-cel infusion in three patients with SCD. HGB-206 is the pivotal Phase I/II trial of lovo-cel for the treatment of severe SCD. Changes to the treatment protocol and enrollment criteria resulted in three study cohorts: Group A, B, and C ([see Supplement Table A1](#)). Patients in the Group C cohort underwent a revised method of stem cell collection to enhance the transduction process in order (plerixafor mobilization and apheresis vs. bone marrow harvesting), thereby improving gene insertion such that later cohorts received a greater cell dose than earlier cohorts, including patients in the HGB-205 trial. bluebird bio is seeking approval for lovo-cel in the US on the basis of clinical data from Group C and as such, efficacy and safety data from this cohort will be the primary focus of this review.

Trial participants of HGB-206 were aged 12 to 50 with severe SCD ( $\beta\text{S}/\beta\text{S}$ ,  $\beta\text{S}/\beta\text{0}$ , or  $\beta\text{S}/\beta\text{+}$  genotype) (Table 3.1). Group C required a minimum of four severe VOs in the 24 months prior to enrollment; this was a more stringent eligibility criterion that was implemented after several participants had already been enrolled. Therefore, not all Group C members had a baseline of four or more severe VOs. Trial participants were also required to have had an intolerance to hydroxyurea or occurrence of VOs despite hydroxyurea treatment as well as an ability to carry out normal activities of daily living with some assistance. Participants were ineligible for the trial if they had a

willing, matched HLA-identical sibling hematopoietic cell donor. A history of overt stroke was later added to the study exclusion criteria; five participants had received infusion of lovo-cel prior to the protocol amendment.

A total of 36 Group C patients received lovo-cel infusion; participants had a median age of 24 years and experienced a median of 3.5 severe VOEs per year in the two years prior to trial enrollment.<sup>37,38</sup> Additional trial enrolment criteria and baseline characteristics are outlined in [Supplement Tables D4 and D5](#).

HGB-210 is an ongoing single-arm multi-site Phase III trial of lovo-cel in patients ages two to 50 with severe SCD with an estimated study completion date of September 2025 ([see Supplement Table D12](#)). The number of participants in the trial and the duration of the follow-up period was not adequate to be incorporated into the evidence base.

LTF-307 is a long-term follow-up study that will evaluate the safety and efficacy of lovo-cel in participants continuing from trials HGB-205, 206, and 210 for an additional 13 years.

**Table 3.1. Overview of Pivotal lovo-cel Clinical Study**

Trial	Study Design	Population	Key Baseline Characteristics
HGB-206	Phase I/II, single-arm, open-label, nonrandomized trial  Follow-up: 24 months	People aged 12 to 50 with severe SCD ( $\beta\text{S}/\beta\text{S}$ , $\beta\text{S}/\beta\text{0}$ , or $\beta\text{S}/\beta+$ genotype)  Group A N=7 Group B N=2 Group C N=36	<u>Group C Cohort:</u> Median age (range): 24 (12-38) Female sex: 37% $\beta\text{S}/\beta\text{S}$ genotype: 100% Annualized incidence VOEs in last 24 months, median (range): 3.5 (0.5-13.5) Total Hb, median: 8.5 g/dL

dL: deciliter, g: gram, Hb: hemoglobin, N: total number, SCD: sickle cell disease, VOE: vaso-occlusive event

### ***exa-cel***

The pivotal trial of exa-cel is CLIMB-121, an ongoing single-arm Phase I/II/III trial of 31 participants. Persons ages 12-35 with severe SCD and a history of greater than two VOCs per year in the two years before screening were enrolled.<sup>39</sup> Patients who had an available HLA-matched related donor, prior HSCT, or clinically significant active infection were excluded from this study. The estimated study completion date is October 2024; efficacy and safety data are reported using a data cut-off of February 2022. Additional trial information can be found in [Supplement Tables D4 and D6](#).

Patients who have completed the two-year follow-up period of CLIMB-121 are eligible for a long-term follow-up study, CLIMB-131.

**Table 3.2. Overview of Pivotal exa-cel Clinical Study**

Trial	Study Design	Population	Key Baseline Characteristics
<b>CLIMB-121</b>	Phase I/II/III, single-arm, open-label, nonrandomized trial  Follow-up: 24 months post-transplant	People with severe SCD and a history of $\geq 2$ VOCs per year in 2 years before screening  N=31	Mean age (range): 22.5 (12-34) Female sex: 48.4% $\beta S/\beta S$ genotype: 93.5% $\beta S/\beta 0$ genotype: 6.5% Severe VOC in last 24 months, mean (range): 3.9 (2-9.5) Total Hb, mean: 9.1 g/dL

dL: deciliter, g: gram, Hb: hemoglobin, N: total number, SCD: sickle cell disease, VOC: vaso-occlusive crisis

## 3.2. Results

### Clinical Benefits

#### *Primary Outcomes*

The primary outcome for both interventions was the proportion of trial participants who were free of VOE/VOCs post-treatment (Table 3.3). Both study outcomes included the occurrence of acute chest syndrome, splenic sequestration, and priapism in their definition of an acute pain episode. A visit to a medical facility was a component in both severe outcomes.

While there are similarities in the outcome definitions between lovo-cel and exa-cel, a few differences are noted. The definition of a severe VOC in the exa-cel trial was more broadly inclusive as compared to the severe VOE in the lovo-cel trial, which included a time component as a measure of severity. A non-severe occurrence of a VOC was not measured in the exa-cel CLIMB-121 trial. While the lovo-cel protocol did not include reference to the administration of pain medication and red blood cell transfusions in their definition of a severe VOE, these treatments are assumed to be included in standard practices.



**Table 3.3. Definitions of Primary Study Outcomes**

	<b>exa-cel CLIMB-121<sup>40</sup></b>	<b>lovo-cel HGB 206<sup>37</sup></b>
<b>VOC/VOE</b>	Not defined/measured in trial	VOE is defined as an episode of acute pain with no medically determined cause other than a vaso-occlusion and included acute episodes of pain, ACS, acute hepatic sequestration, acute splenic sequestration, and acute priapism
<b>Severe VOC/VOE</b>	Severe VOC is defined as any one of the following: <ul style="list-style-type: none"> <li>• Acute pain event that requires a visit to a medical facility and administration of pain medications (opioids or IV NSAIDs) or RBC transfusions</li> <li>• ACS, as indicated by presence of new pulmonary infiltrate associated with pneumonia-like symptoms, pain, or fever</li> <li>• Priapism lasting &gt;2 hours</li> <li>• Splenic sequestration</li> </ul>	Severe VOE is defined as any one of the following: <ul style="list-style-type: none"> <li>• A visit to a hospital or ED that exceeded 24 hours</li> <li>• At least 2 visits to day unit or ED during a 72-hour period (with both visits requiring IV treatment)</li> <li>• Priapism episode lasting more than 2 hours and leading to a medical-facility visit</li> </ul>

ACS: acute chest syndrome, ED: emergency department, IV: intravenous, NSAID: non-steroidal anti-inflammatory drug, RBC: red blood cell, VOC: vaso-occlusive crisis, VOE: vaso-occlusive event

lovo-cel

*Frequency of Vaso-Occlusion/Pain Events*

The primary efficacy endpoint of HGB-206 was the proportion of Group C trial participants who achieved complete resolution of VOEs between six and 18 months after lovo-cel infusion. A VOE was defined as “an episode of acute pain with no medically determined cause other than a vaso-occlusion and included acute episodes of pain, acute chest syndrome, acute hepatic sequestration, acute splenic sequestration, and acute priapism.” In an unplanned interim analysis of HGB-206 trial data using a data cut-off of February 2021, nine of 10 trial participants (90%) were VOE-free between six and 18 months of follow-up (Table 3.3). Patients experienced a reduction in the annualized rate of VOEs, from a median baseline of four VOEs (min-max: 2 to 14.5) to zero (0 to 5.9) post-infusion.

Patients were also assessed for the resolution of *severe* VOEs: an episode of pain requiring a visit to a medical facility. A more recent analysis of the HGB-206 Group C cohort that used a data cut-off date of August 2022 demonstrated that 30 of 31 patients (96.8%) of trial participants were free of severe VOEs between six and 18 months of follow-up.<sup>38</sup> The median annualized rate of severe VOEs was reduced from a baseline of three (min-max: 0.5 to 13.5) to zero (0 to 0.5).

Academic-in-confidence data was provided by the manufacturer on other related outcomes of pain; the average number of annualized hospital days and hospital admissions among Group C trial participants was reduced at 24 months post-infusion (data on file).

**Table 3.4. Key Trial Results of Iovo-cel (HGB-206 Group C)**

Outcomes		N	HGB-206
Number of Subjects Achieving Complete Resolution of VOEs Between 6 Months and 18 Months After Drug Product Infusion, n (%)		10*	9 (90)
Number of Subjects Achieving Complete Resolution of Severe VOEs, Between 6 Months and 18 Months After Drug Product Infusion, n (%)		31	30 (96.8)
Time to Neutrophil Engraftment, Median (Range) Days		35	20 (12-35)
Time to Platelet Engraftment, Median (Range) Days		35	36 (18-136)
Total Hb Level, Median g/dL	At Baseline	22	8.5
	At 6 Months	32	11.5
	At 12 Months	31	12
	At 18 Months	22	12.1
	At 24 Months	16	11.7
Hb <sup>AT87Q</sup> Fraction in Non-Transfused Total Hb, Median %	At 6 Months	32	47
	At 12 Months	31	45
	At 18 Months	22	44
	At 24 Months	16	45

d: deciliter, g: gram, Hb: hemoglobin, n: number, N: total number, NA: not applicable, VOE: vaso-occlusive event

\*The denominator of this proportion was calculated using data from the interim analysis of Group C participants in Figure 3B of the Kanter et al. NEJM publication.<sup>37</sup> At the time of analysis (data cut-off February 17, 2021), only 10 participants had reached a post-infusion follow-up time of 18 months.

#### *Additional Patient-Important Outcomes*

Group C HGB-206 trial participants were assessed for improvements in quality of life across three measures: the PRO Measurement Information System-57, pain intensity numeric rating scale, and the EuroQoL-5D-3L Health Utility Index. These instruments are described in greater detail in [Supplement A1](#).

Analysis of PRO Measurement Information System-57 and pain intensity numeric rating scale outcomes was limited to 25 Group C participants who had a follow-up of up to 24 months ([see Supplement Table D9](#)).<sup>41</sup> There was a mean improvement at last follow-up in all domains except for anxiety.

Data on the EuroQoL-5D-3L Health Utility Index was provided in confidence by bluebird bio for Group C HGB-206 trial participants ages 16 and up; there was an increase in the mean Index at 24 months post-transplant compared to baseline (data on file).

The impact of Iovo-cel on Group C HGB-206 trial participants' employment was assessed using the Work Productivity and Activity Impairment Questionnaire: General Health; the number of work

hours missed due to health problems and total number of weekly work hours were improved from baseline throughout 36 months of follow-up (data on file).

The lovo-cel clinical development program did not measure several patient-important outcomes identified in our scope ([see Supplement D1](#)): cognitive effects, cardiovascular events, hearing or vision loss, caregiver burden and pregnancy complications, and sexual dysfunction. Organ damage and infertility were measured but were unavailable for analysis.

### *Hematological Response*

All patients in the Group C cohort of HGB-206 successfully achieved neutrophil and platelet engraftment at a median of 20 and 36 days, respectively (Table 3.4). Trial participants experienced an increase in total hemoglobin levels from a median baseline of 8.5 gram per deciliter (g/dL) to greater than 11 g/dL through 24 months of follow-up.

HbS is an abnormal hemoglobin type that distorts the shape of red blood cells (sickle shaped), causing a blockage of blood flow and subsequent clinical complications. Levels of HbS as a percentage of all non-transfused hemoglobin were maintained at a level of approximately 50% post-infusion of lovo-cel from month three throughout month 24; unfortunately, the baseline percentage of HbS of trial participants is unknown and thus the exact suppressive effect of lovo-cel on HbS levels is uncertain.

HbA<sup>T87Q</sup> is a modified adult hemoglobin with anti-sickling properties; after infusion of lovo-cel, the median percentage of HbA<sup>T87Q</sup> was greater than 40% of all non-transfused hemoglobin by month three and was sustained throughout 24 months of follow-up.<sup>42</sup> Expression of HbA<sup>T87Q</sup> at a level of 20-30% is hypothesized to meet the minimum threshold of preventing clinical manifestations and complications of SCD.<sup>42</sup> As of February 2021, an average of 85% of red cells contained HbA<sup>T87Q</sup> by 24 months (n=10).<sup>37</sup>

In the interim analysis of Group C HGB-206 trial data, four markers of hemolysis (the breakdown of red blood cells) were reported (reticulocyte count, and levels of haptoglobin, lactate dehydrogenase, and total bilirubin) and generally showed a trend towards normalization, approaching levels observed in a healthy population.<sup>37</sup>

### *exa-cel*

#### *Frequency of Vaso-Occlusion/Pain Events*

The primary efficacy endpoint of CLIMB-121 was the proportion of participants who had not experienced any severe VOCs for at least 12 consecutive months. A severe VOC was defined as an acute pain event requiring administration of pain medication, anemia requiring red blood cell transfusion at a medical facility, acute chest syndrome, priapism lasting greater than two hours, or

splenic sequestration. This was measured from the 60 days after a person's last red blood cell transfusion up to two years after exa-cel infusion.

The mean incidence of severe VOC per year during the two-year period before screening was 3.9 (range: 2-9.5). Of the 31 participants enrolled, seven participants had 12 months of follow-up at the February 2022 data-cutoff. All seven participants remained severe VOC-free.<sup>39</sup>

### *Additional Patient-Important Outcomes*

We are aware that quality of life measures including a weekly pain scale, the EuroQol quality-of-life scale, EQ-5D-Youth scale, functional assessment of cancer therapy-bone marrow transplant, adult sickle cell quality-of-life measurement system, pediatric quality-of-life inventory, and pediatric quality-of-life SCD module are being measured in the CLIMB-121 trial but the data are not publicly available at this time.

We also set out to look additional for patient-important outcomes outlined in our scope, but we did not identify data on chronic pain, fatigue, cognitive effects, mental health effects (e.g., depression, anxiety), cardiovascular events, hearing or vision loss, organ damage, infertility and pregnancy complications, sexual dysfunction, or ability to work or attend school.

### *Hematological Response*

All patients had successful neutrophil and platelet engraftment at a median of 27 (range: 15-37) and 32 (range: 23-74) days, respectively. The median time to last red blood cell transfusion was 19 days (range: 11-52).

Hemoglobin levels were assessed in the entire study population, without regard to the duration of follow-up. However, owing to the limited follow-up and the small size of the sample, the number of participants evaluated at each time point decreased, with only a single patient being evaluated after 24 months. At baseline, the mean hemoglobin level was 9.1 g/dL (n=30). The hemoglobin level increased to 12.1 g/dL at three months (N=25) and remained consistent through month 15 (n=6). However, by month 30, the total hemoglobin concentration had declined to 10.6 g/dL (n=1) ([see Supplement Table D8](#)).<sup>43</sup>

BCL11A is a transcription factor that suppresses fetal hemoglobin in adult cells and editing BCL11A results in increased expression of fetal hemoglobin.<sup>44</sup> Fetal hemoglobin is a modulator of disease severity in SCD. The proportion of edited BCL11A alleles in bone marrow CD34+ HSPCs was 86.6% (n=7) and was 76% (n=17) in peripheral blood mononuclear cells.<sup>43</sup>

Patients had clinically meaningful increases in fetal hemoglobin, defined by an absolute increase to >30%, a threshold that has been hypothesized as a curative target.<sup>45-47</sup> Fetal hemoglobin accounted for 5.1% of the overall hemoglobin at baseline (n=30). The mean proportion of fetal hemoglobin

reached above 30% by month three and was maintained throughout the trial.<sup>39</sup> However, to date, hemolysis data have not been presented and this was considered by clinical experts to be a key component of understanding the clinical relevance of fetal hemoglobin levels.

At baseline, the mean proportion of HbS as a percentage of total hemoglobin was 63.5% (n=30). After exa-cel infusion, levels of HbS were substantially reduced but were stabilized in the low 50s from month five (n=17) and beyond.

## Harms

### *lovo-cel*

All patients in the Group C cohort of HGB-206 experienced at least one adverse event following lovo-cel infusion, many of which were consistent with background SCD and expected events associated with ASCT and myeloablative conditioning. More than half of Group C participants experienced a grade  $\geq 3$  adverse event of stomatitis, thrombocytopenia, and neutropenia ([see Supplement Table D10](#)).

One case of a grade 2 febrile neutropenia was deemed by investigators to be related to lovo-cel infusion; two other adverse events (one grade 2 leukopenia and one grade 1 decreased diastolic blood pressure) were deemed to be possibly treatment-related. All three safety events were resolved within a week of onset.

One death occurred in the HGB-206 Group C cohort; a 27-year-old trial participant with severe baseline SCD (29 VOs in two years prior to trial enrollment) and cardiopulmonary disease experienced a cardiac arrest at 20 months after lovo-cel infusion.<sup>37</sup> This death was attributed to cardiac fibrosis and other chronic cardiopulmonary organ injury and deemed to be unrelated to lovo-cel treatment. Two deaths in an earlier HGB-206 cohort are outlined in greater detail below.

### *Potential Risk of Hematologic Malignancies*

Of note are two instances in which the FDA placed a partial clinical hold on the lovo-cel clinical development program due to safety concerns surrounding hematologic malignancies.

Myelodysplastic syndrome and acute myeloid leukemia are two hematological malignancies that can develop from abnormal blood cell production in the bone marrow. Patients with SCD have an increased risk of developing both myelodysplastic syndrome and acute myeloid leukemia compared to the general population, even outside of myeloablative transplant settings.<sup>48,49</sup> The risk of developing these diseases may also be associated with gene therapy with  $\gamma$ -retroviral vectors and myeloablation with an alkylating agent.<sup>50</sup>

In February of 2021, bluebird bio announced a temporary suspension of trials HGB-206 and HGB-210 due to observed instance of acute myeloid leukemia in two Group A HGB-206 participants.<sup>51,52</sup> The first case of acute myeloid leukemia was diagnosed in 2018 in a patient who received an initial diagnosis of myelodysplastic syndrome three years after lovo-cel infusion; this patient was 42 years old at trial consent.<sup>50</sup> This case of acute myeloid leukemia was fatal.<sup>51</sup> A second patient was diagnosed at the age of 31, approximately 5.5 years after lovo-cel infusion and later died from complications of progressive acute myeloid leukemia.<sup>53</sup> Both cases of acute myeloid leukemia were hypothesized to be related to the baseline risks of SCD and inherent risks of myeloablative conditioning associated with the gene therapy.<sup>53-55</sup> It is important to underscore that although the malignancies were not due to genetic manipulation, chemotherapy and myeloablation is a required precursor to the receipt of gene therapy. This clinical hold was lifted in June of 2021.<sup>56</sup>

In December of 2021, a partial hold was placed on enrollment of patients under 18 into lovo-cel trials due to the potential occurrence of myelodysplastic syndrome in two patients (one adolescent, one adult) in the Group C cohort. Both diagnoses of myelodysplastic syndrome were later revised to persistent anemia.<sup>37</sup> Both participants were found to have two  $\alpha$ -globin deletions ( $-\alpha 3.7/-\alpha 3.7$ ); this alpha thalassemia mutation is hypothesized by bluebird bio to have been the cause of the anemia and has been added to study exclusion criteria for ongoing trials.<sup>38,57</sup> The partial clinical hold was lifted in December of 2022.<sup>58</sup>

### ***exa-cel***

The short median follow-up (10.2 months; range: 2.0-32.3) of patients in CLIMB-121 adds uncertainty and precludes us from making a comprehensive review of the safety profile of exa-cel. As of February 2022, all patients reported grade 3/4 adverse events, all patients reported adverse events related to busulfan conditioning, and nine patients (29%) reported adverse events related to exa-cel treatment. Serious adverse events were reported in 10 patients (32.3%). There were no reported discontinuations or malignancies, though follow-up time is very limited.<sup>39</sup> One patient presented with pneumonia and respiratory failure. This resulted in death and investigators attributed it to a SARS-CoV-2 infection and potentially related to a busulfan lung injury.<sup>39</sup> We learned that at least one patient treated with exa-cel has required ongoing phlebotomy to manage polycythemia.

### ***exa-cel in Other Populations***

Because of limited data, we also reviewed the safety profile of exa-cel in other populations. The CLIMB THAL-111 trial, which evaluated the safety and efficacy of exa-cel in patients with transfusion-dependent beta thalassemia (n=44), reported two patients (4.5%) with serious adverse events related to exa-cel. One patient reported three serious adverse events (hemophagocytic lymphohistiocytosis, acute respiratory distress syndrome, and headache) related to exa-cel treatment and idiopathic pneumonia related to busulfan conditioning. The other patient

experienced delayed neutrophil engraftment and thrombocytopenia following the intervention (i.e., conditioning and exa-cel). All serious adverse events were resolved.<sup>39</sup>

## Subgroup Analyses and Heterogeneity

Limited trial sample size prevented evaluation of the heterogeneity of treatment effect based on age, genotype, or other factors.

## Uncertainty and Controversies

The small sample sizes of the trials of lovo-cel and exa-cel creates uncertainty around the estimates of some of the clinical outcomes, including both efficacy and safety. Given the magnitude of the benefit (e.g., proportion of patients free of VOCs/VOEs) observed for both therapies across the trials, there is high certainty that gene therapies are frequently successful in treating SCD at least in the short run. It is less certain how these therapies will perform in a real world setting and specifically how those therapies might generalize to a broader population beyond the eligibility criteria of a clinical trial. Generalizability outside of the trial setting was a concern raised by clinical experts who estimated that only small proportion (<15%) of people living with severe SCD might satisfy trial criteria.

However, there is much more uncertainty around significant harms such as myelodysplastic events and even mortality. Even though the trials had few participants, two serious hematologic malignancies (both resulting in death) occurred in the trials of lovo-cel and there was one death in the exa-cel trial (attributed to chemotherapy related lung injury and COVID-19). The former is thought not to be due to mutations from the gene therapy itself, but rather the risks of myeloablative chemotherapy in a higher risk patient population. Across all populations, the risk of the chemotherapeutic condition confers some risk of mortality. In addition, clinical experts told us that the risk of malignancy following chemotherapy may be higher in patients with SCD. Other adverse events such as infertility may require more than a decade to assess. Lastly, adverse events often occur more frequently when a therapy is used outside the careful monitoring of a clinical trial.

There is evidence with lovo-cel that some patients continued to have episodes of acute pain during follow-up and it is likely that trials of exa-cel will observe similar treatment response when more participants achieve follow-up milestones. It is also unlikely that gene therapy will modify existing chronic complications (e.g., kidney disease, chronic pain from avascular necrosis). In addition to a small sample, the length of follow-up translates into uncertainty of the durability of treatment effect. Gene therapy experts told us that long-term follow-up (>15 years) is required to establish precision around durability of the treatment effect.

The trials of lovo-cel and exa-cel compared patients after treatment to their results at baseline. They were not directly compared to each other or to curative treatment with allogenic HSCT.


Although trials only included patients who were unable to undergo sibling-matched allogeneic HSCT, it is uncertain whether clinicians and patients will routinely prefer HSCT in patients with a matched sibling donor.

The two gene therapies have substantially different mechanisms of action. Differences in the definitions of outcomes (VOEs vs. VOCs, severe vs. non-severe), reporting of data, and small differences in the enrolled trial population make head-to-head comparisons difficult.

### 3.3. Summary and Comment

An explanation of the ICER Evidence Rating Matrix (Figure 3.1) is provided [here](#).

Figure 3.1. ICER Evidence Rating Matrix



- A = "Superior" - High certainty of a substantial (moderate-large) net health benefit
- B = "Incremental" - High certainty of a small net health benefit
- C = "Comparable" - High certainty of a comparable net health benefit
- D = "Negative" - High certainty of an inferior net health benefit
- B+ = "Incremental or Better" - Moderate certainty of a small or substantial net health benefit, with high certainty of at least a small net health benefit
- C+ = "Comparable or Incremental" - Moderate certainty of a comparable or small net health benefit, with high certainty of at least a comparable net health benefit
- C- = "Comparable or Inferior" - Moderate certainty that the net health benefit is either comparable or inferior with high certainty of at best a comparable net health benefit
- C++ = "Comparable or Better" - Moderate certainty of a comparable, small, or substantial net health benefit, with high certainty of at least a comparable net health benefit
- P/I = "Promising but Inconclusive" - Moderate certainty of a small or substantial net health benefit, small (but nonzero) likelihood of a negative net health benefit
- I = "Insufficient" - Any situation in which the level of certainty in the evidence is low



Given the marked improvement seen with lovo-cel in a small number of patients with severe SCD and the experience with essentially the same gene therapy in beta thalassemia, we have high certainty that there are substantial short-term improvements in clinical symptoms in the vast majority of patients treated. We have uncertainties about the duration of benefit and the frequency of severe harms that have occurred with myeloablative conditioning as well as theoretical less frequent harms such as insertional oncogenesis from the gene insertion itself. Given the severity of disease in the patients being considered for treatment and the rate of treatment success, we think that despite uncertainties around durability and harms, lovo-cel provides at least an incremental net benefit compared with standard of care and may provide a substantial net health benefit. For treatment of severe SCD, we rate lovo-cel compared with standard of care as “Incremental or Better” (B+).

Exa-cel presents similar concerns around duration of benefit and harms including those due to myeloablative conditioning and oncogenesis from CRISPR. Although all seven patients treated experienced resolution of severe VOCs, this very small sample size leads to a much wider confidence interval around the success rate than the situation with lovo-cel. Additionally, we are aware that at least one of the seven patients requires ongoing phlebotomy to manage polycythemia. Given these greater uncertainties, we feel that compared with standard of care, treatment with exa-cel may be comparable, result in incremental net benefit, or result in substantial net benefit. For treatment of severe SCD, we rate exa-cel compared with standard of care as “Comparable or Better” (C++).

Comparison of the therapies to each other is made difficult by the issues raised above around sample size and duration, the different mechanisms of action, and the even more limited experience with CRISPR in humans than with lentiviral gene therapies. Comparing lovo-cel with exa-cel, we rate the evidence as “Insufficient” (I).

**Table 3.5. Evidence Ratings**

Treatment	Comparator	Evidence Rating
<b>Adolescents and Adults with Severe SCD</b>		
lovo-cel	Standard of care (e.g., hydroxyurea, chronic blood transfusions, pain medication, iron chelation)	B+: Incremental or Better
exa-cel	Standard of care (e.g., hydroxyurea, chronic blood transfusions, pain medication, iron chelation)	C++: Comparable or Better
lovo-cel	exa-cel	I: Insufficient

SCD: sickle cell disease

## 4. Long-Term Cost Effectiveness

---

### 4.1. Methods Overview


The primary aim of this analysis was to estimate the lifetime cost effectiveness of lovo-cel and exa-cel for eligible patients with severe SCD using decision-analytic modeling. As stated in the [revised scope](#), the population of focus is adolescents and adults with severe SCD who do not have a matched sibling donor or haploidentical donor for HSCT or are too old for safe HSCT. There is no generally accepted classification of SCD severity; in the studies of the agents under review, patients were required to have a minimum of four severe VOCs in each of the prior two years.

A *de novo* Markov model was developed in Microsoft Excel 2016 to compare each treatment to standard of care using a lifetime horizon. The model estimates outcomes that include life years gained, quality-adjusted life years (QALYs) gained, equal-value life years (evLY) gained, SCD complications, VOCs avoided, and total costs for each intervention over a lifetime time horizon. All costs and outcomes were discounted at 3% per year. Consistent with our prior SCD assessment, we used a co-base case that takes a health care sector perspective (i.e., focuses on direct medical care costs only) as well as a modified societal perspective that also includes productivity changes and caregiver costs ([see Supplement Table E1](#) for an inventory of items included in the health care sector and modified societal perspective analyses). We took a co-base case as the societal costs of care for SCD are large relative to the direct health care costs and the impact of treatment on these costs is substantial (i.e., there are substantial differences in the cost-effectiveness findings between the two perspectives). In this case, the incremental cost-effectiveness ratio from the two perspectives changes by greater than 20% for both of these therapies. Also, as in the clinical evidence review, the comparative value analyses followed the [Single and Short-Term Treatment Value Framework adaptations](#) including the addition of the conservative and optimistic scenarios as well as the shared savings analyses.

The model (Figure 4.1) focused on an intention-to-treat analysis with a hypothetical cohort of patients with severe SCD entering the model. Model cycle length was one year, based on what was observed in prior published economic models/clinical data. The model focused on key acute and chronic complications as well as risk of death. The acute and chronic complications considered in the model are listed in Table 4.1. Age-dependent annual probabilities were used to estimate the proportion of patients with acute and chronic complications each year. Patients remained in the model until death, and the patients transitioned to death based on age-dependent annual mortality probabilities. All complications were modeled independently of each other. Treatments that avoid or reduce acute and chronic complications will improve patients' health and may reduce health care costs. Evidence for avoidance or reduction of VOCs was sourced directly from the trials.<sup>1,2</sup> As there is no direct evidence of avoidance or reduction of acute and chronic complications from the trials,

trial data on VOCs and other supporting outcomes was used to estimate the treatment effect on these complications.

**Figure 4.1. Model Structure**



SCD: sickle cell disease

**Table 4.1. Acute and Chronic Conditions Included in the Model**

Acute	Chronic
VOCs	Avascular necrosis
Acute chest syndrome	Chronic kidney disease
Acute infections (bacteremia and sepsis)	Heart failure
Acute kidney injury	Liver complications
Gallstones	Pulmonary hypertension
Leg ulcers	Retinopathy
Pulmonary embolism	Chronic lung disease
Stroke	Neurocognitive impairment
Myocardial infarction	Pain and fatigue
	Post-stroke

VOC: vaso-occlusive crisis

## 4.2. Key Model Assumptions and Inputs

Below is a list of key model choices:

- Model framework:** We chose a cohort-level *de novo* Markov model rather than a patient-level simulation after consultation with stakeholders. The cohort-level model is appropriate for incorporating the available evidence and allows flexibility in exploring different scenarios.
- Population:** In the base-case analysis, the model used patient characteristics similar to patients with severe SCD enrolled in Medicaid, and the population was categorized into adolescents and adults.

- **Comparator:** We chose to focus on standard of care as the comparator. We did not include HSCT as a comparator in the model as HSCT is expected to be prioritized in cases where a matched sibling donor is available.
- **Treatment effectiveness:** After feedback on the [model analysis plan](#), we chose to anchor successful gene therapy treatment effectiveness for acute, chronic, and mortality events based on general population rates as well as rates for people with SCD who experience no VOCs. Details are provided below, but generally, all complication and mortality rates for all modeled ages are no lower than the US general population rates but are no higher than rates for people with SCD who experience no VOCs. For acute events and for all events modeled for the adolescent subpopulation, the modeled rates for successful gene therapy were below those observed for people with SCD who experience no VOCs. For chronic events and mortality after successful gene therapy for adults were assumed to be consistent with people with SCD who experience no or limited VOCs.

Our model included several assumptions stated on the following page in Table 4.2.

**Table 4.2. Key Model Assumptions**

<b>Assumption</b>	<b>Rationale</b>
A proportion of patients were assumed to die in the first model cycle due to the acute risk associated with transplant.	The model included a 1.4% risk of death from infusion work for gene therapy in line with ICER’s beta thalassemia report, <sup>59</sup> and this value was tested in sensitivity and scenario analyses
Costs for patients who start the process of pre-transplant assessments and preparation but do not proceed with treatment are included in the model.	Preparation for transplant (e.g., assessments, tests, visits) incur additional costs that should be accounted for in the model.
The model included an evidence-based estimate of treatment failure in the first model cycle.	Where the trial data shows a proportion of patients still with VOCs after treatment, this is modeled assuming that these patients have the same rate of complications and mortality as those on standard care.
After year seven, patients on both gene therapies revert to costs and outcomes of standard care at a rate used in ICER’s beta thalassemia report <sup>59</sup>	The long-term durability of treatment effect is unknown. The uncertainty in the durability of treatment effect was also heard from clinical experts and patient stakeholders.
The cycle length of the model was one year.	Given the chronic nature of SCD, a cycle length of one year is expected to appropriately capture health outcomes and costs and allow for sufficient flexibility to explore our planned sensitivity and scenario analyses.
Some patients have chronic complications at the start of the model.	Some chronic complications will have occurred by the age at the start of the model and the prevalence of these complications were sourced from published literature.
The risk of complications and death in the model were populated using data for Medicaid patients.	While some SCD patients have commercial insurance (with lower risk of complications) or Medicare (with higher risk of complications), most of the SCD patients are covered by Medicaid and, as such, the model was populated using data for Medicaid patients.

Assumption	Rationale
All complications (i.e., acute [except VOCs] and chronic) and death were modeled independent of each other.	We used the most relevant robust data sources to model the risk of complications and mortality, which already account for any interdependencies. As the aim is to estimate the cost effectiveness at a population level, this approach is appropriate.
VOC rates are correlated with rates of acute and chronic complications of interest, and mortality.	We used published data on hazard ratios for the complications of interest between SCD patients with zero VOCs and those with 3+ VOCs. Similar approach was also used for mortality rates.
Treatment effect in reducing the VOCs were used to model the impact on risk of complications.	Treatment success was measured as proportion of patients without VOCs, and these patients were modeled with lower risks of acute, chronic complications and mortality.
For chronic complications and mortality, the hazard ratios for adults are different from the adolescents to account for organ damage in the adult population.	Adult patients on SCD are assumed to already accumulate some organ damage before receiving the gene therapy and as such, the treatment effectiveness in reducing chronic complications and mortality is assumed to be lower for adults compared to adolescents (who are less likely to accumulate organ damage).
Health state disutility values were used to estimate QALY losses for acute and chronic complications.	QALY decrements for acute complications were estimated considering the short duration of the disutilities. Chronic complications were assumed to last for lifetime (i.e., until death).
Additive approach was used to estimate the QALYs.	Additive approach was used to estimate the health-related quality of life of patients with multiple complications, to reflect modeling of the complications independently.
For model inputs with no evidence-based specified uncertainty range, we assumed parametric distributions to reflect the uncertainty.	Inclusion of parameter uncertainty within one-way and probabilistic analysis allows for a reasonable characterization of uncertainty.

ICER: Institute for Clinical and Economic Review, QALY: quality-adjusted life year, SCD: sickle cell disease, VOC: vaso-occlusive crisis

**Population**

The population of focus for the economic evaluation consisted of adolescents and adults with severe SCD, defined as having a minimum of four severe VOCs in each of the two prior years and clinically eligible to undergo bone marrow conditioning and who do not have an HSCT matched donor. In the base case, the model used patient characteristics for Medicaid enrollees with severe SCD as shown in Table 4.3, and the population was categorized into adolescents and adults. Although the proportion of adolescents who chose to receive gene therapy may differ from the assumed proportion (28%), we note that 28% is actually higher than the observed percentage studied in the clinical trials. Given known relationships with evidence, higher proportions of adolescent use, all else being equal, may lead to lower incremental cost-effectiveness findings.

**Table 4.3. Baseline Population Characteristics**

Baseline Characteristic	Value	Source
Mean Age	20.5 years (SD 6)	Mahesri et al 2022 <sup>3</sup>
Proportion Female	54.4%	Mahesri et al 2022 <sup>3</sup>
Proportion of Adolescents	28%	Assuming normal distribution (20.5, 6)
Proportion of Adults	72%	Assuming normal distribution (20.5, 6)
Mean Age for Adolescents	15 years	Assuming normal distribution (20.5, 6)
Mean Age for Adults	24 years	Assuming normal distribution (20.5, 6)

SD: standard deviation

## Interventions

The list of interventions was developed with input from patient organizations, clinicians, manufacturers, and payers. The full list of interventions is as follows:

- lovo-cel (bluebird bio)
- exa-cel (Vertex and CRISPR Therapeutics)

## Comparator

The comparator for each intervention was standard of care. The incidence rates of complications for patients on standard of care are presented in [Supplement E](#).

## Modeling Treatment Effectiveness

The primary measure of clinical efficacy was reduction in VOCs consistent with the key endpoint in the trials, and treatment success was measured as proportion of patients without VOCs. The model included a proportion of patients with treatment failure in the first cycle based on those in the trial that continued to have VOCs after treatment, and these patients were modeled to have the same rate of complications and mortality as those on standard care. The proportion of patients achieving treatment success was estimated as 96.8% for both therapies, based on the data from the lovo-cel pivotal trial that suggested 30 out of 31 have no further VOCs. Given the small sample size in the exa-cel trial (n=7), this success rate of 96.8% was also used for exa-cel and the higher uncertainty for exa-cel was reflected in the parametric distribution used for probabilistic sensitivity analysis.

For the patients who do not have any VOCs after gene therapy, hazard ratios were applied to rates of complications for patients on standard care (details are presented in [Supplement E](#)). The hazard ratios for death and acute and chronic complications are estimated using the hazard ratios estimated from published literature (for those with zero VOCs vs. those with 3+ VOCs) with a multiplier on top to capture the additional benefit of gene therapy treatment. The hazard ratio multipliers are different for death, acute and chronic complications based on the age of treatment (i.e., adolescents or adults). Clinical experts suggested that the patients achieving treatment

success on gene therapy are likely to be better than those who had zero VOCs, as such, the hazard ratios estimated from published literature (for patients with zero VOCs vs. 3+ VOCs) were multiplied by 0.5 for all patients for acute complications, and adolescents for chronic complications. The hazard ratio multiplier of 0.5 to estimate the hazard ratios for patients achieving treatment success on gene therapy can be considered as being an average of the hazard ratios for the general population (likely to be close to zero) and the hazard ratios of the patients with zero VOCs compared to those with 3+ VOCs. For chronic complications in adults, the hazard ratios were used directly without any adjustment to account for organ damage in the adult population. That is, in the base case, the hazard ratio multipliers for acute complications are 0.5 for both adults and adolescents while for death and chronic complications, the hazard ratio multipliers are 0.5 for adolescents and 1 for adults. In the model, whilst the baseline rates change when adolescents who go on to become adults (i.e., higher baseline rates of complications are applied when they are over 18), the lower hazard ratios are applied throughout the lifetime (i.e., even after they become adults) as they received the gene therapy while they were adolescents.

The long-term durability of treatment effect is unknown, and this uncertainty in the durability of treatment effect was also heard from clinical experts and patient stakeholders. As such, after year seven, patients on both gene therapies revert to costs and outcomes of standard care at the annual rate of 0.27% used in [ICER's beta thalassemia report](#).<sup>9</sup>

## Health State Utilities

Health state utilities in the model were populated using data from published literature. A recent systematic review by Jiao et al. 2022 was used to identify the sources that best reflect the utilities for US SCD patients eligible for gene therapy.<sup>12</sup> We used consistent health state utility values across treatments evaluated in the model.

The utility value for uncomplicated SCD (i.e., without any complications) is assumed to be 0.80 based on Anie et al. 2012,<sup>60</sup> in line with the previous ICER report.<sup>13</sup> For intervention-related disutility, we used disutility estimated based on Matza et al. 2020, which is assumed to last for one year.<sup>14</sup> We included an additional increase in utility of 0.05 for patients without VOCs after gene therapy to account for the reduction in standard of care day-to-day management including those who receive transfusions based on evidence reviewed from stakeholders and evidence or assumptions made from other gene therapy assessments. This additional increase in utility may be considered an optimistic assumption given this additional utility for gene therapies is separate from the utility benefits of reduced VOCs and complications (which are incorporated separately in the model), potentially double counting the utility benefits.

**Table 4.4. Health State Utilities**

	Utility	Source
<b>SCD Without Complications</b>	0.80	Anie et al. 2012 <sup>13</sup>
<b>Disutility Due to Gene Therapy (for 1 Year)</b>	-0.11	Matza et al. 2020 <sup>14</sup>
<b>Additional Utility for Patients on Gene Therapy Without VOCs</b>	0.05	Assumption

SCD: sickle cell disease, VOC: vaso-occlusive crisis

Disutilities of complications were sourced from Sullivan et al. 2006<sup>61</sup> as reported in [Supplement Table E15](#). The QALY losses for acute complications were estimated considering their short duration and the QALY losses for chronic complications were estimated assuming they last for lifetime (i.e., until death). An additive approach was used to estimate the QALYs to reflect modeling of the complications independently.

## Cost Inputs

All costs used in the model are in 2022 dollars. Details of the costs are presented in [Supplement E](#). For the VOC costs, we used data from Shah et al 2020<sup>62</sup> who report the average cost of VOCs across the different settings (i.e., inpatient, emergency room, outpatient, and office).

## Treatment Costs

There are no prices available yet for lovo-cel and exa-cel. As such, a placeholder value of \$2 million was assumed based on [analyst estimates](#), pending further discussions with the manufacturers around the price and potential for outcomes-based agreements.

**Table 4.5. Treatment Costs**

Drug	Anticipated Acquisition Cost*
lovo-cel	\$2,000,000
exa-cel	\$2,000,000

\*Placeholder value based on [analyst estimates](#).

## Societal Perspective Inputs

A modified societal perspective is included as a dual base case, using estimates of the cure of SCD on patient productivity and caregiver costs. For patient productivity estimates, we used the proportional decrease in annual median income of 34.1% estimated from Graf et al. 2022<sup>63</sup> (who suggest that patients cured from SCD have an annual salary of \$38,618 and having SCD decreased the annual salary to \$25,442 as a result of decreased productivity and different earnings trajectory due to SCD-related health crises and hospitalizations, along with decreased life expectancy and decreased opportunity to pursue education) and applied it to the median wage of US population of \$56,420.<sup>64</sup> This resulted in annual lost patient productivity of \$19,250, which was applied to all



adults in the standard of care arm, and these costs were assumed to be eliminated after successful treatment with gene therapy. Some clinical experts suggested that the proposed approach to modeling lost productivity may be optimistic due to lost opportunities to pursue education (for certain adults) as well as other barriers.

For caregiver estimates, we used Holdford et al. 2021 who estimate the annual losses in unpaid work as \$19,662 per caregiver.<sup>19,20</sup> Caregiver costs were applied for all adolescents in the standard of care arm, and as above, these costs were assumed to be eliminated after successful treatment with gene therapy.

## Model Outcomes

Model outcomes include total life years gained, QALYs gained, evLYs gained, and total costs for each intervention over a lifetime horizon. The model outcomes also include total VOCs as well. Total costs, life years, QALYs, and evLYs gained are reported as discounted values, using a discount rate of 3% per annum (undiscounted results are presented in [Supplement E](#)). Incremental analyses report the cost per evLY gained, cost per QALY, and cost per VOC avoided.

## Model Analysis

The model estimated the average survival, quality-adjusted survival, drug cost, complication cost, and number of acute complications per patient. Time spent in each health state was summed to provide estimates of life expectancy and quality-adjusted life expectancy. Long-term estimates of costs, QALYs, evLYs gained, and life years were discounted at 3% per year following ICER guidelines, to account for the opportunity cost of current spending and preference for current over future benefits. A more detailed description of evLY calculations can be found in [Supplement E](#).

Cost effectiveness was estimated using the incremental cost-effectiveness ratios (including cost per evLY gained and cost per QALY), with incremental analyses comparing lovo-cel and exa-cel to standard of care. The base-case analysis used a co-base case that takes a health care sector perspective (i.e., focused on direct medical care costs only) as well as a modified societal perspective that also includes productivity changes and caregiver costs.

## Sensitivity Analyses

We conducted one-way sensitivity analyses to identify the impact of parameter uncertainty and key drivers of model outcomes. Probabilistic sensitivity analyses were performed by jointly varying all model parameters over the 1,000 simulations, then calculating 95% credible range estimates for each model outcome based on the results. We also performed threshold analyses for drug costs across a range of incremental cost-effectiveness ratios (\$50,000, \$100,000, \$150,000, and \$200,000 per QALY and evLY gained).

## Scenario Analyses

We conducted numerous scenario analyses to assess the robustness of the results across alternative model assumptions and in accordance with the modifications to the ICER value framework for ultra-rare diseases and single and short-term therapies. We include the details and results of scenario analyses below, including the optimistic and conservative benefit scenario, a 50/50 shared savings scenario, and a cost-offset cap scenario. Additional scenario analyses are presented in [Supplement E5](#).

- 1) A) Optimistic and B) conservative assumptions regarding the benefit of treatment presented in conjunction with the base case.
- 2) 50/50 shared savings in which 50% of lifetime health care cost offsets from a new treatment are assigned to the health care system instead of being assigned entirely to the new treatment.
- 3) Cost-offset cap in which health care cost offsets generated by a new treatment are capped at \$150,000 per year but are otherwise assigned entirely to the new treatment.

## 4.3. Results

### Base-Case Results

The total discounted costs, VOCs, QALYs, life years, and evLYs over the lifetime time horizon for the health care system perspective and modified societal perspective are detailed in Tables 4.6 and 4.7, respectively.

**Table 4.6. Results for the Base Case for Iovo-cel Compared to Standard Care**

Treatment	Treatment Cost*	Other Costs	Total Cost*	VOCs	QALYs	Life Years	evLYs
<b>Health Care System Perspective</b>							
Iovo-cel	\$2,000,000	\$823,104	\$2,823,104	3.28	16.38	21.87	17.31
Standard of Care	--	\$1,389,660	\$1,389,660	93.53	9.60	15.80	9.60
<b>Modified Societal Perspective</b>							
Iovo-cel	\$2,000,000	\$833,454	\$2,833,454	3.28	16.38	21.87	17.31
Standard of Care	--	\$1,613,715	\$1,613,715	93.53	9.60	15.80	9.60

evLY: equal-value life year, QALY: quality-adjusted life year, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

**Table 4.7. Results for the Base Case for exa-cel Compared to Standard Care**

Treatment	Treatment Cost*	Other Costs	Total Cost*	VOCs	QALYs	Life Years	evLYs
<b>Health Care System Perspective</b>							
exa-cel	\$2,000,000	\$823,104	\$2,823,104	3.28	16.38	21.87	17.31
Standard of Care	--	\$1,389,660	\$1,389,660	93.53	9.60	15.80	9.60
<b>Modified Societal Perspective</b>							
exa-cel	\$2,000,000	\$833,454	\$2,833,454	3.28	16.38	21.87	17.31
Standard of Care	--	\$1,613,715	\$1,613,715	93.53	9.60	15.80	9.60

evLY: equal-value life year, QALY: quality-adjusted life year, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

Tables 4.8 and 4.9 present the incremental cost-effectiveness ratios (which include estimates for the incremental cost per QALY gained, incremental cost per life year gained, incremental cost per evLY gained, and incremental cost per VOC averted for the base-case analysis from the health care system perspective and modified societal perspective), for lovo-cel and exa-cel respectively.

**Table 4.8. Incremental Cost-Effectiveness Ratios for the Base Case for lovo-cel vs. Standard Care**

Treatment	Comparator	Cost per QALY Gained*	Cost per Life Year Gained*	Cost per evLY Gained*	Cost per VOC Averted*
<b>Health Care System Perspective</b>					
lovo-cel	Standard of care	\$211,000	\$236,000	\$186,000	\$15,900
<b>Modified Societal Perspective</b>					
lovo-cel	Standard of care	\$180,000	\$201,000	\$158,000	\$13,500

evLY: equal-value life year, QALY: quality-adjusted life year, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

**Table 4.9. Incremental Cost-Effectiveness Ratios for the Base Case for exa-cel vs. Standard Care**

Treatment	Comparator	Cost per QALY Gained*	Cost per Life Year Gained*	Cost per evLY Gained*	Cost per VOC Averted*
<b>Health Care System Perspective</b>					
exa-cel	Standard of care	\$211,000	\$236,000	\$186,000	\$15,900
<b>Modified Societal Perspective</b>					
exa-cel	Standard of care	\$180,000	\$201,000	\$158,000	\$13,500

evLY: equal-value life year, QALY: quality-adjusted life year, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

## Sensitivity Analyses


To demonstrate the effects of uncertainty on both costs and health outcomes, we varied input parameters using available measures of parameter uncertainty (i.e., standard errors where available or reasonable ranges) to evaluate changes in findings.

We conducted one-way sensitivity analyses to vary one input parameter at a time across its plausible range for the health care system and the modified societal perspective. Figures 4.2 and

4.3 below present this information graphically by way of a tornado diagram for the health care system perspective for lovo-cel and exa-cel, respectively. Sensitivity analysis demonstrates that, for both treatments, the cost of the VOCs, the utility of patients successfully treated with gene therapy, and the annual number of VOCs are the major drivers of cost per QALY (Figures 4.2 and 4.3). In addition, given the greater uncertainty around the treatment success rate of exa-cel due to the small sample size in the exa-cel trial (n=7), this was also a major driver of cost per QALY for exa-cel as seen in Figure 4.3.

The hazard ratios for death, acute, and chronic complications are estimated as a hazard ratio estimated from published literature (for those with zero VOCs vs. those with 3+ VOCs) with a multiplier added on top to capture the additional benefit of gene therapy treatment. The hazard ratio multipliers are different for death, acute and chronic complications based on the age of treatment (i.e., adolescents or adults). In the base case, the hazard ratio multipliers for acute complications are 0.5 for both adults and adolescents while for death and chronic complications, the hazard ratio multipliers are 0.5 for adolescents and 1 for adults. Given the large number of complications, the hazard ratio multipliers are varied in the one-way sensitivity analysis rather than incorporating all the individual hazard ratio parameters for each of the nine acute complications, 10 chronic complications, and death.


**Figure 4.2. Tornado Diagram for lovo-cel (Health Care System Perspective)**



QALY: quality-adjusted life year, SCD: sickle cell disease, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

**Figure 4.3. Tornado Diagram for exa-cel (Health Care System Perspective)**



QALY: quality-adjusted life year, SCD: sickle cell disease, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

A probabilistic sensitivity analysis was conducted to vary all inputs with noted uncertainty simultaneously, and the results are presented in [Supplement E](#). From a health care system perspective, both lovo-cel and exa-cel had 0% probability of being cost effective at a threshold of \$150,000 per QALY (and lower) while at a threshold of \$200,000 per QALY, lovo-cel had a 27% probability of being cost effective and exa-cel had a 21% probability of being cost effective. When using a modified societal perspective, lovo-cel had 6% probability of being cost effective while it was 5% for exa-cel at a threshold of \$150,000 per QALY, and there is a substantial change at a threshold of \$200,000 per QALY with an 86% probability of being cost effective for lovo-cel and a 74% probability of being cost effective for exa-cel.

## Scenario Analyses

### ***Scenario Analysis 1: Optimistic and Conservative Benefit Scenarios***

Optimistic and conservative assumptions regarding the benefit of treatment with lovo-cel or exa-cel were performed to reflect the uncertainty in the clinical data. Details of the scenarios are provided in [Supplement E](#). In the base-case analysis, we chose to anchor successful gene therapy treatment effectiveness for acute, chronic, and mortality events to be between the general population rates and the patients with SCD who experience no VOCs. If the complication and mortality rates in the gene therapy arm are closer to the US general population rates, then the gene therapies are likely to have an incremental cost effectiveness of around \$150,000 per QALY and below \$150,000 per evLY gained from the health care system perspective. However, if the complication rates for

patients in the gene therapy arm are similar to patients with severe SCD who experience no VOCs, then the gene therapies are likely to have an incremental cost effectiveness above \$250,000 per QALY and \$200,000 per evLY gained from the health care system perspective.

**Table 4.10. Scenario Analysis Results for the Optimistic and Conservative Benefit Scenarios**

Treatment	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained	Cost per VOC Averted
<b>Health Care System Perspective</b>					
<b>Base Case</b>	Standard of care	\$211,000	\$236,000	\$186,000	\$15,900
<b>Optimistic</b>	Standard of care	\$152,000	\$167,000	\$137,000	\$14,500
<b>Conservative</b>	Standard of care	\$269,000	\$279,000	\$225,000	\$16,700
<b>Modified Societal Perspective</b>					
<b>Base Case</b>	Standard of care	\$180,000	\$201,000	\$158,000	\$13,500
<b>Optimistic</b>	Standard of care	\$127,000	\$140,000	\$115,000	\$12,200
<b>Conservative</b>	Standard of care	\$231,000	\$239,000	\$193,000	\$14,300

evLY: -qual value life year, QALY: quality adjusted lifeyears, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

### **Scenario Analysis 2: 50/50 Shared Savings Scenario**

A 50/50 shared savings scenario analysis was undertaken in which 50% of lifetime health care and non-health care (for the modified societal perspective) cost offsets from lovo-cel or exa-cel are assigned to the health care system instead of being assigned entirely to the treatment. Results are presented in Table 4.11.

**Table 4.11. Scenario Analysis Results for the 50/50 Shared Savings Scenario**

Treatment	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained	Cost per VOC Averted
<b>Health Care Perspective</b>					
<b>lovo-cel or exa-cel</b>	Standard of care	\$266,000	\$298,000	\$234,000	\$20,000
<b>Modified Societal Perspective</b>					
<b>lovo-cel or exa-cel</b>	Standard of care	\$256,000	\$286,000	\$225,000	\$19,300

evLY: equal-value life year, QALY: quality-adjusted life year, VOC: vaso-occlusive crisis

\*Placeholder value based on [analyst estimates](#).

### **Scenario Analysis 3: Cost-Offset Cap Scenario**

A cost-offset cap scenario analysis was undertaken in which health care and non-health care (for the modified societal perspective) cost offsets generated are capped at \$150,000 per year but are otherwise assigned entirely to the treatment. Cost offsets did not exceed \$150,000 in any modeled year; therefore, results are aligned with the base-case findings.

## Threshold Analyses

Threshold analyses were conducted to identify at what price lovo-cel or exa-cel would meet certain cost-effectiveness thresholds. Tables 4.12 and 4.13 present the findings from these threshold analyses for the health care system perspective and modified societal perspective using outcomes of both the QALY and evLY, respectively. The prices presented in Table 4.12 do not include costs for workup and preparation, transplant, or post-transplant monitoring costs and therefore represent threshold prices for lovo-cel acquisition alone.

**Table 4.12. QALY-Based Threshold Analysis Results**

Treatment	Placeholder Price per Unit	Unit Price to Achieve \$50,000 per QALY Gained	Unit Price to Achieve \$100,000 per QALY Gained	Unit Price to Achieve \$150,000 per QALY Gained	Unit Price to Achieve \$200,000 per QALY Gained
<b>Health Care System Perspective</b>					
lovo-cel or exa-cel	\$2,000,000	\$900,000	\$1,240,000	\$1,580,000	\$1,920,000
<b>Modified Societal Perspective</b>					
lovo-cel or exa-cel	\$2,000,000	\$1,110,000	\$1,450,000	\$1,790,000	\$2,130,000

QALY: quality-adjusted life year

\*Excludes workup and preparation, transplant, or post-transplant monitoring costs. Unit price represents the placeholder value for the full acquisition cost of lovo-cel per patient.

**Table 4.13. evLY-Based Threshold Analysis Results**

Treatment	Placeholder Price per Unit	Unit Price to Achieve \$50,000 per evLY Gained	Unit Price to Achieve \$100,000 per evLY Gained	Unit Price to Achieve \$150,000 per evLY Gained	Unit Price to Achieve \$200,000 per evLY Gained
<b>Health Care System Perspective</b>					
lovo-cel or exa-cel	\$2,000,000	\$950,000	\$1,330,000	\$1,720,000	\$2,100,000
<b>Modified Societal Perspective</b>					
lovo-cel or exa-cel	\$2,000,000	\$1,160,000	\$1,550,000	\$1,930,000	\$2,320,000

evLY: equal-value life year

\*Excludes workup and preparation, transplant, or post-transplant monitoring costs. Unit price represents the placeholder value for the full acquisition cost of lovo-cel per patient.

## Model Validation

We used several approaches to validate the model. First, we provided preliminary model structure, methods and assumptions to manufacturers, patient groups, and clinical experts. Based on feedback from these groups, we refined data inputs used in the model, as needed. Second, we varied model input parameters to evaluate face validity of changes in results. We performed model verification for model calculations using internal reviewers. As part of ICER's efforts in acknowledging modeling transparency, we also offered to share the model with the relevant manufacturers for external verification around the time of publishing the draft evidence report for

this review. Finally, we compared results to other cost-effectiveness models in this therapy area. The outputs from the model were validated against the trial/study data of the interventions and any relevant observational datasets.

## Uncertainty and Controversies

There have been several publications on SCD in the past couple of years, including on the rate of complications,<sup>65-68</sup> costs,<sup>69</sup> utilities,<sup>70</sup> and conceptual modelling<sup>63,71-73</sup> with a number of them published by the Sickle Cell Clinical and Economic Impact Consortium (including the University of Washington and Fred Hutch Research Center) from their research funded by the National Institutes of Health National Heart, Lung, and Blood Institute. These publications have been instrumental in supporting the development of the cost-effectiveness model as well as assisting to address some of the uncertainties involved in modeling SCD. However, evidence uncertainties remain in estimating a SCD gene therapy's impact on day-to-day quality of life and acute, chronic, and fatal SCD-associated events.

Salcedo et al 2021<sup>63,71-73</sup> estimated the cost effectiveness of a hypothetical single-administration durable treatment for SCD provided at birth, assuming a “fully effective” cure (i.e., no disease-related complications and costs) along with life expectancy and health-related quality of life of general population. Their base-case incremental cost-effectiveness ratio of \$140,877 per QALY relative to standard of care, using a one-off cost of \$2.1 million for the durable treatment, is lower than that estimated from our cost-effectiveness model. This difference is expected as the durable treatment was assumed to be given at birth (thus accumulating benefits over the whole lifetime) along with the optimistic assumptions around a complete cure in Salcedo et al 2021.<sup>63,71-73</sup>

The population of focus for the assessment is patients living with severe SCD, who are defined as having an average of four VOCs each year in the past two years. In the model, the patients on standard care were assumed to have four VOCs per year that required health care use until death (around 93 VOCs over the whole lifetime) while those who were successfully treated with gene therapy were assumed to have no VOCs, which resulted in substantial cost offsets in the treatment arm. The cost per VOC was estimated as \$5,762 as the average cost of VOCs across the different (i.e., inpatient, emergency room, outpatient, and office) settings. If the number of VOCs or cost per VOC in real practice is lower than the values used in the model, this would result in an increase in the incremental cost-effectiveness ratios of gene therapies compared to standard of care.

Estimating the lifetime health outcomes and costs of gene therapies required assumptions and were conducted under conditions of evidence uncertainty. As shown in the scenario analyses, the cost-effectiveness findings are sensitive to the assumptions around the impact of gene therapies in reducing the complications. After feedback on the model analysis plan, we chose to anchor successful gene therapy treatment effectiveness for acute, chronic, and mortality events to be between the general population rates and the patients with SCD who experience no VOCs. If the



complication and mortality rates in the gene therapy arm are closer to the US general population rates, then the gene therapies are likely to have an incremental cost effectiveness of around \$150,000 per QALY and below \$150,000 per evLY gained from the health care system perspective. However, if the complication rates for patients in the gene therapy arm are similar to patients with SCD who experience no VOCs, then the gene therapies are likely to have an incremental cost effectiveness above \$250,000 per QALY and \$200,000 per evLY gained from the health care system perspective. Also, given there is no known transaction price we can observe for either lovo-cel or exa-cel, we have used a placeholder price of \$2 million.

We note that given the increased rate of complications and death with age for patients on standard of care, and the assumptions around treatment effectiveness based on the age at treatment, the population's age will have impact on the cost effectiveness of gene therapies (with all else equal, those of younger age are associated with a lower incremental cost-effectiveness ratio). Although we used a cohort-based model, we did account for known differences between adolescents and adults in costs and outcomes. Because policymaking will remain at the population level, the base-case cost-effectiveness findings and corresponding threshold-based prices presented in this report remain at the population level that average over the eligible population's age.

Additionally, we heard from people living with SCD and their caregivers that some people may not opt for gene therapies, if available and covered under their health benefit, given their preferences and their own risk-benefit tradeoffs. In short, for some people living with SCD, the risks and time invested may not be worth the potential long-run health and other benefits. One major limitation in the cost-effectiveness model is that it assumes risk neutrality in estimating the expected lifetime health gains associated with gene therapies versus standard of care. Therefore, the expected lifetime health gains summarized in this section of the report may be best thought of conditioned on this narrower subpopulation of those who would have considered allogenic HSCT but did not have a matched donor (i.e., those that would consider the net health benefit of opting for gene therapy to be positive). There is strong overlap between a narrower population that may consider gene therapies, if approved, and those who would have considered allogenic HSCT but did not have a matched donor (as like gene therapies, HSCT requires high doses of conditioning chemotherapy and a non-zero risk of short-term death).

As observed in the threshold-based draft price findings, the potential cost savings and health gains are both contributors to the threshold-based draft price justification. The potential cost savings being a factor was also demonstrated by the changes in cost-effectiveness findings to above commonly cited thresholds when assuming a 50/50 cost-savings scenario whereby only 50% of the cost savings were assigned when estimating the cost effectiveness of gene therapies. As highlighted above, the majority of the cost savings are from avoiding VOCs, and if the number of VOCs or cost per VOC in real practice is lower than the values used in the model, this would result in

an increase in the incremental cost-effectiveness ratios of gene therapies compared to standard care.

#### **4.4 Summary and Comment**

Our draft report analyses suggest that treating eligible patients living with SCD with lovo-cel or exa-cel results in lifetime health gains and added costs when compared to standard of care alone. Patients that were treated successfully experienced large health gains both in length of life and quality of life. When assuming a placeholder price for lovo-cel and exa-cel of \$2 million dollars and applying standard 3% per year discounting, these gene therapies have an incremental cost effectiveness that is above commonly cited thresholds from the health care system perspective. Findings from the modified societal perspective that included estimates of productivity loss for patients and caregivers were above but approaching the high end of commonly cited thresholds assuming the \$2 million dollar placeholder price. The draft cost-effectiveness findings were driven by the lifetime opportunity to improve health and reduce VOC-related and other SCD-related costs, and to improve productivity and reduce caregiver costs in the modified societal perspective.

## 5. Contextual Considerations and Potential

### Other Benefits

Our reviews seek to provide information on potential other benefits offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that was not available in the evidence base nor could be adequately estimated within the cost-effectiveness model. These elements are listed in the table below, with related information gathered from patients and other stakeholders. Following the public deliberation on this report the appraisal committee will vote on the degree to which each of these factors should affect overall judgments of long-term value for money of the intervention(s) in this review.

**Table 5.1. Contextual Considerations**

Contextual Consideration	Relevant Information
Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability	People with SCD are at risk for many acute, severe complications, particularly in setting of VOs including but not limited to infection, stroke, myocardial infarction, blood clots, and renal infarctions. The complications can lead to significant disability and death.
Magnitude of the lifetime impact on individual patients of the condition being treated	Patients with SCD are born with the condition, often experience their first symptoms during the first year of life and have significant morbidity and mortality even at a young age. The cumulative burden of disease is substantial.

**Table 5.2. Potential Other Benefits or Disadvantages**

Potential Other Benefit or Disadvantage	Relevant Information
Patients' ability to achieve major life goals related to education, work, or family life	If gene therapies effectively cure SCD, it is expected that people will experience increases in quality of life and their ability to achieve major life goals related to education, work, or family life. A negative effect may be the impact of myeloablative condition on fertility and family planning.
Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life	With a clinical cure for SCD, there is a high likelihood that caregivers' ability to return to school and/or work and overall productivity will improve.
Patients' ability to manage and sustain treatment given the complexity of regimen	Curative therapy will reduce the need for other long-term medical therapies (standard of care). However, gene therapies will require patients to be hospitalized for treatment and undergo myeloablative conditioning. Periods of hospitalization can last several weeks and come with potential risks.
Society's goal of reducing health inequities	SCD primarily affects the Black population in the US. It appears that there has been less research into this devastating condition than would have been expected had the disease comparably affected the majority White population. Additionally, people with SCD frequently experience undertreatment for pain in part because of issues around implicit bias and systemic racism. SCD is also a condition that subject to inequity in health care due to racial bias and stigma. While gene therapies do not specifically address implicit bias, stigma, or racism, they represent a long overdue focus on new therapies for vulnerable patients with a high illness burden.

## 6. Health-Benefit Price Benchmarks

---

ICER does not provide health-benefit price benchmarks as part of draft reports because results may change with revision following receipt of public comments. We therefore caution readers against assuming that the values provided in the threshold prices section of this draft report will match the health-benefit price benchmarks that will be presented in the next version of this report.

Further, as stated in ICER's [Single and Short-Term Therapy Adaptation](#) to the Value Assessment Framework, shared savings threshold analyses for estimating treatment price may be presented and may be considered as guides to ICER's pricing if the following two criteria are met:

- 1) A large percentage of the traditional value-based price comes from cost offsets of comparator (e.g., standard of care) therapy.
- 2) Comparator therapy price is not known to meet common cost-effectiveness thresholds.

For this assessment, the modeled comparator (e.g., standard of care without costly treatments that have limited evidence of effectiveness) generally does not include costly treatments or practices thought to be consistent with low value care. Therefore, the shared savings analyses are not likely to be considered as the primary guide to ICER's health-benefit price benchmarks in the next version of this report.

# 7. Potential Budget Impact

---

## 7.1. Overview of Key Assumptions

Results from the cost-effectiveness model from the health care system perspective were used to estimate the potential total budgetary impact of lovo-cel and exa-cel for eligible people with severe SCD. We used a placeholder price of \$2 million per treated patient to be paid up front, the same as in the base-case cost-effectiveness analysis, and the three threshold prices (at \$50,000, \$100,000, and \$150,000 per health unit gained) in our estimates of budget impact. For this report version, given that the deterministic cost-effectiveness findings are the same for lovo-cel and exa-cel, we present one set of budget impact findings that may be assigned to either lovo-cel or exa-cel. If numerically different for future versions of this report, findings will be presented by product.


This potential budget impact analysis included the estimated number of people in the US who are likely to be eligible for treatment. We acknowledge that those eligible may be larger than the number of people who may ultimately choose to receive either lovo-cel or exa-cel. Therefore, these results should be interpreted as the potential budget impact rather than a forecast of what might be. To estimate the size of the potential candidate populations for treatment, we used manufacturer data submissions and literature (De Martino et al. 2021) to consider those who are likely to be eligible for lovo-cel or exa-cel to be between 20,000 and 25,000 people living with severe SCD in the US.<sup>74,75</sup> We used the upper end of this range (25,000) and divide this estimate in two for those eligible for lovo-cel (N=12,500) and separately, exa-cel (N=12,500) as per ICER's Reference Case. For the purposes of this analysis, we assume that 20% of these people would initiate treatment in each of the five years, or 2,500 people per year per gene therapy. The aim of the potential budgetary impact analysis is to document the percentage of people who could be treated at selected prices without crossing a potential budget impact threshold that is aligned with overall growth in the US economy. For 2022-2023, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately \$777 million per year for new drugs.

## 7.2. Results

Results showed that at the placeholder price of \$2 million per treatment course for lovo-cel or exa-cel (to be paid up front), 15.4% of people (N=385 people per year) could be treated over the span of five years without crossing the ICER budget impact threshold of \$777 million per year. Similarly, 33.9%, 24.7%, and 19.4% could be treated with either lovo-cel or exa-cel without reaching the potential budget impact threshold at the three threshold prices (approximately \$0.90 million, \$1.24 million, and \$1.58 million per treatment) (Figure 7.1).

The cumulative per patient budgetary impact findings using the placeholder acquisition price for lovo-cel or exa-cel are presented in [Supplement F](#).

**Figure 7.1. Budgetary Impact of lovo-cel or exa-cel in Severe SCD**



PBI: potential budget impact, QALY: quality-adjusted life year

# References

---

1. Rouse C. *Uncertain Suffering: Racial Health Disparities and Sickle Cell Disease*. University of California Press; 2009.
2. Hassell KL. Population Estimates of Sickle Cell Disease in the U.S. *American Journal of Preventive Medicine*. 2010;38(4):S512-S521.
3. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. *Nat Rev Dis Primers*. 2018;4:18010.
4. Huo J, Xiao H, Garg M, Shah C, Wilkie DJ, Mainous Iii A. The Economic Burden of Sickle Cell Disease in the United States. *Value in Health*. 2018;21:S108.
5. Food and Drug Administration C. Voice of the Patient: Sickle Cell Disease 2014.
6. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. *Blood*. 2016;127(7):810-819.
7. Zaidi AU, Glaros AK, Lee S, et al. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease. *Orphanet Journal of Rare Diseases*. 2021;16(1):460.
8. Dick MH, Abdelgadir A, Kulkarni VV, et al. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review. *Cureus*. 2022;14(5):e24920.
9. Bradt P SE, Synnott P, et al.; *Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value*. 2020.
10. Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. *The Lancet Haematology*. 2019;6(11):e585-e596.
11. Brazauskas R, Scigliuolo GM, Wang H-L, et al. Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. *Blood*. 2020;136(5):623-626.
12. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. *Blood, The Journal of the American Society of Hematology*. 2017;129(11):1548-1556.
13. Pecker LH, Darbari DS. Psychosocial and affective comorbidities in sickle cell disease. *Neurosci Lett*. 2019;705:1-6.
14. van Tuijn CF, van Beers EJ, Schnog JJ, Biemond BJ. Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. *Am J Hematol*. 2010;85(7):532-535.
15. Sil S, Cohen LL, Dampier C. Psychosocial and Functional Outcomes in Youth With Chronic Sickle Cell Pain. *Clin J Pain*. 2016;32(6):527-533.
16. Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing Health Care Disparities in Sickle Cell Disease: A Review. *Public Health Rep*. 2019;134(6):599-607.
17. Tanabe P, Myers R, Zosel A, et al. Emergency department management of acute pain episodes in sickle cell disease. *Acad Emerg Med*. 2007;14(5):419-425.
18. Connolly ME, Bills SE, Hardy SJ. Neurocognitive and psychological effects of persistent pain in pediatric sickle cell disease. *Pediatr Blood Cancer*. 2019;66(9):e27823.
19. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. *Jama*. 2010;303(18):1823-1831.
20. Sanger M, Jordan L, Pruthi S, et al. Cognitive deficits are associated with unemployment in adults with sickle cell anemia. *J Clin Exp Neuropsychol*. 2016;38(6):661-671.

21. Toumi ML, Merzoug S, Boulassel MR. Does sickle cell disease have a psychosomatic component? A particular focus on anxiety and depression. *Life Sci.* 2018;210:96-105.
22. Wakefield EO, Pantaleao A, Popp JM, et al. Describing Perceived Racial Bias Among Youth With Sickle Cell Disease. *J Pediatr Psychol.* 2018;43(7):779-788.
23. Gold JS. Sickle cell patients fight uphill battle for research, treatment -- and compassion. <https://www.statnews.com/2017/12/26/sickle-cell-research-treatment/>. Published 2017. Accessed.
24. Strouse JJ, Lobner K, Lanzkron S, M, Haywood C, Jr. NIH and National Foundation Expenditures For Sickle Cell Disease and Cystic Fibrosis Are Associated With Pubmed Publications and FDA Approvals. *Blood.* 2013;122(21):1739-1739.
25. Smith LA, Oyeku SO, Homer C, Zuckerman B. Sickle cell disease: a question of equity and quality. *Pediatrics.* 2006;117(5):1763-1770.
26. Bahr NC, Song J. The Effect of Structural Violence on Patients with Sickle Cell Disease. *J Health Care Poor Underserved.* 2015;26(3):648-661.
27. Haywood C, Jr., Beach MC, Lanzkron S, et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. *J Natl Med Assoc.* 2009;101(10):1022-1033.
28. Labbé E, Herbert D, Haynes J. Physicians' attitude and practices in sickle cell disease pain management. *J Palliat Care.* 2005;21(4):246-251.
29. Freiermuth CE, Haywood C, Jr., Silva S, et al. Attitudes toward patients with sickle cell disease in a multicenter sample of emergency department providers. *Adv Emerg Nurs J.* 2014;36(4):335-347.
30. Brown SE, Weisberg DF, Balf-Soran G, Sledge WH. Sickle cell disease patients with and without extremely high hospital use: pain, opioids, and coping. *J Pain Symptom Manage.* 2015;49(3):539-547.
31. Centers for Medicare & Medicaid Services OoMH. Opioid Prescription in Medicare Beneficiaries: Prescription Opioid Policies and Implications for Beneficiaries with Sickle Cell Disease. <https://www.cms.gov/About-CMS/Agency-Information/OMH/Downloads/OpioidPrescription-in-Medicare-Beneficiaries-Report.pdf>. Published 2019. Accessed.
32. Mississippi Division of Medicaid. Medicaid to implement new opioid initiative effective Aug. 1. <https://medicaid.ms.gov/medicaid-to-implement-new-opioid-initiative-effective-aug-1/>. . Published 2019. Accessed.
33. Begley S S. 'Every time it's a battle': In excruciating pain, sickle cell patients are shunted aside. <https://www.statnews.com/2017/09/18/sickle-cell-pain-treatment/>. Published 2017. Accessed.
34. Mainous AG, 3rd, Tanner RJ, Harle CA, Baker R, Shokar NK, Hulihan MM. Attitudes toward Management of Sickle Cell Disease and Its Complications: A National Survey of Academic Family Physicians. *Anemia.* 2015;2015:853835.
35. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. *Blood.* 2010;115(17):3447-3452.
36. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). *Pediatr Blood Cancer.* 2013;60(9):1482-1486.
37. Kanter J, Walters MC, Krishnamurti L, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. *New England Journal of Medicine.* 2021;386(7):617-628.
38. Walters MC, Thompson AA, Kwiatkowski JL, et al. Iovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study. Paper presented at: 64th ASH: Annual Meeting and Exposition2022.



39. Frangoul H, Locatelli F, Bhatia M, et al. Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent  $\beta$ -Thalassemia and Severe Sickle Cell Disease. Paper presented at: 64th ASH: Annual Meeting and Exposition 2022.
40. Frangoul H, Altshuler D, Cappellini MD. CLIMB-121 Protocol 2020, *New England Journal of Medicine*.
41. Walters MC, Tisdale JF, Mapara MY, et al. Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. *Blood*. 2021;138(Supplement 1):7-7.
42. Negre O, Eggimann AV, Beuzard Y, et al. Gene Therapy of the  $\beta$ -Hemoglobinopathies by Lentiviral Transfer of the  $\beta$ (A(T87Q))-Globin Gene. *Hum Gene Ther*. 2016;27(2):148-165.
43. Frangoul H, Locatelli F, Bhatia M, et al. 12 Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Paper presented at: 64th ASH: Annual Meeting and Exposition; December 10, 2022, 2022.
44. National Cancer Institute. Autologous CD34-positive BCL11a - disrupted hematopoietic progenitor cells BIVV003. <https://www.cancer.gov/publications/dictionaries/cancer-drug/def/796965>. Published 2023. Accessed.
45. Steinberg MH, Chui DHK, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? *Blood*. 2014;123(4):481-485.
46. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. *N Engl J Med*. 1991;325(1):11-16.
47. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is There a Threshold Level of Fetal Hemoglobin That Ameliorates Morbidity in Sickle Cell Anemia? *Blood*. 1984;63(4):921-926.
48. Seminog OO, Ogunlaja OI, Yeates D, Goldacre MJ. Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. *J R Soc Med*. 2016;109(8):303-309.
49. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among sickle cell disease patients in California. *Blood*. 2017;130(13):1597-1599.
50. Hsieh MM, Bonner M, Pierciey FJ, Jr, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. *Blood Advances*. 2020;4(9):2058-2063.
51. Kanter J, Thompson AA, Pierciey Jr FJ, et al. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. *American Journal of Hematology*. 2023;98(1):11-22.
52. bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) [press release]. February 16, 2021 2021.
53. Goyal S, Tisdale J, Schmidt M, et al. Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. *New England Journal of Medicine*. 2021;386(2):138-147.
54. Magrin E, Semeraro M, Hebert N, et al. Long-term outcomes of lentiviral gene therapy for the  $\beta$ -hemoglobinopathies: the HGB-205 trial. *Nature Medicine*. 2022;28(1):81-88.
55. Philippidis A. After Analysis, Bluebird Bio Says Vector “Very Unlikely” Cause of Acute Myeloid Leukemia. *Human Gene Therapy*. 2021;32(7-8):332-334.
56. bluebird bio. bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and  $\beta$ -Thalassemia Studies. 2021.
57. Walters MC, Thompson AA, Kwiatkowski JL, et al. Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study. *Blood*. 2022;140(Supplement 1):26-28.

58. FDA Lifts Partial Clinical Hold for bluebird bio's Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18 [press release]. December 19, 2022 2022.
59. Beaudoin FL RM, Synnott PG, Lancaster V, Fluetsch N, HerceHagiwara B, Campbell JD, Pearson SD, Rind DM. *Betibeglogene Autotemcel for Beta Thalassemia: Effectiveness and Value*. 2022 2022.
60. Anie KA, Grocott H, White L, Dzingina M, Rogers G, Cho G. Patient self-assessment of hospital pain, mood and health-related quality of life in adults with sickle cell disease. *BMJ open*. 2012;2(4):e001274.
61. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. *Medical Decision Making*. 2006;26(4):410-420.
62. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: a retrospective claims study. *Journal of health economics and outcomes research*. 2020;7(1):52.
63. Graf M, Tuly R, Gallagher M, Sullivan J, Jena AB. Value of a cure for sickle cell disease in reducing economic disparities. *American Journal of Hematology*. 2022;97(8):E289.
64. statistics Bol. Usual Weekly Earnings of Wage and Salary Workers Fourth Quarter 2022. In:2022.
65. Shah N, Bhor M, Xie L, et al. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: a retrospective claims-based study. *Journal of Health Economics and Outcomes Research*. 2019;6(3):106.
66. Desai RJ, Mahesri M, Globe D, et al. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. *Annals of Hematology*. 2020;99:2497-2505.
67. Shah NR, Bhor M, Latremouille-Viau D, et al. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance—the perspective of private and public payers. *Journal of Medical Economics*. 2020;23(11):1345-1355.
68. Ramsey SD, Bender M, Li L, et al. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance—A retrospective cohort study. *Plos one*. 2022;17(11):e0278137.
69. Baldwin Z, Jiao B, Basu A, et al. Medical and non-medical costs of sickle cell disease and treatments from a US perspective: a systematic review and landscape analysis. *PharmacoEconomics-Open*. 2022;6(4):469-481.
70. Jiao B, Basu A, Ramsey S, et al. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review. *Value in Health*. 2022;25(2):276-287.
71. Salcedo J, Bulovic J, Young CM. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. *Scientific Reports*. 2021;11(1):10838.
72. Johnson KM, Jiao B, Bender M, Ramsey SD, Devine B, Basu A. Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. *Plos one*. 2022;17(4):e0267448.
73. Winn A, Basu A, Ramsey SD. A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America. *PharmacoEconomics-Open*. 2023:1-8.
74. bluebird bio. bluebird bio J.P. Morgan Presentation. Paper presented at: 41st Annual J.P. Morgan Healthcare Conference2023.
75. Vertex Pharmaceuticals. Vertex Pharmaceuticals Incorporated (VRTX) Q4 2022 Earnings Call Transcript. Seeking Alpha. <https://seekingalpha.com/article/4576163-vertex-pharmaceuticals-incorporated-vrtx-q4-2022-earnings-call-transcript>. Published 2023. Updated February 7, 2023. Accessed February 14, 2023.

76. Field J. Acute Chest Syndrome in Adults with Sickle Cell Disease. <https://www.uptodate.com/contents/acute-chest-syndrome-in-adults-with-sickle-cell-disease>. Published 2019. Accessed.
77. Bourgault M, Grimbert P, Verret C, et al. Acute renal infarction: a case series. *Clin J Am Soc Nephrol*. 2013;8(3):392-398.
78. Indiana Hemophilia & Thrombosis Center. Sickle Cell Disease Spleen Complications. <https://www.ihtc.org/sickle-cell-splenic-sequestration/>. Published 2020. Accessed.
79. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and  $\beta$ -thalassemia. *New England Journal of Medicine*. 2021;384(3):252-260.
80. National Cancer Institute. Stem Cell Engraftment. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/stem-cell-engraftment>. Published 2023. Accessed.
81. UpToDate. Fetal hemoglobin (hemoglobin F) in health and disease. <https://www.uptodate.com/contents/fetal-hemoglobin-hemoglobin-f-in-health-and-disease>. Published 2021. Accessed.
82. Centers for Disease Control and Prevention. Sickle Cell Disease (SCD). Published 2019. Accessed.
83. Barcellini W, Fattizzo B. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. *Dis Markers*. 2015;2015:635670.
84. PROMIS P-ROMIS. PROMIS Adult Profile Instruments. [https://staging.healthmeasures.net/images/PROMIS/manuals/PROMIS\\_Adult\\_Profile\\_Scoring\\_Manual.pdf](https://staging.healthmeasures.net/images/PROMIS/manuals/PROMIS_Adult_Profile_Scoring_Manual.pdf). Published 2021. Accessed.
85. Liem RI, Lanzkron S, T DC, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. *Blood Adv*. 2019;3(23):3867-3897.
86. American Society of Hematology. Don't routinely transfuse patients with sickle cell disease (SCD) for chronic anemia or uncomplicated pain crisis without an appropriate clinical indication. Choosing Wisely. <https://www.choosingwisely.org/clinician-lists/american-society-hematology-routine-transfusions-for-sickle-cell-disease-or-chronic-anemia/>. Published 2014. Updated December 3, 2014. Accessed March 16, 2023.
87. Kanter J, Liem RI, Bernaudin F, et al. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. *Blood Adv*. 2021;5(18):3668-3689.
88. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. *Blood Adv*. 2020;4(12):2656-2701.
89. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. *Blood Adv*. 2020;4(2):327-355.
90. National Heart Lung and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. 2014.
91. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med*. 1997;126(5):376-380.
92. Higgins J, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, Welch, VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). <https://training.cochrane.org/handbook/current>. Published 2020. Accessed.
93. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
94. Ollendorf D, Pearson, SD. ICER Evidence Rating Matrix: A User's Guide. <https://icer.org/evidence-rating-matrix/>. Published 2020. Updated January 31, 2020. Accessed.
95. Ollendorf DA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. *Medical care*. 2010;48(6 Suppl):S145-152.

96. Kassim AA, Leonard A. Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy. *J Clin Med*. 2022;11(16).
97. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. 2016;316(10):1093-1103.
98. McClish DK, Smith WR, Levenson JL, et al. Comorbidity, pain, utilization, and psychosocial outcomes in older versus younger sickle cell adults: the PiSCES project. *BioMed research international*. 2017;2017.
99. Antwi-Boasiako C, Andemariam B, Colombatti R, et al. A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis. *Annals of hematology*. 2020;99:2073-2079.
100. Allali S, de Montalembert M, Brousse V, et al. Hepatobiliary complications in children with sickle cell disease: a retrospective review of medical records from 616 patients. *Journal of clinical medicine*. 2019;8(9):1481.
101. Vinay A. Shah M.D. DS, MD, Peter Bracha, MD, Harikrishnan Vannadil, MD, MS (Ophthal), Jason Hsu, MD, Jennifer I Lim MD. Sickle Cell Retinopathy. In: Jason Hsu M, ed. *American Academy of Ophthalmology EyeWiki*2022.
102. Bailey M, Abioye A, Morgan G, et al. Relationship between vaso-occlusive crises and important complications in sickle cell disease patients. *Blood*. 2019;134:2167.
103. Herquelot E, Morgan G, Lamarsalle L, et al. PSY38 marginal structural model for studying the causal effect between vaso-occlusive crises and occurrence of death or complications in the sickle-cell disease patients. *Value in Health*. 2019;22:S908.
104. Gallagher ME, Chawla A, Brady BL, Badawy SM. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis. *Journal of Medical Economics*. 2022;25(1):1140-1148.
105. Song X, Campbell AD, Cong Z, et al. Economic burden of end organ damage among patients with sickle cell disease in the US. *Blood*. 2019;134:3388.
106. Khoury H, Lyons R, Sanaiha Y, Rudasill S, Shemin RJ, Benharash P. Deep venous thrombosis and pulmonary embolism in cardiac surgical patients. *The Annals of Thoracic Surgery*. 2020;109(6):1804-1810.
107. Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. *JAMA network open*. 2020;3(4):e201997-e201997.
108. Nguyen HV, Schatz DA, Mital S, Jacobsen LM, Haller MJ. Cost-effectiveness of low-dose antithymocyte globulin versus other immunotherapies for treatment of new-onset type 1 diabetes. *Diabetes Technology & Therapeutics*. 2022;24(4):258-267.
109. ur Rehman A, Ahmad Hassali MA, Muhammad SA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. *Expert review of pharmacoeconomics & outcomes research*. 2020;20(6):661-672.
110. Pickard AS, Law EH, Jiang R, et al. United States Valuation of EQ-5D-5L Health States Using an International Protocol. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2019;22(8):931-941.
111. Pearson SD. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2018;21(3):258-265.

112. Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework. <https://icer.org/our-approach/methods-process/value-assessment-framework/>. Published 2020. Accessed.

## Supplemental Materials

# A. Background: Supplemental Information

Some of these definitions are adapted from the 2020 ICER SCD review.

## **A1. Definitions**

**Acute chest syndrome**<sup>76</sup>: Defined as a new radiodensity on chest radiography accompanied by fever and/or respiratory symptoms. Acute chest syndrome in adults with SCD requires prompt management to prevent clinical deterioration.

**Acute kidney injury/renal infarction**<sup>77</sup>: A condition resulting from a sudden disruption of blood flow to the renal artery. This may cause irreversible damage to kidney tissues.

**Acute splenic sequestration**<sup>78</sup>: Pooling of sickled red blood cells trapped in the spleen. This can cause the spleen to become enlarged, damaged, and not function properly. Splenic sequestration occurs more commonly in children and may cause sudden and severe anemia.

**BCL11A**<sup>44</sup>: A transcription factor that suppresses fetal hemoglobin. Disruption of this transcription factor results in increased expression of fetal hemoglobin.

**Chronic kidney disease (nephropathy)**: Defined in trials as either having a glomerular filtration rate of less than 60 ml/min/1.73 m<sup>2</sup> for greater than or equal to three months with or without kidney damage or having evidence of kidney damage for greater than or equal to three months, with or without decreased glomerular filtration rate, manifested by either pathologic abnormalities or markers of kidney damage independent of cause.

**Clustered regularly interspaces short palindromic repeats (CRISPR)-Cas9**<sup>79</sup>: Bacterial immune system that enables insertion or deletion at certain genomic DNA sites.

**Engraftment**<sup>80</sup>: An indicator of a successful stem cell transplantation where an individual's body accepts transplanted bone marrow/stem cells and new blood cells begin to produce.

**Fetal hemoglobin**<sup>81</sup>: A type of hemoglobin that is produced by a fetus's body during gestation and is replaced by adult hemoglobin during the first year of life. Fetal hemoglobin has a higher oxygen affinity than adult hemoglobin.

**HbA**<sup>T87Q42</sup>: Modified adult hemoglobin designed to inhibit the polymerization of sickle hemoglobin.

**HbS $\beta^0$  thalassemia**<sup>82</sup>: Occurs in patients who inherit one sickle cell gene and one beta thalassemia gene that results in no production of HbA.

**HbSβ<sup>+</sup> thalassemia<sup>82</sup>:** Occurs in patients who inherit one sickle cell gene and one beta thalassemia gene resulting in reduced production of HbA.

**HbSC<sup>82</sup>:** One inherited sickle cell gene (“S”) and one abnormal Hb gene (“C”), which typically presents as milder anemia.

**HbSD, HbSE and HbSO<sup>82</sup>:** One inherited sickle cell gene (“S”) and one gene from an abnormal type of Hb (“D,”“E,” or “O”).

**HbSS<sup>82</sup>:** Two inherited sickle cell genes (“S”) resulting in sickle cell anemia, the most common and severe form of SCD.

**Hemolysis<sup>83</sup>:** The breakdown of red blood cells. Common markers of hemolysis are reticulocyte count (elevated in hemolysis), levels of haptoglobin (decreased), lactate dehydrogenase (elevated during hemolysis, and total bilirubin (elevated).

**Patient-Reported Outcome Measurement System<sup>®</sup> – Profile 57<sup>84</sup>:** A self-reported questionnaire for adults ≥18 years old measuring physical, mental, and social health with seven domains and one pain intensity question. Domains include physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, and pain intensity.

**Pulmonary arterial hypertension<sup>85</sup>:** An elevation of pulmonary arterial systolic pressure (greater than 20 mmHg at rest or greater than 30 mmHg with exercise) determined by right heart catheterization.

**Vaso-occlusive crisis (VOC):** Pain as a result of decreased blood flow in the microcapillaries (can include blood vessel blockage) resulting in tissue ischemia, occurring most commonly in bone or bone marrow. VOCs are also known as vaso-occlusive episodes or acute pain crises. Definitions between pivotal trials vary and are listed in Table 3.3.

**Table A1. Group Definitions of HGB-206 Trial Participants<sup>37</sup>**

	Group A	Group B	Group C
<b>Pre-Collection Transfusion Time</b>	≤7 days	≥60 days	≥60 days
<b>Method of HSPC Collection</b>	Bone marrow harvest	Bone marrow harvest	Plerixafor and apheresis
<b>AUC Target for Conditioning, uM* Min Per Dose</b>	4000-4500 (medium)	5000 (high)	5000 (high)
<b>Target Number of CD34+ Cells</b>	≥1.5x10 <sup>6</sup> per kg (low)	≥2x10 <sup>6</sup> per kg (medium)	≥3x10 <sup>6</sup> per kg (high)
<b>Manufacturing Process</b>	Original	Patient 1: Original/refined Patient 2: Refined	Refined

AUC: area under the curve, HSPC: hematopoietic stem and progenitor cell, kg: kilogram



## A2. Potential Cost-Saving Measures in SCD

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, see <https://icer.org/our-approach/methods-process/value-assessment-framework/>). These services are ones that would not be directly affected by therapies for SCD (e.g., reduction in disability), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of SCD beyond the potential offsets that arise from a new intervention. During stakeholder engagement and public comment periods, ICER encouraged all stakeholders to suggest services (including treatments and mechanisms of care) currently used for patients with SCD that could be reduced, eliminated, or made more efficient. No suggestions were received.

In December of 2014, the American Society of Hematology put out a Choosing Wisely® recommendation against unnecessary routine red blood cells transfusions in SCD patients with chronic anemia or an uncomplicated pain crisis.<sup>86</sup> This recommendation was based on the potential increased risks of alloimmunization to minor blood group antigens and iron overload from repeated transfusions, as well as the lack of evidence in reduction in pain during an uncomplicated crisis.

## B. Patient Perspectives: Supplemental Information

### **B1. Methods**

During ICER’s scoping phase and public comment periods, we received public comment submissions from two manufacturers and participated in conversations with nine key informants (four clinicians, one patient advocacy group, one person living with SCD, one caregiver, and two manufacturers). Organized by Sick Cells, we also conducted two focus groups with a total of 10 participants who were either people living with SCD or current or former caregivers. The feedback received from written input and scoping conversations helped us to understand and discuss the impact of SCD on patients and caregivers described in Section 2 of the report.

## C. Clinical Guidelines

Some of the guideline descriptions are adapted from the 2020 report.

### **American Society of Hematology**

#### ***2021 Guidelines for SCD: Stem Cell Transplantation<sup>87</sup>***

A multidisciplinary guideline panel formed by the American Society of Hematology agreed on eight recommendations to guide patients with SCD and their providers in the consideration of HSCT. All recommendations outlined below are classified by the panel as conditional recommendations (described as suggestions) meaning there is “very low certainty in the evidence about effects.”

For patients who have experienced overt stroke or an abnormal transcranial Doppler ultrasound, the panel suggests HLA-matched related HSCT over standard of care, which may include hydroxyurea or transfusion. For patients with an indication for HSCT but lack a matched-sibling donor, the panel suggests transplants for alternative donors. Patients who are eligible for HSCT are suggested to use allogeneic transplantation at earlier ages rather than older.

For patients with frequent pain or recurrent episodes of acute chest syndrome, the panel suggests matched allogeneic transplantations over standard of care. For allogeneic HSCT, using chemotherapy-based conditioning regimens or total body irradiation  $\leq 400$  cGy is suggested.

For children with an indication for allogeneic HSCT and matched-sibling donor, the panel suggests myeloablative condition rather than reduced-intensity conditioning. Alternatively, for adults with the same indication and matched-sibling donor, nonmyeloablative conditioning is suggested over reduced-intensity conditioning.

Lastly, the guideline suggests the use of HLA-identical sibling cord blood when available over bone marrow.

#### ***2020 Guidelines for SCD: Management of Acute and Chronic Pain<sup>88</sup>***

A multidisciplinary guideline panel formed by the American Society of Hematology agreed on 18 recommendations to guide patients and providers in pain management decisions. These range from strong recommendations based on low certainty to conditional recommendations based on low certainty in evidence about the effects, with the majority being conditional.

For children and adults with SCD with acute pain related to SCD in an acute care setting, the panel recommends both a rapid assessment and analgesic administration to manage pain levels. If opioid therapy is indicated for a patient in this scenario, tailored-opioid dosing is suggested. In addition, a

short course of non-steroidal anti-inflammatory drugs (NSAIDs) is suggested. The guideline panel suggests against the use of corticosteroids for acute pain. If an adult or child is hospitalized due to acute pain, the panel suggests an analgesic ketamine infusion if pain is not resolved from opioid treatment. Regional anesthesia is suggested for localized pain if opioid treatment does not effectively reduce pain. SCD-specific hospital acute care facilities are suggested over traditional emergency room care for people requiring hospital care for acute pain episodes.

For adults with SCD with chronic pain from avascular necrosis of the bone, duloxetine, and NSAIDs as management treatments are suggested. For adults with chronic pain but no cause beyond SCD complications, the use of serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, and gabapentinoids as options for treatment are suggested.

For adults and children with SCD-related chronic pain, cognitive and behavioral treatment plans are suggested. Additionally, alternative approaches (e.g., acupuncture) are suggested for adults.

If a person's chronic pain is recent, the initiation of chronic opioid therapy is not suggested unless they are refractory to other treatment methods. If chronic opioid therapy is initiated for a person with chronic pain and is showing a benefit, shared decision making to assess the continuation of chronic opioid therapy is suggested. However, if benefit is not shown from chronic opioid therapy, discontinuation is suggested.

Lastly, monthly transfusion therapy is not suggested as a first-line treatment for adults and children with SCD and recurrent acute pain. The panel does not provide a suggestion for the use of monthly transfusion therapy for the treatment of chronic pain from SCD.

### ***2020 Guidelines for SCD: Transfusion Support<sup>89</sup>***

A multidisciplinary guideline panel formed by the American Society of Hematology agreed on 10 recommendations for the screening, prevention, and management of iron overload, alloimmunization, and delayed hemolytic transfusion reactions.

Before the first transfusion or at the earliest opportunity, the panel suggests obtaining an extended red cell antigen profile by genotype or serology for all SCD patients and recommends prophylactic red cell antigen matching for Rh and K antigens for those receiving transfusions. The panel suggests immunosuppressive therapy in SCD patients with an acute need for transfusion and who are at increased risk of acute hemolytic transfusion reactions or with a history of multiple or delayed hemolytic transfusion reactions and ongoing hyperhemolysis.

For SCD patients receiving chronic transfusions, the panel suggests using automated red cell exchange transfusions rather than simple or manual red cell exchange; either conventional red cell exchange or red cell exchange with isovolemic hemodilution is recommended for this population.

In addition, the panel suggests iron overload screening for liver iron content by magnetic resonance imaging every one to two years.

For patients with severe acute chest syndrome, the panel suggests automated transfusion over manual red cell exchange and in those with moderate acute chest syndrome, the panel suggests automated red cell exchange, manual red cell exchange or simple transfusion methods.

For pregnant patients with SCD, the panel suggests either standard care or prophylactic transfusion at regular intervals. More broadly, for patients with SCD undergoing surgery requiring general anesthesia or lasting more than an hour, preoperative transfusion is suggested.

### ***2019 Guidelines for SCD: Cardiopulmonary and Kidney Disease*<sup>85</sup>**

A multidisciplinary guideline panel formed by the American Society of Hematology agreed on 10 recommendations to support the screening, diagnosis, and management of SCD and its cardiopulmonary and renal complications. Due to a lack of direct, high-quality evidence on the SCD outcomes of interest, the majority of recommendations were conditional rather than strong. Although these recommendations advise on management of patients with pulmonary arterial hypertension, albuminuria, unprovoked venous thromboembolism, and sleep-disordered breathing, we have summarized only the two recommendations pertaining to outcomes relevant to our review: chronic kidney disease and management with hydroxyurea.

The panel suggests referral for a renal transplant for those with advanced chronic kidney disease or end-stage renal disease. For those with worsening anemia associated with chronic kidney disease, the panel suggest combination therapy with hydroxyurea and erythropoiesis-stimulating agents.

## **National Heart, Lung, and Blood Institute**

### ***Evidence-Based Management of SCD: Expert Panel, 2014*<sup>90</sup>**

The National Heart, Lung, and Blood Institute convened a multidisciplinary panel to develop guidelines for the management, recognition, and treatment of acute and chronic complications of SCD, for patients ranging from infancy through adulthood. These guidelines cover an extensive list of recommendations and for the purpose of this report, we have summarized only those which are most strongly recommended and focus on the outcomes and management options related to our review: acute pain crisis, acute chest syndrome, acute and chronic transfusion, hemoglobin, hydroxyurea, and stroke.

### Health Maintenance (With Focus on Outcomes Listed Above)

- Only in children with sickle cell anemia (does not include those with HbSC, HbSD, HbS $\beta$ 0 thalassemia, or HbS $\beta$ + thalassemia), from age two through at least 16, the panel strongly recommends annual screening with transcranial doppler (imaging for the risk of stroke).

### Management of Acute Complications of SCD (With Focus on Outcomes Listed Above)

- The panel strongly recommends treatment with parenteral opioids for adults and children experiencing an acute pain crisis with severe pain.
- For those hospitalized for an acute pain crisis, the panel recommends incentive spirometry while awake to reduce the risk of acute chest syndrome.
- For patients who have acute chest syndrome, the panel strongly recommends treatment with 1) IV cephalosporin, 2) an oral macrolide antibiotic, 3) supplemental oxygen, and 4) monitoring for hypoxemia, acute anemia, and bronchospasm.
- Among all patients, when there is rapid progression of acute chest syndrome, the guidelines recommend urgent exchange transfusion and use of incentive spirometry while awake.

### Hydroxyurea Therapy for Management of SCD (With Focus on Outcomes Listed Above)

- The panel strongly recommends treatment with hydroxyurea among adults with sickle cell anemia for all of the following: those who have at least three moderate to severe pain crises within a year, those whose pain interferes with daily activities and quality of life, those who have a history of severe and/or recurrent acute chest syndrome, and those who have severe symptomatic chronic anemia.
- For infants at least nine months of age, and children and adolescents with sickle cell anemia, treatment with hydroxyurea to reduce SCD-related complications is recommended regardless of clinical severity.

### Blood Transfusions for Management of SCD (With Focus on Outcomes Listed Above)

- Prior to undergoing a surgical procedure, the guidelines state that all adults and children with sickle cell anemia are to be transfused with red blood cells to raise hemoglobin level to 10 g/dL.
- For both children and adults, the guidelines suggest consulting a blood bank for a workup of possible delayed hemolytic transfusion reaction, for patients showing signs of acute anemia, jaundice, or pain within three weeks after a blood transfusion.
- For patients receiving chronic transfusion therapy, the guidelines recommend performing serial assessment of iron overload.

- In children with transcranial doppler results  $>170$  cm/sec, the guidelines recommend referral to a specialist who may initiate chronic transfusion therapy for the prevention of stroke.

# D. Comparative Clinical Effectiveness: Supplemental Information

## **D1. Detailed Methods**

### **Population, Interventions, Comparators, Outcomes, Timing, Settings**

#### ***Population***

The population of focus for this review is adolescents and adults with severe SCD and who do not have a matched sibling donor or haploidentical donor for HSCT or are too old for safe HSCT. There is no generally accepted classification of SCD severity; in the studies of the agents under review, patients were required to have a minimum of four severe vaso-occlusive events in the prior two years.

Data permitting, we intend to assess evidence on treatment for SCD for groups stratified by:

- Age
- Genotype (e.g., hemoglobin SS, SC, SD).

#### ***Interventions***

The full list of interventions is as follows:

- lovo-cel (bluebird bio)
- exa-cel (Vertex and CRISPR Therapeutics)

#### ***Comparators***

Data permitting, we intend to compare both agents to standard of care (may include hydroxyurea and chronic blood transfusions) and to each other.

#### ***Outcomes***

The outcomes of interest are described in the list below.

- Patient-important outcomes
  - Acute pain crisis (i.e., VOC)
  - Chronic pain
  - Hospitalization



- Mortality
- Fatigue
- Cognitive effects
- Acute chest syndrome
- Mental health effects (e.g., depression, anxiety)
- Cardiovascular events (e.g., stroke and silent infarcts, pulmonary hypertension, heart failure)
- Hearing loss
- Vision loss
- Organ damage
- Infertility and pregnancy complications
- Sexual dysfunction
- Quality of life
- Ability to work or attend school
- Other adverse events including:
  - Serious adverse events (e.g., delayed neutrophil engraftment, thrombocytopenia, malignancies)
  - Adverse events related to gene therapy treatment
- Other outcomes
  - Laboratory evidence of SCD severity
    - Hemoglobin (e.g., total hemoglobin, fetal hemoglobin, HbAT87Q, HbS)
    - Hemolysis markers (e.g., reticulocyte count, indirect bilirubin levels, haptoglobin, lactate dehydrogenase)
  - Caregiver burden
  - Health resource utilization

### ***Timing***

Evidence on intervention effectiveness and harms will be derived from studies of any duration that meet the study design criteria set forth above and measure the outcomes of interest.

### ***Settings***

All relevant settings will be considered, including inpatient, outpatient/clinic, office, and home settings.

### ***Study Design***

Evidence will be abstracted from randomized controlled trials as well as high-quality single-arm trials and systematic reviews; high-quality comparative cohort studies will be considered, particularly for long-term outcomes and uncommon adverse events.

**Table D1. PRISMA 2020 Checklist**

Section and Topic	Item #	Checklist Item
<b>TITLE</b>		
<b>Title</b>	1	Identify the report as a systematic review.
<b>ABSTRACT</b>		
<b>Abstract</b>	2	See the PRISMA 2020 for Abstracts checklist.
<b>INTRODUCTION</b>		
<b>Rationale</b>	3	Describe the rationale for the review in the context of existing knowledge.
<b>Objectives</b>	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.
<b>METHODS</b>		
<b>Eligibility Criteria</b>	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.
<b>Information Sources</b>	6	Specify all databases, registers, websites, organizations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.
<b>Search Strategy</b>	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.
<b>Selection Process</b>	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.
<b>Data Collection Process</b>	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.
<b>Data Items</b>	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect.
	10b	List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.
<b>Study Risk of Bias Assessment</b>	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.
<b>Effect Measures</b>	12	Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results.
<b>Synthesis Methods</b>	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.

Section and Topic	Item #	Checklist Item
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression).
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.
<b>Reporting Bias Assessment</b>	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).
<b>Certainty Assessment</b>	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.
<b>RESULTS</b>		
<b>Study Selection</b>	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.
<b>Study Characteristics</b>	17	Cite each included study and present its characteristics.
<b>Risk of Bias in Studies</b>	18	Present assessments of risk of bias for each included study.
<b>Results of Individual Studies</b>	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots.
<b>Results of Syntheses</b>	20a	For each synthesis, briefly summarize the characteristics and risk of bias among contributing studies.
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.
	20c	Present results of all investigations of possible causes of heterogeneity among study results.
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.
<b>Reporting Biases</b>	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.
<b>Certainty of Evidence</b>	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.
<b>DISCUSSION</b>		
<b>Discussion</b>	23a	Provide a general interpretation of the results in the context of other evidence.
	23b	Discuss any limitations of the evidence included in the review.
	23c	Discuss any limitations of the review processes used.
	23d	Discuss implications of the results for practice, policy, and future research.
<b>OTHER INFORMATION</b>		
<b>Registration and Protocol</b>	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.

Section and Topic	Item #	Checklist Item
	24c	Describe and explain any amendments to information provided at registration or in the protocol.
<b>Support</b>	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.
<b>Competing Interests</b>	26	Declare any competing interests of review authors.
<b>Availability of Data, Code, and Other Materials</b>	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.

From: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *PLoS Med.* 2021;18(3):e1003583.

## Data Sources and Searches

Procedures for the systematic literature review assessing the evidence on gene therapies for sickle cell disease followed established best research methods.<sup>91,92</sup> We conducted the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>93</sup> The PRISMA guidelines include a checklist of 27 items.

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. We included abstracts from conference proceedings identified from the systematic literature search. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and Emtree terms in EMBASE) as well as free-text terms.

To supplement the database searches, we performed manual checks of the reference lists of included trials and systematic reviews and invited key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, see <https://icer.org/policy-on-inclusion-of-grey-literature-in-evidence-reviews/>). Where feasible and deemed necessary, we also accepted data submitted by manufacturers “in-confidence,” in accordance with ICER’s published guidelines on acceptance and use of such data (<https://icer.org/guidelines-on-icers-acceptance-and-use-of-in-confidence-data-from-manufacturers-of-pharmaceuticals-devices-and-other-health-interventions/>).

---

**Table D2. Search Strategy of Medline 1996 to Present with Daily Update and Cochrane Central Register of Controlled Trials**

1	exp anemia, sickle cell/
2	((sickle adj3 (disease or an?emia)) or "sickle cell" or meniscocyt* or drepanocyte* or sickl* or (SC adj3 (disease or an?emia))).ti,ab.
3	hemoglobin, sickle/ or (h?emoglobin adj5 sickl*).ti,ab.
4	((h?emoglobin or hb or hb- or hgb) adj3 (SS or S-S or SC or S-C or SB* or b0 or S-beta or thalassemia or beta-zero or beta plus)).ti,ab.
5	1 or 2 or 3 or 4
6	(lovo-cel or "lovo cel" or lovocel or "lovotibeglogene autotemcel" or bb1111 or "bb 1111" or bb-1111 or LentiGlobin or "LentiGlobin SCD" or BB305).ti,ab.
7	(exa-cel or "exa cel" OR exacel OR CTX001 OR "CTX 001" OR CTX-001).ti,ab.
8	6 or 7
9	5 and 8
10	("address" or "autobiography" or "bibliography" or "biography" or "case reports" or "comment" or "congress" or "consensus development conference" or "duplicate publication" or "editorial" or "guideline" or "interview" or "lecture" or "legal case" or "legislation" or "letter" or "news" or "newspaper article" or "patient education handout" or "periodical index" or "personal narrative" or "portrait" or "practice guideline" or "review" or "video-audio media").pt.
11	9 not 10
12	(animals not (humans and animals)).sh.
13	11 not 12
14	Limit 13 to English language
15	Remove duplicates from 14


Search last updated on January 4, 2023.

**Table D3. Search Strategy of EMBASE SEARCH**

#1	'sickle cell anemia'/exp
#2	((sickle NEAR/3 (disease OR an*emia)):ti,ab) OR 'sickle cell':ti,ab OR meniscocyt*:ti,ab OR drepanocyte*:ti,ab OR sickl*:ti,ab OR ((sc NEAR/3 (disease OR an*emia)):ti,ab)
#3	'hemoglobin s'/exp OR ((h?emoglobin NEAR/5 sickl*):ti,ab)
#4	((h?emoglobin OR hb OR 'hb-' OR hgb) NEAR/3 (ss OR 's-s' OR sc OR 's-c' OR 'sb' OR b0 OR 's-beta' OR thalassemia OR 'beta-zero' OR 'beta plus')):ti,ab
#5	#1 OR #2 OR #3 OR #4
#6	'lovotibeglogene autotemcel'/exp
#7	('lovo-cel' OR 'lovo cel' OR lovo cel OR bb1111 OR 'bb 1111' OR 'bb-1111' OR LentiGlobin OR 'LentiGlobin SCD' OR BB305):ti,ab
#8	#6 OR #7
#9	'exagamglogene autotemcel'/exp
#10	('exa-cel' OR 'exa cel' OR exacel OR CTX001 OR 'CTX 001' OR 'CTX-001'):ti,ab
#11	#9 OR #10
#12	#8 OR #11
#13	#5 AND #12
#14	('addresses' OR 'autobiography' OR 'bibliography' OR 'biography' OR 'case report' OR 'comment' OR 'congresses' OR 'consensus development conference' OR 'duplicate publication' OR 'editorial' OR 'guideline' OR 'in vitro' OR 'interview' OR 'lecture' OR 'legal cases' OR 'legislation' OR 'letter' OR 'news' OR 'newspaper article' OR 'patient education handout' OR 'periodical index' OR 'personal narratives' OR 'portraits' OR 'practice guideline' OR 'review' OR 'video audio media')/it
#15	#13 NOT #14
#16	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
#17	#15 NOT #16
#18	#17 AND [English]/lim

Search last updated on January 4, 2023.

Figure D1. PRISMA Flowchart Showing Results of Literature Search for Gene Therapies for SCD





## Study Selection

We performed screening at both the abstract and full-text level. Two investigators independently screened all abstracts identified through electronic searches according to the inclusion and exclusion criteria described earlier. We did not exclude any study at abstract-level screening due to insufficient information. For example, an abstract that did not report an outcome of interest would be accepted for further review in full text. We retrieved the citations that were accepted during abstract-level screening for full text appraisal. Two investigators reviewed full papers and provided justification for exclusion of each excluded study.

## Data Extraction and Quality Assessment

Data were extracted into Excel. The basic design and elements of the extraction forms followed those used for other reports. Elements included a description of patient populations, sample size, duration of follow-up, funding source, study design features, interventions (agent, dosage, frequency, schedules), concomitant therapy allowed and used (agent, dosage, frequency, schedules), outcome assessments, and results. The data extraction was performed in the following steps:

- 1) One reviewer extracted information from the full articles, and a second reviewer validated the extracted data.
- 2) Extracted data was reviewed for logic, and a random proportion of data was validated by a third investigator for additional quality assurance.

Because studies in our evidence base were non-randomized and lacked a placebo or active control group, we did not assign any quality ratings to these trials. The limitations, uncertainties, and gaps in evidence of these trials are discussed in the Uncertainty and Controversies section.

## Assessment of Level of Certainty in Evidence

We used the [ICER Evidence Rating Matrix](#) to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus (see [Supplement D](#)).<sup>94,95</sup>

## Assessment of Bias

As part of our quality assessment, we evaluated the evidence base for the presence of potential publication bias. Given the emerging nature of the evidence base for these newer treatments, we performed an assessment of publication bias on for lovo-cel and exa-cel using ClinicalTrials.gov. Search terms included “lovotibeglogene autotemcel,” “lovo-cel,” “exagamglogene autotemcel,” and “exa-cel.” We scanned the site to identify studies which would have met our inclusion criteria and for which no findings have been published and did not find any evidence of publication bias.

---

## **Data Synthesis and Statistical Analyses**

Data on key outcomes of the main studies were summarized in evidence tables (see Section D2 below) and synthesized qualitatively and quantitatively in the body of the report. Key differences between studies (study design, patient characteristics, interventions, outcomes, study quality) were explored in the text of the report. We assessed the feasibility of quantitative synthesis and due to differences in the trials, we did not conduct a meta-analysis or network meta-analysis to compare lovo-cel to exa-cel.



## D2. Evidence Tables

Table D4. Study Design

Trial (NCT)	Study Design & Follow-Up	Population, N	Arms & Dosing Regimen	Inclusion / Exclusion Criteria	Key Outcomes [Timepoint]
<p><b>HGB-206</b></p> <p>Kanter 2022 &amp; Walters 2022<sup>37,38,57</sup></p> <p>NCT02140554</p>	<p>Phase I/II, single-arm, open-label, nonrandomized trial</p> <p>Follow-up: 24 months post-transplant</p>	<p>Modified Group C (TPVOE subgroup): Patients with severe SCD with ≥4 severe VOCs in 2 years before screening</p> <p>N=29</p>	<p>LentiGlobin BB305 (lovo-cel) administered by IV infusion following myeloablative conditioning with busulfan</p>	<p><b>Inclusion (For Group C TPVOE Subgroup):</b></p> <ul style="list-style-type: none"> <li>-Be ≥12 and ≤50 of age</li> <li>-Have severe SCD (≥4 severe VOEs in the 24 months prior to informed consent), with either βS/βS or βS/β0 or βS/β+ genotype</li> <li>-Karnofsky performance status of ≥ 60 (age ≥16 years) or a Lansky performance status of ≥60 (age &lt;16 years)</li> <li>-Hydroxyurea failure or intolerance</li> <li>-Treated/followed for ≥24 months prior to consent in medical center(s) with records on SCD history</li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>-HIV-1, HIV-2, HBV, HCV</li> <li>-Infection, advanced liver disease, inadequate bone marrow function, malignancy or immunodeficiency disorder</li> <li>-History of severe cerebral vasculopathy</li> <li>-Contraindications to plerixafor, busulfan and any other conditioning medicinal products</li> <li>-Prior receipt of allogeneic transplant or gene therapy</li> <li>-Immediate family with familial cancer syndrome</li> <li>-Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception</li> <li>-Need therapeutic anticoagulation therapy during conditioning</li> <li>-Unable to receive RBC transfusion</li> </ul>	<p>Proportion of subjects achieving complete resolution of severe VOEs (6-18 mo. post-transplant)</p>
<p><b>HGB-205</b></p>	<p>Phase I/II, single-arm, open-label,</p>	<p>Subgroup of interest: Patients</p>	<p>LentiGlobin BB305 (lovo-cel)</p>	<p><b>Inclusion (Overall population):</b></p> <ul style="list-style-type: none"> <li>-Ages 5-35 years with severe SCD or transfusion</li> </ul>	<p>-Participants with successful neutrophil</p>

Trial (NCT)	Study Design & Follow-Up	Population, N	Arms & Dosing Regimen	Inclusion / Exclusion Criteria	Key Outcomes [Timepoint]
Magrin 2022 <sup>54</sup> NCT02151526	nonrandomized trial  Follow-up: 24 months post-transplant	with SCD with recurrent VOCs  N=3	administered by IV infusion following myeloablative conditioning with busulfan	dependent beta-thalassemia major -Eligible for allogeneic HSCT without a matched related donor -Treated/followed for ≥2 years in a specialized center with maintained detailed medical records -Participants with severe SCD also must: fail hydroxyurea treatment for ≥4 months and must have ≥1 poor prognostic risk factor: 1) recurrent VOCs (≥2 episodes in preceding year) 2) significant cerebral abnormality on MRI 3) stroke without severe cognitive disability 4) osteonecrosis of ≥2 joints 5) anti-erythrocyte alloimmunization 6) sickle cell cardiomyopathy 7) ACS (≥2 episodes) <b>Exclusion:</b> -Availability of 10/10 matched HLA identical sibling hematopoietic cell donor -Infection, malignancy, myeloproliferative, or immunodeficiency disorder -WBC count <3×10 <sup>9</sup> /L and/or platelet count <120×10 <sup>9</sup> /L -History of major organ damage	and platelet engraftment [through mo. 24] -Time to neutrophil and platelet engraftment [through mo. 24] -Transplant related mortality [through 1-year post-transplant] -Participants with OS events [from infusion through mo. 24] -Participants with vector-derived RCL [from infusion through mo. 24] -Participants with >% contribution of an individual clone as per ISA [through mo. 24] -AEs and SAEs [up to mo. 24]
CLIMB-121 Frangoul 2022 <sup>39,43</sup> NCT03745287	Phase I/II/III, single-arm, open-label, nonrandomized trial  Follow-up: 24 months post-transplant	Patients with severe SCD and a history of ≥2 VOCs per year in 2 years before screening  N=31	CTX001 by IV infusion following myeloablative conditioning with busulfan	<b>Inclusion:</b> -Ages 12-35 years with a diagnosis of severe SCD defined by: 1) documented severe SCD genotype and 2) history of at least 2 severe VOCs per year for 2 years prior to enrollment -Eligible for ASCT  <b>Exclusion:</b> -An available 10/10 HLA-matched related donor -Prior HSCT -Significant or active infection	-Proportion of subjects free of severe VOCs for at least 12 mo. [up to 2 years after infusion] -Proportion of subjects with neutrophil engraftment [within 42 days after infusion]

Trial (NCT)	Study Design & Follow-Up	Population, N	Arms & Dosing Regimen	Inclusion / Exclusion Criteria	Key Outcomes [Timepoint]
					-Time to engraftment [up to 2 years after infusion] -Frequency and severity of AEs [up to 2 years after infusion] -Incidence of TRM [within 100 days after infusion] -Incidence of TRM within 1 year after CTX001 infusion [up to 1 year after infusion] -All-cause mortality [2 years after mobilization]

ACS: acute chest syndrome, AE: adverse event, ER: emergency room, HBV: hepatitis B virus, HCV: hepatitis C virus, HIV: human immunodeficiency virus, HLA: human leukocyte antigen, HSCT: hematopoietic stem cell transplantation, IV: intravenous, L: liter, N: total number, NCT: National Clinical Trial, NR: not reported, NSAID: nonsteroidal anti-inflammatory drug, RBC: red blood cell, SAE: serious adverse event, SCD: sickle cell disease, TPVOE: transplant population with vaso-occlusive events, VOC: vaso-occlusive crisis, VOE: vaso-occlusive event, WBC: white blood cell



**Table D5. Baseline Characteristics: Iovo-cel<sup>37,38,57</sup>**

		<b>HGB-206</b>	
<b>Characteristic</b>		<b>N</b>	<b>Iovo-cel: Group C</b>
<b>Age, Median Years (Range)</b>		35	24 (12-38)
<b>Age Distribution, n (%)</b>	<b>12-17 Years</b>	35	8 (23)
	<b>18-50 Years</b>	35	27 (77)
<b>Female Sex, n (%)</b>		35	13 (37)
<b>Race (Black), n (%)</b>		35	34 (97)
<b>βS/βS Genotype, n (%)</b>		35	35 (100)
<b>βS/β0 Genotype, n (%)</b>		35	0 (0)
<b>Annualized Incidence of Severe VOs* in 24 Months Before Enrollment, Median (Range)</b>		32	3.5 (0.5-13.5)
<b>Hydroxyurea Use ≤3 Months Before Enrollment, n (%)</b>		35	23 (66)
<b>History of Stroke, n (%)</b>		35	5 (14)
<b>History of Tricuspid Regurgitant Jet Velocity of ≥2.5 m Per Second, n (%)</b>		35	6 (17)
<b>Total Hb Level, Median g/dL</b>		22	8.5

dL: deciliter, g: gram, Hb: hemoglobin, m: meter, n: number, N: total number, VOE: vaso-occlusive event

\*Severe VOE was defined in the protocol as an event, with no medically determined cause other than a vaso-occlusion, requiring a ≥24-hour hospital or ER observation unit visit or at least 2 visits to a day unit or ER over 72 hours with both visits requiring IV treatment. Refer to [Table A1](#) for a more detailed definition.

**Table D6. Baseline Characteristics: exa-cel<sup>39,43</sup>**

<b>CLIMB-121</b>		
<b>Characteristic</b>		<b>exa-cel</b>
<b>N</b>		<b>31</b>
<b>Age, Mean Years (Range)</b>		22.5 (12-34)
<b>Age Distribution, n (%)</b>	<b>12-17 Years</b>	6 (19.4)
	<b>18-34 Years</b>	25 (80.6)
<b>Female Sex, n (%)</b>		15 (48.4)
<b>βS/βS Genotype, n (%)</b>		29 (93.5)
<b>βS/β0 genotype, n (%)</b>		2 (6.5)
<b>Severe VOC* Incidence per Year during 2-Year Period before Screening, Mean (Range)</b>		3.9 (2-9.5)
<b>Total Hb Level, Mean g/dL</b>		9.1

dL: deciliter, g: gram, Hb: hemoglobin, n: number, N: total number, VOC: vaso-occlusive crisis

\*Severe VOC was defined in the protocol as the occurrence of at least two of the following events each year during the two-year period before screening: acute pain event that requires a visit to a medical facility and administration of pain medications or RBC transfusions, ACS, priapism lasting >2 hours and requiring a visit to a medical facility, or splenic sequestration. Refer to Table A1 for a more detailed definition.

**Table D7. Efficacy Outcomes: lovo-cel<sup>37,38,57</sup>**

<b>HGB-206</b>			
<b>Outcome</b>	<b>Timepoint</b>	<b>N</b>	<b>lovo-Cel: Group C</b>
<b>Group C TPVOE Subgroup</b>			
<b>Proportion of Subjects Achieving Complete Resolution of VOEs*, n (%)</b>	6-18 months post-transplant	10†	9 (90)
<b>VOE*, Median Rate Per Year (Range)</b>	6-18 months post-transplant	10†	0 (0-5.9)
<b>Proportion of Subjects Achieving Complete Resolution of Severe VOEs*, n (%)</b>	6-18 months post-transplant	31	30 (96.8)
<b>Severe VOE*, Median Rate Per Year (Range)</b>	6-18 months post-transplant	31	0 (0-0.5)
<b>Group C Overall</b>			
<b>Total Hb Level, Median g/dL</b>	Baseline	22	8.5
	3 months	35	11.4
	6 months	32	11.5
	9 months	32	11.5
	12 months	31	12
	15 months	23	12
	18 months	22	12.1
	21 months	14	11.9
	24 months	16	11.7
<b>Vector Copy Number in Peripheral Blood, Median c/dg</b>	12 months	24	1.2
	36 months	4	2.3
<b>HbAT87Q Fraction in Non-Transfused Total Hb, Median %</b>	Baseline	22	NA
	3 months	35	46
	6 months	32	47
	9 months	32	45
	12 months	31	45
	15 months	23	46
	18 months	22	44
	21 months	14	44
24 months	16	45	
<b>Successful Neutrophil/Platelet Engraftment, n (%)</b>	After infusion	35	100 (100)
<b>Time to Neutrophil Engraftment, Median (Range) Days</b>	After infusion	35	20 (12-35)
<b>Time to Platelet Engraftment, Median (Range) Days</b>	After infusion	35	36 (18-136)



HGB-206			
Outcome	Timepoint	N	lovo-Cel: Group C
Days of Hospitalization from Conditioning to Discharge, Mean (Range) Days	After infusion	35	35 (26-65)

c: copies, dg: diploid genome, dL: deciliter, g: gram, Hb, hemoglobin, n: number, N: total number, NA: not applicable, TPVOE: transplant population with vaso-occlusive events, VOC: vaso-occlusive event

\*Severe VOE was defined in the protocol as an event, with no medically determined cause other than a vaso-occlusion, requiring a  $\geq 24$ -hour hospital or ER observation unit visit or at least two visits to a day unit or ER over 72 hours with both visits requiring intravenous treatment. Refer to [Table A1](#) for a more detailed definition.

**Table D8. Efficacy Outcomes: exa-cel<sup>39,43</sup>**

CLIMB-121			
Outcome	Timepoint	N	Exa-cel
<b>Proportion of Subjects Who Have Not Experienced Any Severe VOCs* for at Least 12 Consecutive Months, n (%)</b>	From 60 days after last RBC transfusion up to 2 years after exa-cel infusion	7†	7 (100)
<b>Time to Last RBC Transfusion, Median Days (Range)</b>	After infusion	31	19 (11-52)
<b>Proportion of HbF Against Total Hb, Mean %</b>	Baseline	30	5.1
	3 months	25	36.6
	6 months	17	44.1
	9 months	15	42.9
	12 months	9	42.5
	15 months	6	41.5
<b>Total Hb Level, Mean g/dL</b>	Baseline	30	9.1
	3 months	25	12.1
	6 months	17	12.7
	9 months	15	13.3
	12 months	9	12.5
	15 months	6	13.7
<b>Successful Neutrophil/Platelet Engraftment, n (%)</b>	After infusion	31	31 (100)
<b>Time to Neutrophil Engraftment, Median (Range) Days</b>	After infusion	31	27 (15-38)
<b>Time to Platelet Engraftment, Median (Range) Days</b>	After infusion	31	32 (23-74)
<b>Proportion of Edited BCL11A Alleles in Bone Marrow CD34+HSPCs, Mean %</b>	6 months	7	86.6%
<b>Proportion of Edited BCL11A Alleles in Peripheral Blood Mononuclear Cells, Mean %</b>	6 months	17	76.0%

dL: deciliter, g: gram, Hb: hemoglobin, HbF: fetal hemoglobin, HSPC: hematopoietic stem and progenitor cell, n: number, N: total number, RBC: red blood cell, VOC: vaso-occlusive crisis

\*Severe VOC was defined in the protocol as the occurrence of at least 2 of the following events each year during the 2-year period before screening: acute pain event that requires a visit to a medical facility and administration of pain medications or RBC transfusions, ACS, priapism lasting >2 hours and requiring a visit to a medical facility, or splenic sequestration. Refer to [Table A1](#) for a more detailed definition.

†Based off the number of participants with 12 months of follow-up 60 days after RBC infusion.

**Table D9. Patient-Reported Outcomes: Lovo-cel<sup>41</sup>**

		HGB-206: Group C Overall							
		Patients with Baseline Score "Worse" than Population Norm				Patients with Baseline Score "Better or Near" than Population Norm			
		Timepoint: At Month 6 Up to Month 24							
		Baseline		Last Visit		Baseline		Last Visit	
		Score	n	Score	n	Score	n	Score	n
PROMIS-57	Pain Intensity	6.5	15	1.8	5	2	9	2.8	4
	Pain Interference	64.2	16	44.5	5	46.4	8	45.9	4
	Fatigue	64.6	8	46.9	1	47.7	16	43.4	9

n: number, PROMIS: Patient-Reported Outcomes Measurement Information System



**Table D10. Safety: Lovo-cel<sup>37</sup>**

<b>HGB-206</b>			
<b>Outcome</b>		<b>N</b>	<b>lovo-Cel: Group C Overall</b>
<b>AE, n (%)</b>	<b>Due to Plerixafor Mobilization or Apheresis</b>	43*	22 (51)
	<b>Due to Conditioning</b>	35	35 (100)
	<b>After lovo-cel Infusion</b>	35	35 (100)
<b>SAE, n (%)</b>	<b>Due to Plerixafor Mobilization or Apheresis</b>	43*	5 (12)
	<b>Due to Conditioning</b>	35	5 (14)
	<b>After lovo-cel Infusion</b>	35	15 (43)
<b>≥ Grade 3 AE, n (%)</b>	<b>Due to Plerixafor Mobilization or Apheresis</b>	43*	11 (26)
	<b>Due to Conditioning</b>	35	32 (91)
	<b>After lovo-cel Infusion</b>	35	34 (97)
	<b>Stomatitis</b>	35	24 (69)
	<b>Thrombocytopenia</b>	35	23 (66)
	<b>Neutropenia</b>	35	19 (54)
	<b>Febrile Neutropenia</b>	35	15 (43)
	<b>Anemia</b>	35	13 (37)
	<b>Leukopenia</b>	35	11 (31)
<b>Treatment-Related AE after Infusion, n (%)</b>		35	3 (9)
<b>Death, n (%)</b>		35	1 (2.9)
<b>Hematologic Malignancies, n (%)</b>		35	0 (0)
<b>Veno-Occlusive Liver Disease</b>		35	0 (0)
<b>Graft Failure</b>		35	0 (0)
<b>Vector-Mediated Insertional Oncogenesis</b>		35	0 (0)
<b>Replication-Competent Lentivirus Incidence, n (%)</b>		35	0 (0)

AE: adverse event, n: number, N: total number, NR: not reported, SAE: serious adverse event

\*Refers to number of patients who underwent stem cell collection. Not all 43 patients received lovo-cel infusion.

**Table D11. Safety: exa-cel<sup>39,43</sup>**

<b>CLIMB-121</b>		
<b>Outcome</b>		<b>Exa-Cel</b>
<b>N</b>		<b>31</b>
<b>AE, n (%)</b>	<b>Any</b>	31 (100)
	<b>Related to exa-cel</b>	9 (29)
	<b>Related to Busulfan</b>	31 (100)
	<b>Grade 3/4</b>	31 (100)
<b>SAE, n (%)</b>	<b>Any</b>	10 (32.3)
	<b>Related to exa-cel</b>	0 (0)
<b>Discontinuation, n (%)</b>		0 (0)
<b>Death, n (%)</b>		1 (3.2)*
<b>Malignancies, n (%)</b>		0 (0)

AE: adverse event, n: number, N: total number, SAE: serious adverse event

\*Death occurred after the February 2022 data cut-off. An adult participant developed pneumonia and respiratory failure, resulting in death. The investigator attributed this to SARS-CoV-2 infection, potentially related to busulfan lung injury, but unrelated to exa-cel.

### D3. Ongoing Studies

Table D12. Ongoing Studies

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcome(s)	Estimated Completion Date
<b>lovo-cel</b>					
<p>A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in SCD (HGB-210)</p> <p>Bluebird bio  <a href="https://clinicaltrials.gov/ct2/show/study/NCT04293185">NCT04293185</a></p>	<p>Phase III Single-arm, open-label, nonrandomized trial</p> <p>N~35</p>	<p>LentiGlobin BB305 (lovo-cel) administered by IV infusion following myeloablative conditioning with busulfan</p>	<p><b>Inclusion Criteria:</b></p> <ul style="list-style-type: none"> <li>-Diagnosed with SCD, with <math>\beta S/\beta S</math>, <math>\beta S/\beta 0</math>, or <math>\beta S/\beta +</math> genotype</li> <li>-<math>\geq 2</math> and <math>\leq 50</math> years of age and weigh <math>\geq 6</math> kg</li> <li>-Karnofsky performance status of <math>\geq 60</math> (age <math>\geq 16</math> years) or Lansky performance status of <math>\geq 60</math> (age <math>&lt; 16</math> years)</li> <li>-Treated and followed for <math>\geq 24</math> months in medical center with records on SCD history</li> <li>-Experienced <math>\geq 4</math> VOs in 24 months</li> <li>-HU failure/intolerance</li> </ul> <p><b>Exclusion Criteria:</b></p> <ul style="list-style-type: none"> <li>-Appropriate allo-HSCT and available HLA-matched related hematopoietic stem cell donor</li> <li>-Severe cerebral vasculopathy</li> <li>-HIV-1, HIV-2, HTLV-1, HBV, HCV, active syphilis</li> <li>-Active infection, advanced liver disease, inadequate bone marrow function</li> <li>-Contraindication to plerixafor, busulfan, other conditioning products</li> <li>-Needing therapeutic anticoagulation treatment during conditioning</li> <li>-Unable to receive PRBC transfusion</li> <li>-Receipt of allogeneic transplant or gene therapy</li> <li>-Malignancy or immunodeficiency disorder</li> <li>-Family with familial cancer syndrome</li> <li>-Breastfeeding or pregnant</li> <li>-Ineligible for HSCT</li> </ul>	<p><b>6-18 months post-transplant:</b></p> <ul style="list-style-type: none"> <li>-Proportion of subjects achieving complete resolution of VOs (VOE-CR)</li> </ul>	<p>February 2025</p>

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcome(s)	Estimated Completion Date
			-Abnormality or genetic mutation that may increase risk of MDS or AML -Genetic mutations resulting in inactivation of $\geq 2$ $\alpha$ -globin genes		
Long-term Follow-up of Subjects With SCD Treated With Ex Vivo Gene Therapy  Bluebird bio <a href="#">NCT04628585</a>	Long-term follow-up observational study  N~85	LentiGlobin BB305 (lovo-cel) administered by IV infusion following myeloablative conditioning with busulfan (followed 15 years post-drug infusion)	<b>Inclusion Criteria:</b> -Ages 2-53 years -Subjects with SCD treated with ex vivo gene therapy product in bluebird bio-sponsored clinical studies (HGB-210, HGB-206, HGB-205)	<b>Up to 15 years post-infusion:</b> -Immune-related AEs -New/worsening hematologic disorders -New/worsening neurologic disorders -Malignancies	January 2038
<b>exa-cel</b>					
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe SCD (CLIMB-151)  Vertex Pharmaceuticals Incorporated <a href="#">NCT05329649</a>	Phase III Single-arm, open-label, nonrandomized trial  N~12	CTX001 by IV infusion following myeloablative conditioning with busulfan	<b>Inclusion Criteria:</b> -Ages 2 to 11 years -Diagnosis of severe SCD as defined by history of $\geq 2$ severe VOCs events per year for 2 years prior to enrollment -HU failure/intolerance -Eligible for ASCT  <b>Exclusion Criteria:</b> -10/10 HLA-matched related donor -HSCT -Active infection	<b>Up to 24 months post-infusion:</b> -No severe VOCs for $\geq 12$ months	May 2026
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent $\beta$ -Thalassemia and Severe SCD	Phase IIIb Single-arm, open-label, nonrandomized trial  N~12	CTX001 by IV infusion following myeloablative conditioning with busulfan	<b>Inclusion Criteria:</b> -For participants with TDT and SCD (overall): Eligible for ASCT -For participants with TDT: 1) homozygous $\beta$ -thalassemia or compound heterozygous $\beta$ -thalassemia 2) history of $\geq 100$ mL/kg/year or 10	<b>Up to 12 months post-infusion:</b> -HbF Concentration Over Time	February 2025

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcome(s)	Estimated Completion Date
Vertex Pharmaceuticals Incorporated <a href="#">NCT05477563</a>			units/year of PRBC transfusions in 2 years before consent -For participants with SCD: severe SCD with 1) SCD genotypes, 2) $\geq 2$ severe VOCs events/year for 2 years prior to enrollment  <b>Exclusion Criteria:</b> -For Participants with TDT and SCD (overall): 1) HLA-matched related donor is available, 2) prior HSCT, 3) active infection -For participants with TDT: 1) Associated $\alpha$ -thalassemia and $>1$ alpha deletion, or alpha multiplications, 2) sickle cell $\beta$ -thalassemia variant -For participants with SCD: Moyamoya syndrome	-Hb Concentration Over Time	
A Long-term Follow-up Study in Subjects Who Received CTX001  Vertex Pharmaceuticals Incorporated <a href="#">NCT04208529</a>	Phase III Long-term follow-up observational study  N~114	CTX001 by IV infusion following myeloablative conditioning with busulfan (followed 15 years post-drug infusion)	<b>Inclusion Criteria:</b> -Ages 2 years and older -Completed or discontinued the parent study (CTX001-111 or CTX001-121 or VX21-CTX001-141 or VX21-CTX001-151) after CTX001 infusion	<b>Up to 15 years post-infusion:</b> -New malignancies -New/worsening hematologic disorders -All-cause mortality -SAEs -CTX001-related AEs	September 2039

AE: adverse event, AML: acute myeloid leukemia, CR: complete resolution, Hb: hemoglobin, HbF: fetal hemoglobin, HBV: hepatitis B, HCV: hepatitis C, HIV: human immunodeficiency virus, HLA: human leucocyte antigen, HSCT: hematopoietic stem cell transplantation, HTLV: human T-lymphotropic virus, HU: hydroxyurea, IV: intravenous, kg: kilogram, N: number, MDS: myelodysplastic syndrome, PRBC: packed red blood cell, RBC: red blood cell, SAE: serious adverse event, SCD: sickle cell disease, TDT: transfusion-dependent thalassemia, VOC: vaso-occlusive crisis, VOE: vaso-occlusive event  
 Source: [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) (NOTE: studies listed on site include both clinical trials and observational studies)



## D4. Previous Systematic Reviews and Technology Assessments

We identified one ongoing health technology assessment conducted by the National Institute for Health and Care Excellence and one previously conducted review of curative therapies for SCD. Both are briefly summarized below.

### National Institute for Health and Care Excellence Technology Assessments

[CTX001 for treating severe sickle cell disease \[ID4016\]](#)

An appraisal of the clinical and cost effectiveness of CTX001 for the treatment of SCD is in development. As of March 2023, there is no expected publication date posted.

### Previous Reviews

**Kassim, et al. (2022). “Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy.”<sup>96</sup>**

This paper discusses current and emerging curative therapies for SCD, HSCT, and gene therapy. HSCT with an HLA-matched sibling donor is a curative therapy that has been established for patients with SCD, however, this is not accessible to most patients due to a lack of matched donor. HSCT with an HLA-haploidentical donor with post-transplant cyclophosphamide and gene therapy broadens the pool of patients eligible for curative treatment. These two therapies are compared across categories such as donor availability, intensity of regimen, stem cell procurement, complications, and long-term effects.

The authors explore the pros and cons of gene therapy methods relevant to our review, lentiviral vector gene addition and nuclease editing (CRISPR/Cas9). Lentiviral vector gene addition has stable integration into the genome which can allow for long-term expression, there is no immunogenicity and can accommodate large transgenes, but can lead to potential off-target effects or mutagenesis. The pros cited for nuclease editing are that it is non-integrating, the tools are transient, and there is high editing efficiency. The cons are the requirement for DSB, potential for off-target editing, and can induce a p53 response. It is concluded that although data is currently limited, gene therapy appears to be effective and safe.

---

# E. Long-Term Cost-Effectiveness: Supplemental Information

## E1. Detailed Methods

Table E1. Impact Inventory

Sector	Type of Impact (Add Additional Domains, as Relevant)	Included in This Analysis from [...] Perspective?		Notes on Sources (if Quantified), Likely Magnitude and Impact (if Not)
		Health Care Sector	Societal	
<b>Formal Health Care Sector</b>				
<b>Health Outcomes</b>	Longevity effects	X	X	
	Health-related quality of life effects	X	X	Includes caregiver impacts for modified societal perspective
	Adverse events	X	X	
<b>Medical Costs</b>	Paid by third-party payers	X	X	
	Paid by patients out-of-pocket	X	X	
	Future related medical costs	X	X	
	Future unrelated medical costs	X	X	
<b>Informal Health Care Sector</b>				
<b>Health-Related Costs</b>	Patient time costs	N/A	X	
	Unpaid caregiver-time costs	N/A	X	
	Transportation costs	N/A	--	
<b>Non-Health Care Sector</b>				
<b>Productivity</b>	Labor market earnings lost	N/A	X	
	Cost of unpaid lost productivity due to illness	N/A	X	
	Cost of uncompensated household production	N/A	X	
<b>Consumption</b>	Future consumption unrelated to health	N/A	--	
<b>Social Services</b>	Cost of social services as part of intervention	N/A	--	
<b>Legal/Criminal Justice</b>	Number of crimes related to intervention	N/A	--	
	Cost of crimes related to intervention	N/A	--	
<b>Education</b>	Impact of intervention on educational achievement of population	N/A	--	
<b>Housing</b>	Cost of home improvements, remediation	N/A	--	
<b>Environment</b>	Production of toxic waste pollution by intervention	N/A	--	
<b>Other</b>	Other impacts (if relevant)	N/A	--	

N/A: not applicable

Adapted from Sanders et al. (2016).<sup>97</sup>

**Table E2. Key Model Assumptions**

Assumption	Rationale
Costs for patients who start the process of pre-transplant assessments and preparation but do not proceed with treatment are included in the model.	Preparation for transplant (e.g., assessments, tests, visits) incur additional costs that should be accounted for in the model.
The model included an evidence-based estimate of treatment failure in the first model cycle.	Where the trial data shows a proportion of patients still with VOCs after treatment, this is modeled assuming that these patients have the same rate of complications and mortality as those on standard care.
After year seven, patients on both gene therapies revert to costs and outcomes of standard care at a rate used in ICER’s beta thalassemia report. <sup>59</sup>	The long-term durability of treatment effect is unknown. The uncertainty in the durability of treatment effect was also heard from clinical experts and patient stakeholders.
The cycle length of the model was one year.	Given the chronic nature of SCD, a cycle length of one year is expected to appropriately capture health outcomes and costs, and allow for sufficient flexibility to explore our planned sensitivity and scenario analyses.
Some patients have chronic complications at the start of the model.	Some chronic complications will have occurred by the age at the start of the model and the prevalence of these complications were sourced from published literature.
The risk of complications and death in the model were populated using data for Medicaid patients.	While some SCD patients have commercial insurance (with lower risk of complications) or Medicare (with higher risk of complications), most of the SCD patients are covered by Medicaid and, as such, the model was populated using data for Medicaid patients.
All complications (i.e., acute [except VOCs] and chronic) and death were modeled independent of each other.	We used the most relevant robust data sources to model the risk of complications and mortality, which already account for any interdependencies. As the aim is to estimate the cost-effectiveness at a population level, this approach is appropriate.
VOC rates are correlated with rates of acute and chronic complications of interest, and mortality.	We used published data on hazard ratios for the complications of interest between SCD patients with zero VOCs and those with 3+ VOCs. Similar approach was also used for mortality rates.
Treatment effect in reducing the VOCs were used to model the impact on risk of complications.	Treatment success was measured as proportion of patients without VOCs, and these patients were modelled with lower risks of acute, chronic complications and mortality based on the hazard ratios from published literature.
For chronic complications and mortality, the hazard ratios for adults are different from the adolescents to account for organ damage in the adult population.	Adult patients on SCD are assumed to already accumulate some organ damage before receiving the gene therapy and as such, the treatment effectiveness in reducing chronic complications and mortality is assumed to be lower for adults compared to adolescents (who are less likely to accumulate organ damage).
Health state disutility values were used to estimate QALY losses for acute and chronic complications.	QALY decrements for acute complications were estimated considering the short duration of the disutilities. Chronic complications were assumed to last for lifetime (i.e., until death).

Assumption	Rationale
Additive approach was used to estimate the QALYs.	Additive approach was used to estimate the health-related quality of life of patients with multiple complications, to reflect modeling of the complications independently.
For model inputs with no evidence-based specified uncertainty range, we assumed parametric distributions.	Inclusion of parameter uncertainty within one-way and probabilistic analysis allows for a reasonable characterization of uncertainty.

ICER: Institute for Clinical and Economic Review, QALY: quality-adjusted life year, SCD: sickle cell disease, VOC: vaso-occlusive crisis

### Rates of Acute and Chronic Complications for Patients on Standard of Care

The transition probabilities for annual risk of complications were estimated from the incidence rates reported in published literature presented in Table E3. Most of the incidence rates were sourced from Shah et al. 2019 and Shah et al. 2020, which present the complication rates for patients insured on Medicaid.<sup>62,65</sup> These were supplemented with data from the previous ICER SCD report.<sup>9</sup> It was assumed that some adult patients have chronic complications at the start of the model, and this was estimated as prevalence of complications in commercially insured patients aged less than 18 years from Ramsey et al 2022.<sup>68</sup> The use of data from commercially insured patients and those less than 18 years of age would mean that the model uses a lower prevalence of chronic complications than what is likely to be observed in patients with severe SCD. The prevalence of heart failure was assumed to be zero as these patients would not receive gene therapy.

In the model, the rates of complications for adolescents are used for patients starting as adolescents and the rates change to the rates of complications for adults when the adolescents are over 18 years of age (i.e., when they become adults). For adults, the rates for adults are used throughout their lifetime. In each model cycle, the proportions of patients with acute complications are estimated by multiplying the patients alive with the risk of acute complications. For each chronic complication, in each model cycle, the proportions of patients alive without that complication are multiplied by the annual risk of that chronic complication to estimate the proportion of patients getting that complication in that model cycle. It is assumed the chronic complications last until death, and as such, in each model cycle the proportions of patients in each chronic complication are capped at the proportion of patients alive.

**Table E3. Annual Incidence Rates of Complications**

Complications	Incidence Rate for Adolescents*	Incidence Rate for Adults*	Source
VOCs	4†	4†	Assumption
Acute Chest Syndrome	0.0698	0.0571	Shah et al. 2019 <sup>65</sup>
Acute Infections (Bacteremia and Sepsis)	0.017	0.038‡	McClish et al <sup>98</sup>
Acute Kidney Injury	0.0000	0.0006	Bradt et al. 2020 <sup>9</sup>
Gallstones	0.0293	0.0452	Shah et al. 2019 <sup>65</sup>
Leg Ulcers	0.0235§	0.0235§	Antwi-Boasiako et al 2020 <sup>99</sup>
Pulmonary Embolism	0.0011	0.0208	Shah et al. 2019 <sup>65</sup>
Stroke	0.011	0.021	Bradt et al. 2020 <sup>9</sup>
Myocardial Infarction	0.0009	0.0069	Bradt et al. 2020 <sup>9</sup>
Avascular Necrosis	0.0142	0.0536	Shah et al. 2019 <sup>65</sup>
Chronic Kidney Disease	0.0143	0.0262#	Bradt et al. 2020 <sup>9</sup>
Heart Failure	0.0075	0.0198#	Bradt et al. 2020 <sup>9</sup>
Liver Complications	0.0067⌘	0.0067 ⌘	Allali et al. 2019 <sup>100</sup>
Pulmonary Hypertension	0.0027	0.0159	Shah et al. 2019 <sup>65</sup>
Retinopathy	0.0050	0.0050	Shah et al. 2022 <sup>101</sup>
Chronic Lung Disease	0.0341	0.0341	Winn et al 2023 <sup>73</sup>
Neurocognitive Impairment	0.00045	0.0034	Manwani et al. 2022
Pain and Fatigue	0.033	0.033	Bradt et al. 2020 <sup>9</sup>

VOC: vaso-occlusive crisis

\*Annual incidence rates of complications per patient.

†Annual number of VOCs.

‡Estimated as average of the different age groups.

§Prevalence of ulcers used as a proxy for annual incidence.

#Estimated as average of the 18-30 and 30-45 age groups.

⌘Annual rate estimated using data from Allali et al. 2019 suggesting 6.5% prevalence over 10 year follow up.

## Mortality for Patients on Standard Care

The risk of mortality for patients on standard care was estimated from the rates reported in Desai et al. 2020, based on analysis of 44,033 SCD patients insured on Medicaid.<sup>66</sup> Data on cumulative incidence over 13 year follow up for patients with ≥5 VOC episodes in the baseline year, who reflect the more severe SCD population, was converted into annual mortality risk assuming constant rate (i.e., exponential distribution) as shown in Table E4. For each age category, this annual mortality risk was compared to the mortality risk in general US population (at the mean age within each category) to estimate the standardized mortality ratio to be used in the model.

To estimate the mortality for a given age in the model, the general population mortality for that age was multiplied with the standardized mortality ratio for that age group i.e., standardized mortality ratio of 40.07 was applied to estimate the mortality risk for adolescents, standardized mortality ratio of 24.24 for ages 19-35, and a standardized mortality ratio of 17.48 for ages 35 and above.

**Table E4. Mortality Inputs**

Age Group	Mean Age	Cumulative Incidence* (95% CI)	Annual Mortality Risk	Standardized Mortality Ratio	Source
<b>Ages 13-18</b>	15	15.0% (11.8-18.2%)	0.0124 (0.0096, 0.0153)	40.07 (31.00, 49.46)	Desai et al. 2020 <sup>66</sup>
<b>Ages 19-35</b>	25	27.3% (24.9-29.6%)	0.0242 (0.0218, 0.0266)	24.24 (21.80, 26.65)	Desai et al. 2020 <sup>66</sup>
<b>Ages 35+</b>	45	45.41% (41.4-49.2%)	0.0455 (0.0403, 0.0508)	17.48 (15.47, 19.50)	Desai et al. 2020 <sup>66</sup>

CI: confidence interval

\*Over 13 year follow up.

## Treatment Effectiveness on Acute Complications

The acute complication rates for the patients without VOCs after gene therapies were modeled by applying the hazard ratios reported in Table E5 to the baseline complication rates for patients on standard care (as presented in Table E3).

Bailey et al. and Herquelot et al. 2019 report the hazard ratios for patients who have 3+ VOCs compared to zero VOCs based on analysis of 15,076 patients were identified with a diagnosis of SCD using the Hospital Episode Statistics database in the United Kingdom.<sup>102,103</sup> Where there were data gaps, these were supplemented with data from the previous ICER report as presented in Table E5.<sup>9</sup> The hazard ratios for patients achieving treatment success on gene therapy were estimated as half of the inverse of the hazard ratios reported in Bailey et al. and Herquelot et al. 2019.<sup>102,103</sup> The reason for halving these hazard ratios is that the patients achieving treatment success on gene therapy are likely to be better than those who had zero VOCs. The “halving” to estimate the hazard ratios for patients achieving treatment success on gene therapy can be considered as being an average of the hazard ratios for the general population (likely to be close to zero) and the hazard ratios of the patients with zero VOCs.

**Table E5. Treatment Effectiveness on Acute Complications**

Complications	Hazard Ratio for Patients Without VOCs After Gene Therapy (95% CI)	Hazard Ratio for Patients With 0 VOCs Compared to Those With 3+ VOCs (95% CI)	Hazard Ratio for Patients With 3+ VOCs Compared to Those With 0 VOCs (95% CI)	Source
VOCs	0	--	--	Assumption
ACS	0.094 (0.076, 0.117)	0.188 (0.151, 0.233)	5.33 (4.29,6.62)	Bailey et al. 2019 <sup>102</sup>
Acute Infections (Bacteremia and Sepsis)	0.181 (0.109, 0.299)	0.362 (0.219, 0.599)	2.76 (1.67, 4.57)	Bailey et al. 2019 <sup>102</sup>
Acute Kidney Injury	0.131 (0.038, 0.450)	0.262 (0.077, 0.901)	3.81 (1.11, 13.0)	Bailey et al. 2019 <sup>102</sup>
Gallstones	0.185 (0.125, 0.273)	0.370 (0.251, 0.546)	2.70 (1.83, 3.99)	Bailey et al. 2019 <sup>102</sup>
Leg Ulcers	0.238 (0.107, 0.532)	0.476 (0.214, 1.064)	2.10 (0.94, 4.68)	Bailey et al. 2019 <sup>102</sup>
Pulmonary Embolism	0.450 (0.231, 0.877)	0.901 (0.463, 1.754)	1.11 (0.57, 2.16)	Bailey et al. 2019 <sup>102</sup>
Stroke	0.221 (0.190, 0.258)	0.442 (0.380, 0.515)	2.26 (1.94, 2.63)	Bradt et al. 2020 <sup>9</sup> Shah et al. 2019 <sup>4</sup>
Myocardial Infarction	0.388 (0.173, 0.862)	0.775 (0.346, 1.724)	1.29 (0.58, 2.89)	Bailey et al. 2019 <sup>102</sup>

ACS: acute chest syndrome, CI: confidence interval, VOC: vaso-occlusive crisis

## Treatment Effectiveness on Chronic Complications

The chronic complication rates for the patients without VOCs after gene therapies were modeled by applying the hazard ratios reported in Table E6 to the baseline complication rates for patients on standard of care (as presented in Table E3).

The hazard ratios for patients without VOCs after receiving treatment as adolescent population were estimated as half of the inverse of the hazard ratios reported in Bailey et al. 2019,<sup>102</sup> and the previous ICER report<sup>9</sup> as presented in Table 4.7. The reason for halving the hazard ratios is that the patients achieving treatment success on gene therapy are likely to be better than those who had zero VOCs. However, the hazard ratios for patients without VOCs after receiving treatment as adult population were estimated as inverse of hazard ratios (i.e., without further halving) to account for accumulated organ damage before receiving the gene therapy. Adult patients on SCD are assumed to already accumulate some organ damage before receiving the gene therapy and as such, the treatment effectiveness in reducing chronic complications is assumed to be lower for adults compared to adolescents (who are less likely to accumulate organ damage).

**Table E6. Treatment Effectiveness on Chronic Complications**

Complications	Hazard Ratios for Patients without VOCs After Receiving Gene Therapy as Adolescents (95% CI)	Hazard Ratios for Patients without VOCs After Receiving Gene Therapy as Adults (95% CI)	Hazard Ratios for Patients with 3+ VOCs Compared to Those with 0 VOCs (95% CI)	Source
Avascular Necrosis	0.202 (0.132, 0.309)	0.403 (0.263, 0.617)	2.48 (1.62, 3.80)	Bailey et al. 2019 <sup>102</sup>
Chronic Kidney Disease	0.422	0.844	1.185	Bradt et al. 2020 <sup>9</sup>
Heart Failure*	0.388 (0.173, 0.862)	0.775 (0.346, 1.724)	1.29 (0.58, 2.89)	Bailey et al. 2019 <sup>102</sup>
Liver Complications	0.161 (0.038, 0.685)	0.322 (0.075, 1.370)	3.11 (0.73, 13.25)	Bailey et al. 2019 <sup>102</sup>
Pulmonary Hypertension	0.192 (0.105, 0.352)	0.385 (0.211, 0.704)	2.60 (1.42, 4.75)	Bailey et al. 2019 <sup>102</sup>
Retinopathy†	0.321	0.641	1.56	Bailey et al. 2019 <sup>102</sup>
Chronic Lung Disease‡	0.163 (0.106, 0.250)	0.326 (0.212, 0.500)	3.07 (2.0, 4.72)	Bailey et al. 2019 <sup>102</sup>
Neurocognitive Impairment§	0.190 (0.089, 0.407)	0.380 (0.177, 0.813)	2.63 (1.23, 5.64)	Bailey et al. 2019 <sup>102</sup>
Pain and Fatigue	0.255	0.509	--	Assumed to be average of the hazard ratios

CI: confidence interval, VOC: vaso-occlusive crisis

\*Hazard ratio for cardiac complications used as a proxy for hazard ratio for heart failure.

†Hazard ratio for retinal vascular occlusion from sensitivity analysis of Bailey et al. 2019<sup>102</sup> as main analysis suggested increased risk for those with 0 VOCs.

‡Hazard ratio for cardiomegaly from Bailey et al. 2019<sup>102</sup> used as a proxy for hazard ratio for chronic lung disease.

§Hazard ratio for central nervous system complications from Bailey et al. 2019<sup>102</sup> used as a proxy for hazard ratio for neurocognitive impairment.

## Treatment Effectiveness on Mortality

The mortality rates for the patients without VOCs after gene therapies were modeled by applying the hazard ratios reported in Table E7 to the baseline mortality rates for patients on standard care (estimated based on rates as presented in Table E4).

The relationship between the number of VOCs experienced in the previous year and mortality was sourced from Desai et al. 2020 who report a hazard ratio of 3.23 (2.95-3.53) using unadjusted extended Cox models for patients with ≥5 VOCs compared to patients with <2 VOCs.<sup>66</sup> The use of this study is deemed reasonable given the higher mortality rates for standard care patients based on data for patients with ≥5 VOC episodes in the baseline year.



The hazard ratios for patients without VOCs after receiving treatment as adolescent population were estimated as half of the inverse of the hazard ratios reported in Desai et al. 2020.<sup>66</sup> The reason for halving these hazard ratios is that the patients achieving treatment success on gene therapy are likely to be better than those who had zero VOCs. The hazard ratios for patients without VOCs after receiving treatment as adult population were estimated as inverse of hazard ratios (i.e., not halved) to account for accumulated organ damage before receiving the gene therapy.

**Table E7. Treatment Effectiveness on Mortality**

	<b>Hazard Ratios for Adolescents With No VOCs After Gene Therapy (95% CI)</b>	<b>Hazard Ratios for Adults With No VOCs After Gene Therapy Compared to Severe SCD Patients (95% CI)</b>	<b>Hazard Ratios for Patients With ≥5 VOCs vs. Those With &lt;2 VOCs (95% CI)</b>	<b>Source</b>
<b>Base-Case Analysis</b>	0.155 (0.142, 0.169)	0.310 (0.283, 0.339)	3.23 (2.95; 3.53)	Desai et al. 2020 <sup>66</sup>

CI: confidence interval, VOC: vaso-occlusive crisis

## Disutilities

Disutilities of complications were sourced from Sullivan et al. 2006<sup>61</sup> as reported in Table E8. The QALY losses for acute complications were estimated considering their short duration and the QALY losses for chronic complications were estimated assuming they last for lifetime (i.e., until death). An additive approach was used to estimate the QALYs to reflect modeling of the complications independently.

**Table E8. Disutilities Associated with Acute and Chronic Complications**

Complications	Disutility	Source
VOCs*	-0.23	Anie et al. 2012, <sup>60</sup>
ACS*	-0.0412	Sullivan et al 2006 <sup>61</sup>
Acute Infections (Bacteremia and Sepsis)*	-0.05	Assumption
Acute Kidney Injury*	-0.0527	Sullivan et al 2006 <sup>61</sup>
Gallstones†	-0.0288	Sullivan et al 2006 <sup>61</sup>
Leg Ulcers†	-0.0272	Sullivan et al 2006 <sup>61</sup>
Pulmonary Embolism*	-0.0198	Sullivan et al 2006 <sup>61</sup>
Stroke‡	-0.0524	Sullivan et al 2006 <sup>61</sup>
Myocardial Infarction‡	-0.0409	Sullivan et al 2006 <sup>61</sup>
Post Stroke	-0.0524	Sullivan et al 2006 <sup>61</sup>
Avascular Necrosis	-0.0380	Sullivan et al 2006 <sup>61</sup>
Chronic Kidney Disease	-0.0603	Sullivan et al 2006 <sup>61</sup>
Heart Failure	-0.0635	Sullivan et al 2006 <sup>61</sup>
Liver Complications	-0.0567	Sullivan et al 2006 <sup>61</sup>
Pulmonary Hypertension	-0.0428	Sullivan et al 2006 <sup>61</sup>
Retinopathy	-0.0498	Sullivan et al 2006 <sup>61</sup>
Chronic Lung Disease	-0.0667	Sullivan et al 2006 <sup>61</sup>
Neurocognitive Impairment	-0.0494	Sullivan et al 2006 <sup>61</sup>
Pain and Fatigue	-0.05	Assumption

ACS: acute chest syndrome, QALY: quality-adjusted life year, VOC: vaso-occlusive crisis

\*Assumed to last for two weeks.

†Assumed to last for three months.

‡Assumed to last for half year.

## Costs

The model also included upfront costs of \$114,227 associated with the gene therapies after inflating the costs used in the beta thalassemia ICER report to 2022 values.<sup>59</sup> This included \$3,023 for the work-up costs, \$18,967 for pre-transplant costs, \$89,419 for transplant costs, and \$2,818 for the costs of infertility treatments due to myeloablative conditioning. In line with the beta thalassemia ICER report,<sup>59</sup> monitoring costs of \$8,653 per year were also included for first three years for those receiving gene therapy. Patients who start the process of pre-transplant assessments and preparation but do not proceed with gene therapy, estimated as 16.3% based on the data from the trials that seven out of 43 patients did not proceed to gene therapy, are assumed to incur the work-up costs and pre-transplant costs, and these costs were included in the gene therapy arms.

## Standard of Care Costs

The costs of standard of care were estimated from Gallagher et al 2022,<sup>104</sup> who present the five-year costs of severe SCD for Medicare, Medicaid and commercially insured patients. We used the costs of outpatient pharmacy, outpatient other services, and outpatient visits for Medicaid patients as they are considered to be a reasonable estimate of standard of care costs (as they include the

costs of hydroxyurea, chronic blood transfusions, and iron chelation therapies). These five-year costs were inflated to 2022 costs using the personal consumption expenditure health care indices, and then divided by five to estimate the annual costs as shown in Table E9 below.

We assumed that the standard of care costs would be eliminated for patients with successful gene therapy treatment (i.e., patients without VOCs). While some outpatient visits and services may still exist for successfully treated gene therapy patients, we have used an optimistic assumption on eliminating these standard of care costs for patients successfully treated with gene therapy.

**Table E9. Standard of Care Costs**

	Five-Year Costs (in 2018 Values)	Five-Year Costs (in 2022 Values)	Annual Costs (in 2022 Values)	Source
Outpatient Pharmacy	\$24,721	\$27,168	\$5,434	Gallagher et al 2022 <sup>104</sup>
Outpatient Other Services	\$32,714	\$35,953	\$7,191	Gallagher et al 2022 <sup>104</sup>
Outpatient Visits	\$4,062	\$4,464	\$893	Gallagher et al 2022 <sup>104</sup>
<b>Total Costs of Standard of Care</b>	<b>\$61,497</b>	<b>\$67,585</b>	<b>\$13,517</b>	Gallagher et al 2022 <sup>104</sup>

## Non-Drug Costs

The costs for complications in the model were populated using most relevant data from published literature and inflated to 2022 costs using the personal consumption expenditure health care indices. These costs were used consistently across treatments evaluated in the model. A recent systematic review by Baldwin et al. 2020<sup>69</sup> was used to identify the sources that best reflect the costs for US SCD patients, with most of the costs from the previous ICER SCD report.<sup>9</sup> The costs of VOCs were sourced from Shah et al 2020<sup>62</sup> who report the average cost of VOCs for Medicaid patients across different settings (i.e., inpatient, emergency room, outpatient, and office), as these costs were considered to most likely reflect the cost of VOCs (rather than assuming that all VOCs are costed assuming an inpatient visit).

The costs for acute complications were modeled as one-off costs while the costs for chronic complications are modeled as annual costs, as shown in Table E10. Whilst there are studies that present annual “overall” health costs after a complication, these are not considered appropriate for inclusion in the model. This is because these estimates include all health care costs (i.e., SCD standard of care costs, costs of complications and non-SCD related health care costs) while the model uses costs specific to the complications, and using the overall annual health care costs for complications results in double counting and overestimation of costs of complications.

**Table E10. Costs of SCD-Related Complications**

Complications	Costs (In 2019 Values)	Costs (In 2022 Values)	Source
VOCs	\$5,335	\$5,762	Baldwin et al. 2020 <sup>69</sup>
ACS	\$26,299	\$28,403	Baldwin et al. 2020 <sup>69</sup>
Acute Infections (Bacteremia and Sepsis)*	--	\$11,354	Song et al 2019 <sup>105</sup>
Acute Kidney Injury	\$8,205	\$8,861	Bradt et al. 2020 <sup>9</sup>
Gallstones*	--	\$14,328	Song et al 2019 <sup>105</sup>
Leg Ulcers*	--	\$8,110	Song et al 2019 <sup>105</sup>
Pulmonary Embolism	\$13,879	\$14,989	Khoury et al 2020 <sup>106</sup>
Stroke†	\$57,780	\$62,403	Bradt et al. 2020 <sup>9</sup>
Myocardial Infarction	\$53,458	\$57,735	Bradt et al. 2020 <sup>9</sup>
Post Stroke	\$9,807	\$10,592	Bradt et al. 2020 <sup>9</sup>
Avascular Necrosis*	--	\$14,869	Song et al 2019 <sup>105</sup>
Chronic Kidney Disease	\$20,708	\$22,365	Bradt et al. 2020 <sup>9</sup>
Heart Failure	\$32,505	\$35,106	Bradt et al. 2020 <sup>9</sup>
Liver Complications	\$16,919	\$18,273	Hirode et al 2020 <sup>107</sup>
Pulmonary Hypertension	\$19,343	\$20,891	Bradt et al. 2020 <sup>9</sup>
Retinopathy	\$13,595	\$14,683	Nguyen et al 2022 <sup>108</sup>
Chronic Lung Disease	\$10,367	\$11,196	Ur Rehman et al 2020 <sup>109</sup>
Neurocognitive Impairment	\$11,687	\$12,622	Bradt et al. 2020 <sup>9</sup>
Pain and Fatigue	\$4,398	\$4,750	Bradt et al. 2020 <sup>9</sup>

ACS: acute chest syndrome, VOC: vaso-occlusive crisis

\*Costs estimated by multiplying the coefficients of the regression equations in Song et al 2019<sup>105</sup> with the 2022 standard of care costs, and subtracting the standard of care costs to estimate the additional costs associated with the complications. Also, these costs are not inflated as they are based on 2022 standard of care costs.

†Additional costs of \$77,951 are incorporated on top of \$62,403 for stroke in adolescent patients in line with the previous ICER SCD report.<sup>9</sup>

## Description of evLY Calculations

The evLY considers any extension of life at the same “weight” no matter what treatment is being evaluated or what population is being modeled. Below are the stepwise calculations used to calculate the evLY.

- 1) First, we attribute a utility of 0.851, the age- and gender-adjusted utility of the general population in the US that are considered healthy.<sup>110</sup>
- 2) We calculate the evLY for each model cycle.
- 3) Within a model cycle, if using the intervention results in additional life years versus the primary comparator, we multiply the general population utility of 0.851 with the additional life years gained within the cycle.
- 4) The life years shared between the intervention and the comparator use the conventional utility estimate for those life years within the cycle.
- 5) The total evLY for a cycle is calculated by summing steps 3 and 4.

- 6) The evLY for the comparator arm is equivalent to the QALY for each model cycle.
- 7) The total evLYs are then calculated as the sum of evLYs across all model cycles over the time horizon.

Finally, the evLYs gained is the incremental difference in evLYs between the intervention and the comparator arm.

## Description of Optimistic and Conservative Scenarios

Optimistic and conservative assumptions regarding the benefit of treatment with Lovo-cel and exa-cel were performed to reflect the uncertainty in the clinical data. Details of the scenarios are provided below.

**Table E11. Assumptions for Optimistic and Conservative Scenarios Analysis Results**


	Base Case	Optimistic Scenario	Conservative Scenario
<b>Treatment Waning (0.27% Reverting)</b>	After 7 years	Never	After 7 years
<b>Additional Utility for Patients without VOCs on Gene Therapy</b>	0.05	0.05	0.03
<b>Hazard Ratio Multipliers for Acute Complications</b>	0.5	0.5	1
<b>Hazard Ratio Multipliers for Adolescents for Chronic Complications</b>	0.5	0.5	1
<b>Hazard Ratio Multipliers for Adults for Chronic Complications</b>	1	0.5	1
<b>Hazard Ratio Multipliers for Adults for Death</b>	1	0.5	1

VOC: vaso-occlusive crisis


## Results of Probabilistic Sensitivity Analysis

Figures E1 and E2 present the scatterplot of the incremental costs and QALYs for lovo-cel and exa-cel, respectively. There is greater spread in the incremental QALYs for exa-cel (Figure E2) due to the greater uncertainty around the treatment success rate of exa-cel. Tables E11 and E12 present the percent of iterations that were beneath thresholds of \$50,000, \$100,000, \$150,000, and \$200,000 per QALY gained from both the health care system perspective and the modified societal perspective for lovo-cel and exa-cel, respectively.

**Figure E1. Scatterplot for Lovo-Cel (Health Care System Perspective)**



**Figure E2. Scatterplot for Exa-Cel (Health Care System Perspective)**



**Table E11. Probabilistic Sensitivity Analysis Cost per QALY Gained Results: lovo-cel vs. Standard of Care**

	Probability of being Cost Effective at \$50,000 per QALY Gained	Probability of being Cost Effective at \$100,000 per QALY Gained	Probability of being Cost Effective at \$150,000 per QALY Gained	Probability of being Cost Effective at \$200,000 per QALY Gained
<b>Health Care System Perspective</b>				
<b>lovo-cel</b>	0%	0%	0%	27%
<b>Modified Societal Perspective</b>				
<b>lovo-cel</b>	0%	0%	6%	86%

QALY: quality-adjusted life year

**Table E12. Probabilistic Sensitivity Analysis Cost per QALY Gained Results: exa-cel vs. Standard of Care**

	Probability of being Cost Effective at \$50,000 per QALY Gained	Probability of being Cost Effective at \$100,000 per QALY Gained	Probability of being Cost Effective at \$150,000 per QALY Gained	Probability of being Cost Effective at \$200,000 per QALY Gained
<b>Health Care System Perspective</b>				
<b>exa-cel</b>	0%	0%	0%	21%
<b>Modified Societal Perspective</b>				
<b>exa-cel</b>	0%	0%	5%	74%

QALY: quality-adjusted life year

# F. Potential Budget Impact: Supplemental Information

## **Methods**

Potential budget impact was defined as the total differential cost of using each gene therapy rather than standard of care for people living with severe SCD in the US, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. All costs were undiscounted and estimated over a five-year time horizon. The five-year timeframe was chosen given the potential for cost offsets to accrue over time and to provide a more realistic uptake assumption on the number of patients treated with lovo-cel and exa-cel.

This potential budget impact analysis included the estimated number of people in the US who are likely to be eligible for treatment. Those eligible may be different from the number of people who may ultimately choose to receive either lovo-cel or exa-cel. To estimate the size of the potential candidate populations for treatment, we used manufacturer data submissions and literature (De Martino et al. 2021) and consider between 20,000 and 25,000 people living with severe SCD in the US to be eligible for lovo-cel or exa-cel.<sup>74,75</sup> We used the upper end of this range (25,000) and divide this estimate in two for those eligible for lovo-cel (N=12,500) and separately, exa-cel (N=12,500) as per ICER's Reference Case. For the purposes of this analysis, we assume that 20% of these patients would initiate treatment in each of the five years, or 2,500 patients per year per gene therapy.

ICER's methods for estimating potential budget impact are described in detail elsewhere.<sup>111,112</sup> The intent of our approach to budgetary impact is to document the percentage of patients that could be treated at selected prices without crossing a budget impact threshold that is aligned with overall growth in the US economy.

Once estimates of budget impact are calculated, we compare our estimates to an updated budget impact threshold that represents a potential trigger for policy mechanisms to improve affordability, such as changes to pricing, payment, or patient eligibility. As described in ICER's methods presentation (<https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework-2/>), this threshold is based on an underlying assumption that health care costs should not grow much faster than growth in the overall national economy. From this foundational assumption, our potential budget impact threshold is derived using an estimate of growth in US gross domestic product +1%, the average number of new drug approvals by the FDA over the most recent two-year period, and the contribution of spending on retail and facility-based drugs to total health care spending.



For 2022-2023, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately \$777 million per year for new drugs.

## Results

Table F1 illustrates the average annual per-patient budget impact calculations for lovo-cel or exa-cel over 5 years at placeholder acquisition price (\$2 million [per treatment course]), and the prices to reach \$150,000, \$100,000, and \$50,000 per QALY (\$1.58 million, \$1.24 million, and \$0.9 million per treatment course, respectively) when comparing lovo-cel or exa-cel to standard of care. Note that the average annual per-patient budget impact must be multiplied by five in order to capture the cumulative budget impact of lovo-cel or exa-cel for a cohort of US patients living with severe SCD over five years (see Figure F1 for an additional visualization regarding cumulative budget impact at lovo-cel’s or exa-cel’s placeholder acquisition price).

**Table F1. Average Annual Per-Patient Budget Impact Calculations Over a Five-year Time Horizon**

	Average Annual Per-Patient Budget Impact			
	Placeholder Acquisition Price	\$150,000/QALY	\$100,000/QALY	\$50,000/QALY
lovo-cel or exa-cel vs. Standard of Care	\$935,000	\$743,000	\$588,000	\$432,000

QALY: quality-adjusted life year

**Figure F1. Per-Patient Cumulative Budget Impact of lovo-cel or exa-cel over Five Years Assuming 20% Uptake Per Year at Placeholder Acquisition Price of \$2 Million**

